# U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

+ + + + +

# ADVISORY BOARD ON RADIATION AND WORKER HEALTH

+ + + + +

# SUBCOMMITTEE ON PROCEDURES REVIEW

+ + + + +

WEDNESDAY APRIL 11, 2012

+ + + + +

The Subcommittee convened in the Brussels Room of the Cincinnati Airport Marriott, 2395 Progress Drive, Hebron, Kentucky, at 9:00 a.m., Wanda I. Munn, Chair, presiding.

#### PRESENT:

WANDA I. MUNN, Chair MICHAEL H. GIBSON, Member\* PAUL L. ZIEMER, Member

# ALSO PRESENT:

TED KATZ, Designated Federal Official BOB ANIGSTEIN, SC&A\*
HANS BEHLING, SC&A\*
KATHY BEHLING, SC&A\*
STU HINNEFELD, DCAS
JENNY LIN, HHS
STEPHEN MARSCHKE, SC&A
JOHN MAURO, SC&A\*
MUTTY SHARFI, ORAU\*
MATTHEW SMITH, ORAU\*
JOHN STIVER, SC&A
ELYSE THOMAS, ORAU\*
BRANT ULSH, DCAS

\*Participating via telephone

#### CONTENTS

Welcome and Introductions 4
Database review and comments [SC&A/NIOSH] . 6
OTIB-0070 status of DB entry review for accuracy [NIOSH-Sharfi]
Status of PERs
- 020 any claimants affected by items 1 or 2? [NIOSH]
OTIB-54 [Munn] 74
Carry-over items:
TIB 0010 Updated database status cont'd TIB-013 status - 04 re-review - overarching or site applicable [DCAS] OTIB-0052 Rev 1 review status [SC&A]
Introduction of new Overarching Issues database list [NIOSH] Status of 2-pagers. [Munn]
Off-agenda items       250         OTIB-6 [Munn]       250         IG-003/IG-005 two-pagers [Katz]       252         PERs 17 and 29 [Stiver]       261         OTIB-52 [Marschke]       272         Administrative detail [All]       280
Adjournment 283

#### P-R-O-C-E-E-D-I-N-G-S

(9:00 a.m.)

MR. KATZ: Good morning everyone in the room and on the line. This is the Advisory Board on Radiation and Worker Health Procedures Review Subcommittee.

We are getting started. We will begin with roll call. There are no conflict of issue matters with our Members for this group for this agenda today so we don't need to address conflict of interest.

But let's go with roll call. Board Members, beginning in the room.

(Roll call.)

MR. KATZ: Very good. There's an agenda for the meeting. It's posted on the NIOSH web page under the Board section, meetings. And off we go. Wanda.

CHAIR MUNN: I assume everyone in the room has a copy of the agenda. If anyone needs a hard copy let me know. I have one extra copy here for you if you need it.

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

Before we go any further, are there any additions or corrections to the agenda other than the two items that Ted had mentioned, were not specifically called out?

MR. STIVER: If I could say something. This is John Stiver. We do have a kind of a draft PER-12 dose reconstruction report that we -- if we have time for it this afternoon, Kathy put that together kind of at the 11th hour, but -- so we'd like to discuss it.

We have one case of the nine that's addressed, and before we were to, you know, go ahead with the process we have in place and the format and everything, we would like to discuss it with the Subcommittee.

CHAIR MUNN: Very good. We'll see if we -- with any luck at all, I think we'll have adequate time for that and we'll just do that before we get to administrative detail in the afternoon.

Anything else?

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

# (No response.)

CHAIR MUNN: Then let's move forward with the agenda. Our first item is to take a look at the database review and the comments. Steve Marschke. I want to thank Steve personally and all of the people that work with him to get a familiar format for our reporting of status to the Board Members today.

This was certainly very helpful for me and I don't know whether everyone else feels that way or not, but this is by far the most meaningful presentation of the data that we have had in a long time, I think.

Thank you again, Steve, and if you want to go through our report and give yourself and anyone else who wants to comment about it our usual discussion on where we are with our tracking system and how well we are doing in terms of being able to access the data we want, when we want, in the format we'd like to see.

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

Go ahead, Steve.

MR. MARSCHKE: Okay well first, I think, Brant, I think you want to say something along the lines of Wanda's summary table?

DR. ULSH: Yes, for the past, I don't know how many meetings, the Committee's expressed top priority has been to generate within the Board Review System the ability to generate this table that Steve did by brute force this time.

I'm happy to report that you can now do it, and Steve is going to show you.

MR. MARSCHKE: If you go up here onto the reports and you click on summary finding status report, on a dropdown menu you get voila. You get the summary table comes up, automatically generated, and so in the future we won't have to be generating this by brute force. We can basically use the BRS to generate this, and so that's very good news.

CHAIR MUNN: Wait, let me do that.

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	That is wonderful, just
2	MR. MARSCHKE: Go back here to
3	where it says reports, Wanda, and you get a
4	little dropdown menu, and it says summary
5	finding status report, you click on that.
6	CHAIR MUNN: That's it.
7	MR. HINNEFELD: Now, there's an
8	export by the printer icon there's a button
9	that says export.
10	MR. MARSCHKE: Is that up here?
11	MR. HINNEFELD: That corner where
12	Steve is showing it. You can select the
13	format in that dropdown list. And you can
14	export that report into a Word file or Excel.
15	(Simultaneous speaking.)
16	MR. MARSCHKE: If you want to
17	include this report into a Word document that
18	you are sending out, you can export it
19	directly, right into your document.
20	CHAIR MUNN: Oh, that's going to be
21	so convenient.
22	MS. LIN: You're missing a 3D

1	option.
2	(Laughter.)
3	CHAIR MUNN: Thank you. Yes.
4	That's about the only thing that's missing.
5	MR. HINNEFELD: We don't have the
6	glasses yet.
7	CHAIR MUNN: That is very, very
8	nice, complete with a PDF file. Thank you so
9	much.
10	MR. HINNEFELD: You laugh. Those
11	guys might do it.
12	(Laughter.)
13	MR. STIVER: We'd probably make it
14	a video game.
15	CHAIR MUNN: Really looking forward
16	to it. That is wonderful. Thank you all. Go
17	ahead Steve. Thank you, Brant. Thank
18	everybody behind the scenes who worked on
19	this.
20	DR. ULSH: Yes, that's it, we're
21	done. We're going home now.
22	(Laughter.)

DR. ULSH: There is also, just so you know, Steve, if you could go back to the first page, the summary page. Yes. The cumulative totals chart, this is the graph that typically goes with the -- what we call the Wanda report. CHAIR MUNN: Yes. Now, be careful with ULSH: this one for now. This is all late-breaking, and neither Steve nor I are quite sure how these bars are built. I mean, it looks like we want it to look in the past, but I have to double check with Tom James to make sure that all the numbers are --(Simultaneous speaking.) CHAIR MUNN: And how did you get to that, Steve? MR. MARSCHKE: Basically you go to the same -- where did it go? Cumulative totals MR. STIVER: chart.

#### NEAL R. GROSS

MR. MARSCHKE: I lost -- I --

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

10

11

12

13

14

15

16

17

18

19

20

21

STIVER: Back under Board MR. review. MR. HINNEFELD: Yes, once you get to the report, you get back to the main screen and you close out --(Simultaneous speaking.) MR. MARSCHKE: -- to the reports button, it's the second one underneath. CHAIR MUNN: Okay. Okay. It's the 10 graph, I got it. MR. MARSCHKE: But, again, use it 11 with care because we don't -- we aren't sure 12 13 exactly what's being put in there, because typically the BRS or the Access database 14 before the BRS did not keep track of --15 16 historical track. Now you can see, basically he's got 17 18 every month, May, June, July, August, 19 September, October, and that's not what I -that's not what we typically do. We typically 20 have these bars. These charts are typically 21 the dates of the Subcommittee meetings, like 22

March 2008 and so on and so forth.

So I'm not sure, you know, I'm not sure that this chart that is being automatically generated is what we need.

CHAIR MUNN: Well, it was certainly helpful to me as an overall visual summary.

MR. MARSCHKE: Well we can -- but you have to be careful of the way you summarize it because you have to know what's in it before you can really, you know -- and it only goes back -- it doesn't go back -- it only goes back to May of last year.

So you know, what we've been doing in the past is, again, I've been keeping the historical record of these in kind of like a separate Excel file and generating these charts from a separate Excel file which has the history back through time.

CHAIR MUNN: Well, that seems the logical thing to do unless we have some really compelling reason to transfer that material into the new system.

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

DR. ULSH: Well, let me -- let me make sure that I understand what you want in this draft, and if it's the Subcommittee's desire, now that we've had the Wanda table up, if this is your new top priority, then I can, you know, prioritize that appropriately with Tom James.

But from what I hear, you want the dates along the bottom to be the dates of the Procedures Subcommittee meetings rather than monthly, and for each bar, let's say if I'm looking at the June 8th bar, the third bar in, you see the different colored bars there corresponding to different finding status. So the way I interpret that is, as of June 8th, the bottom bar shows you how many were closed, and on top of that on June 8th, how many were in abeyance, et cetera et cetera.

Right? That's what we --

CHAIR MUNN: Correct. That was my interpretation as well.

DR. ULSH: Okay. I will work with

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

Tom to make sure that that graph reflects what you want it to reflect. I'm just saying the shell is there now, but don't put a lot of trust in that data until we V&V it.

CHAIR MUNN: That's fine, and if there are -- yes, it seems logical to me to chart this from our Subcommittee view of it, which would be per our meetings rather than in -- by month or annually.

Paul, do you agree that our meetings should be the -- that is to say at our meetings, that's when we have input to this, and other times we, as a Subcommittee really and truly don't.

So from my perspective, that's ideal.

MR. MARSCHKE: Also, Wanda, the only -- in theory the only time the statuses are supposed to change is at the Subcommittee meeting, and by the Subcommittee.

So going month to month, when there's no Subcommittee, it would not -- the

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	bars would be unchanged from one month to the
2	next.
3	CHAIR MUNN: It would be
4	meaningless to us because we wouldn't know who
5	changed it and why.
6	DR. ULSH: Can you go back to the
7	one that we generated in the system because
8	it's month to month and you see there are some
9	changes, so that
10	MR. MARSCHKE: Well there might
11	have been some meetings because there might
12	have been a meeting in September, and there
13	might have been a meeting in January. There
14	was a meeting in January.
15	MR. STIVER: Yes, you can see
16	there's kind of a step function there.
17	DR. ULSH: Okay, well maybe you're
18	right then.
19	MR. STIVER: So, this looks like it
20	reflects three different meetings here, which
21	seems to be about right.
22	CHAIR MUNN: We were meeting much
1	

1	more frequently.
2	MR. MARSCHKE: So it's only but
3	in between, it's level.
4	DR. ULSH: Yes, which is not
5	terribly informative.
6	MR. MARSCHKE: Which is not, you
7	know
8	DR. ULSH: Okay.
9	CHAIR MUNN: Yes, I think we were
10	changing it, essentially when we met.
11	MR. KATZ: So this is consistent
12	with what you'd expect. The data is probably
13	right.
14	DR. ULSH: Let me make sure.
15	CHAIR MUNN: Good. Has anybody
16	else been working with this and having any
17	problems at all with it? Have you tried
18	working with the PDF files, et cetera?
19	MR. MARSCHKE: Well, you know, if I
20	could continue on, Wanda
21	CHAIR MUNN: Please.
22	MR. MARSCHKE: Preparing for the
	NEAL R. GROSS

meeting, I guess it was the end of March, when I sent -- we were working with it and we found a few glitches and I sent an email, and I think they've been mostly taken care of. I CC'd you, Wanda, on this email --CHAIR MUNN: Yes. MR. MARSCHKE: -- that I sent to Brant. CHAIR MUNN: I have it. I did not cc the MARSCHKE: rest of the Subcommittee. I don't know how much the Subcommittee wants to follow the nuts and bolts of the BRS. Well, I think it's CHAIR MUNN: worthwhile for us at least to touch on it and get it into the record, because it's helpful for anyone who is going to be working with it to kind of stay up to speed with where we are and our eventual goal to have this really super-smooth. DR. ULSH: Now these should be

addressed by now, but you know, we have to

10

11

12

13

14

15

16

17

18

19

20

21

make sure --

10

11

12

13

14

15

16

17

18

19

20

21

22

CHAIR MUNN: Let's touch on it to find out.

MR. MARSCHKE: The -- I checked it this morning and I think TIB-9, OCAS-TIB-9 and OCAS-TIB-11 I believe are now in the system, so that's a good thing.

The only thing is they have not been populated.

DR. ULSH: Right, let me explain that. We discovered -- I can't remember who discovered it -- but I became aware that when we built the Board Review System from the Access database, there was a problem with not just 9 and 11, but I think many more of the DCAS TIBs or OCAS TIBs. Remember the names changed.

And that is that those findings were not ported over into the new system. So we are aware of that issue, and we are working on it.

CHAIR MUNN: Do we know why?

DR. ULSH: No. CHAIR MUNN: We love a mystery. MARSCHKE: See, you can MR. OCAS-TIB-9 for example is here. When you click on it, basically it says there are no findings to display. So that's what they're -- they're working on that right now. DR. ULSH: And I'd asked Elyse, and I think she did it, to go back into the Access 10 database and kind of print out that history so that we can then populate it here in the Board 11 Review System. 12 MR. MARSCHKE: I think it's only --13 I think one of them had two findings and the 14 15 other one might have had one finding, and I 16 think all of them are either closed or in abeyance or something. It's very -- they're 17 very -- there weren't many findings. 18 19 CHAIR MUNN: Well, I see 11 on my list, showing two findings. 20 MR. STIVER: I'm not seeing nine on 21 mine. 22

1	CHAIR MUNN: But I don't see nine.
2	MR. MARSCHKE: What list are you
3	looking at?
4	CHAIR MUNN: I'm looking at the
5	master list. There's OTIB-0011, tritium
6	calculated missed dose estimates.
7	MR. STIVER: Yes, I go from TIB-8
8	to 13.
9	CHAIR MUNN: Yes. I go from 8 to
10	10. And then 11, 12, 13, 14, everybody but 9.
11	DR. ULSH: So we know that this is
12	an issue and it's being worked right now.
13	CHAIR MUNN: Okay. We can make a
14	note of that.
15	MR. MARSCHKE: The other one I saw
16	was, when we were generating some of the PDF
17	files I got some errors, when I was doing it
18	for some of the findings, and I'm going to
19	check that this morning, that seems to be
20	working.
21	The one that doesn't seem to be
22	fixed, Brant, is the first one, OCAS-PER-3.

	There was an issue loading this comment and I
	don't know what that OCAS OCAS-PER-3.
	When I click on that, I get this I get this
	error message.
	DR. ULSH: OCAS-PER-003.
	MR. STIVER: Yes, I get the same
,	message.
	CHAIR MUNN: I thought we had PER-3
)	MR. MARSCHKE: And also when you
	basically do you get the same message when
	you do ORAU-OTIB-10. You click on that, you
	get that same, there was an issue loading
	comment/finding details. So I don't know.
	There could be some corruption in someone's
	files someplace or something.
	CHAIR MUNN: That was OTIB what?
	MR. MARSCHKE: That was OTIB-10.
	CHAIR MUNN: We had a we had 10
)	on our carryover items.
	MR. MARSCHKE: Was the this is
	ORAU-OTIB-10. I don't think we've had OCAS

1	CHAIR MUNN: No, we had OCAS-OTIB-
2	10.
3	MR. MARSCHKE: OCAS, yes we had
4	CHAIR MUNN: Updated you later.
5	MR. KATZ: I wonder if you could
б	have just an administrator, database
7	administrator email set up so you know, as you
8	do with other CDC systems, so that when these
9	just sort of unique little problems like this,
10	someone can just send an email to the email
11	box saying there's a problem
12	They ought to involve you in all
13	that each time.
14	MR. HINNEFELD: Let me tell you
15	what that address is. Hang on.
16	CHAIR MUNN: I'm sorry, Stu, I
17	missed that.
18	MR. HINNEFELD: I'll tell you what
19	the address is, what address to send it to.
20	CHAIR MUNN: Okay.
21	MR. HINNEFELD: It's this is all
22	caps, but I don't think it matters. CIN, as
	NEW D. ODGGG

in Cincinnati, hyphen OCAS, hyphen NOCTS space
-- support. Support is no longer in caps.
Actually, I'm sorry. That's -- it's CIN-OCASNOCTSsuppor, all one word. I was reading the
shorthand. The actual address is, and this is
not all caps, but it won't matter, cin-ocasnoctssuppor -- doesn't have room for the T -@cdc.gov

And specify that you are sending it for the Board review application. That's our NOCTS support inbox. And so that's our guys. You can send it for -- even though it's not a NOCTS issue, you can send it to us.

MR. KATZ: Sure, yes. It looks like that will be more efficient.

MR. HINNEFELD: And then, Brant, we need to warn them that they will be getting emails from perhaps Work Group Members, Subcommittee Members and Steve and perhaps John or Kathy or some people like that.

MR. KATZ: And then down the road, in case someone loses it, I don't know if it's

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

easy for them to just put this help number at the top of this system or something so that --MR. HINNEFELD: Oh, I suppose they could. MR. KATZ: If they can --MR. HINNEFELD: In fact --MR. KATZ: If that's easy to do, that would be nice, and they --(Simultaneous speaking.) 10 MR. KATZ: help number --There's a link in 11 MR. HINNEFELD: NOCTS that takes you to it, so they have to 12 13 only put that same type of link on --MR. KATZ: Okay. So that would be 14 15 perfect. 16 MR. HINNEFELD: You got that? DR. ULSH: Yes. 17 MR. MARSCHKE: The other thing that 18 19 we have talked about -- and I haven't checked this out so maybe it's been taken care of --20 but the other thing that we had talked about 21 meetings are basically the 22 other

and the total active findings findings columns, and what is meant by active findings. The last time we checked -- the last time we tried to do this, I think we used DR. ULSH: That should be fixed Should be. I told Tom to redefine the now. definition. Sorry, redefine total active findings to be all findings except closed --CHAIR MUNN: Closed, transferred --10 Transferred and in 11 MR. STIVER: abeyance. 12 13 CHAIR MUNN: In abeyance. DR. ULSH: Whatever it is 14 we 15 decided, I told Tom to change it and he 16 reported back to me that it had in fact been changed. This was late last week so I haven't 17 had a chance to verify that. 18 19 CHAIR MUNN: Yes, I think we had --20 MR. MARSCHKE: The one that we were looking at was actually OTIB-54 and kind of 21 22 using that as an example.

MR. STIVER: ORAU-OTIB-54? See basically the MR. MARSCHKE: problem I have is, if you look at OTIB-54, it shows 26 findings and 26 active findings and that's not right. So somehow it's not getting updated. MR. STIVER: Oh, here it is. 26, 26. MR. MARSCHKE: And if you go, down, if you go into the details, you can see 10 basically that the first one is in abeyance, 11 the second one is closed, the third one and 12 13 fourth one are closed. So a lot of them have been closed 14 15 or in abeyance, and it's just really -- so 16 something's not being updated probably. But I mean he made -- probably made the changes to 17 the definition but somewhere there has to be 18 19 an update of that first table. 20 There were nine MR. STIVER: All the rest are either closed or 21 progress. 22 in abeyance.

CHAIR MUNN: In abeyance. two, three, four, five, six, seven, eight. I have eight in progress, but you say there's more? might MR. STIVER: I have miscounted, point being there's quite a few that are already closed. CHAIR MUNN: Yes. MR. STIVER: This is OTIB-54. 10 under all Work Groups and then --(Simultaneous speaking.) 11 CHAIR MUNN: Five, six, seven in 12 13 abeyance. And it's not picking it up. MR. MARSCHKE: Yes, that's the main 14 15 point is, whether or not there's how there are, specifically the fact that it's not 16 picking them up. 17 CHAIR MUNN: Well now --18 19 MR. MARSCHKE: So the question is, I mean, it's obviously, I think it's picking 20 them up, obviously on the -- when it does the 21 Wanda summary table, the new Wanda summary 22

table, it's doing it right. So the data is being, you know, somewhere -- this screen is not being updated with the latest information. Should be a relatively minor thing. CHAIR MUNN: This is one of those that Ted had on his note that I had overlooked in my --Well, we weren't MR. MARSCHKE: 10 sure what Ted meant on his note, whether he meant this or whether he meant -- because we 11 haven't really talked about OTIB-54 12 except for to use it as this example. 13 haven't talked about it itself since I think 14 it was January of 2011. 15 16 MR. KATZ: That's why I didn't have it for this particular concern. 17 MR. MARSCHKE: Right, no. 18 Yes. 19 That's what I kind of thought. 20 So, we'll just keep CHAIR MUNN: that as a checkpoint for how well the system 21 is working next time, right? 22

MR. MARSCHKE: Yes, I mean this could be a very handy thing to have Wanda, because you could click on, you know, total active findings and it will order them in order and you could then use it and see which of the procedures are -- still have the most active findings associated with it so they can maybe pop up to the top of the list.

CHAIR MUNN: Yes, that's marvelous.

That was one of the big things that I had on my list of things to check out here, so the fact that you can get active findings is great. We'll just check 54 next time.

All right. Anything else, Steve?

MR. MARSCHKE: I think that's all I wanted to say about the BRS.

CHAIR MUNN: Does anyone else who has been using the database have anything to add or anything to complain about?

I still find this a little bit cumbersome, but I think it's my lack of facility with the process, not the database

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	itself, as best I can determine.
2	You doing okay with it, Paul?
3	MEMBER ZIEMER: Yes, gradually.
4	CHAIR MUNN: Good. And we don't
5	have anyone on the line who do we have Mike
6	on the line?
7	MR. STIVER: Mike Smith?
8	CHAIR MUNN: No. No.
9	MEMBER ZIEMER: No, Mike Gibson.
10	MEMBER GIBSON: I'm here.
11	CHAIR MUNN: Have you had occasion
12	to play with this at all, Mike?
13	MEMBER GIBSON: No, I haven't,
14	Wanda.
15	CHAIR MUNN: Okay. Very good.
16	Then I trust you don't have any complaints?
17	MEMBER GIBSON: I don't.
18	CHAIR MUNN: That's good. And,
19	Dick, are we going to have Dick at any time on
20	the line?
21	MR. KATZ: No.
22	CHAIR MUNN: No, okay. All right
	NEAL R. GROSS

then.	Thank you very much Steve and all your
associa	ates. Brant, thanks. We really
appreci	iate that. I feel like this is a
signifi	icant help for me certainly.
	I would call to your attention a
small,	tiny little thing Steve, on the primary
chart,	the heading says, "Number 2, total
finding	gs" of the first column. I think you
want th	hat to be total of total findings.
	MR. MARSCHKE: Yes, well okay,
well,	the thing is what the, did they put
it righ	ht in the
	CHAIR MUNN: Yes, it says, "Number
2, tota	al findings."
	MR. MARSCHKE: Well they just have
total	findings. The new one, we will in
the fu	uture we will be using the automatic
system	one.
	CHAIR MUNN: And the automatic
system	one says
	MR. MARSCHKE: It just says total
finding	gs.

CHAIR MUNN: -- total findings, it doesn't say any of two or anything. That's good. MR. MARSCHKE: So, it doesn't have that problem. CHAIR MUNN: Okay. That's good. Then my little picky is of no consequence at all. All right. I guess, I don't MR. MARSCHKE: 10 know if you want to talk about it now, but I mean we can basically talk about you know, 11 where we are a little bit, if you want to look 12 at this chart that was associated with the 13 handout, as opposed to the one that was on the 14 15 automatic chart with the system, you 16 really look and it gives you a good idea of the status that we are making and you see we 17 18 are over 50 percent --19 CHAIR MUNN: Done. Closed. -- closed. 20 MR. MARSCHKE: Well over 50 percent closed. Maybe 55 percent 21 closed, if you look at the second one --22

CHAIR MUNN: Yes. MR. MARSCHKE: -- which is not, which is not bad, and if you add in the ones that are in abeyance, that means we are over 70 percent have resolutions to them. CHAIR MUNN: Yes. The ones that are MR. MARSCHKE: open is less than 10 percent, those are the ones we haven't talked about at all. It looks like we've got about 10 percent that are also 10 11 (Simultaneous speaking.) 12 13 CHAIR MUNN: So go ahead, Steve, you're 11 percent --14 15 MR. MARSCHKE: Well, I was just 16 looking at the in progress one looks to be about, well, according to the chart it's about 17 18 seven percent --

CHAIR MUNN: Yes, right.

MR. MARSCHKE: -- in progress, and so you know, if you look at the previous -- the previous chart, you can see for a long

#### **NEAL R. GROSS**

19

20

21

time, from May of 2009 to October of 2010, we didn't really add any new findings.

CHAIR MUNN: No.

MR. MARSCHKE: But since we've added a few findings since October of 2010 to today, not very many, maybe a handful, I think most of these have, you know, came from Hans in his PER reviews --

CHAIR MUNN: I think so.

MR. MARSCHKE: -- and maybe Report 44 is in there. But again, you can basically go back up and look at either the summary -- the Wanda version here and you can see the from 2009 or from 2010 to now, you can see there's been 5, 10, depending on whether or not report PER-18 is included, findings that have been added since.

CHAIR MUNN: True. Now, it would be -- I was going to do this if we had time to do it later, but this is an excellent time for us to use the status filter to bring up all the open items to see if there's any way that

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

we can specifically bring those up a little higher in our priority list, if it's feasible to do that so that we get a better feel for exactly what we have open that we have not addressed at all. We haven't done that in six or eight months, and it looks like we have IG-1 with a bunch of them open. MARSCHKE: We can basically MR. order them.

CHAIR MUNN: Yes, we have -- PER-3 five. PR-3, has PER-7 has that one. surprises me, we have done a lot with that but it still has one open.

have OTIB-13 open. We have three open Paducah 37, a couple on Rocky, 38, eight on Hanford 39. That's interesting.

MR. MARSCHKE: I don't know if this is correct.

CHAIR MUNN: Well, if it's not correct, then the data isn't where it needs to be as far as status is concerned, so it might be wise for us to take a look at those.

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

Stu, Brant, do you have any thoughts about those open items that we show on the list? Yes, one thing that I DR. ULSH: asked Elyse to do for specific documents this time was to go through and make sure that the findings in the Board Review System were up to date, the status of them. At the appropriate time, whenever 10 you want to during this meeting, I think, you know, I'll ask Elyse to report what she has 11 found, but we can also make that a priority 12 13 for the next meeting as well. I think that there's going to be 14 15 history, some actions that have been 16 taken on some of these findings that have not yet been loaded into the Board Review System 17 and we can make a list of those. 18 19 CHAIR MUNN: Is Elyse on now? DR. ULSH: Elyse, are you there? 20 Yes, yes I am, and MS. THOMAS: 21 I've started that, but I don't really have 22

anything yet to report, but I'll have
something by the next meeting. It really just
means going through a lot of different
documents to, you know, see what the current
status is.
So it's just time-consuming, but
you know, I'll go through that for next time,
so I have something to report for next time.
DR. ULSH: This is one of those
things where I think perhaps since we are not
going to be changing the status, we can report
to Steve, you know if we find some that are
out of date, because Steve will be the one to
change them or someone on your side will be
the one to
MR. HINNEFELD: Well, we'll change
it at the meeting, right?
MR. MARSCHKE: Usually we wait
until the meeting.
DR. ULSH: That's true.
CHAIR MUNN: Well, if we find
situations where we have at some meeting done

something and it just for some reason is not being accurately reflected in the database, then there is no reason why that can't be taken care of. But, yes, you're right --

MR. MARSCHKE: It's your call, Wanda, if that's the way you want to -- I would prefer to keep a list of them and then do it -- maybe to bring that list to your attention at the next status meeting and kind of do a real quick look at it, so that the Board is aware, or that the Subcommittee is aware when the BRS statuses are changing.

MR. KATZ: But that's not necessary if this is -- if the -- if the Subcommittee has already taken its action and it's just that it's not correct in the system.

DR. ULSH: Well, yes, I tell you what we'll do. We'll -- at least we'll proceed with our work, and when we are at a reasonable point, we'll send an email to you, Wanda, and to you, Steve, and you can decide whatever you want to do with it.

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	CHAIR MUNN: Great, that's great.
2	My note is that Elyse is on the hot seat for
3	next time as far as accuracy of the database
4	is concerned.
5	DR. ULSH: Elyse is always on the
6	hot seat.
7	CHAIR MUNN: Thank you, Elyse.
8	MEMBER ZIEMER: Am I understanding
9	this correctly? On the first one there for
10	example, there's seven of them listed even
11	though there should be eight open. Is that
12	how to understand this?
13	MR. MARSCHKE: Well let's go to
14	some time to think. That would be kind of a
15	different there may be a difference between
16	active finding because again, going back,
17	Paul
18	MEMBER ZIEMER: Active and open may
19	be different.
20	MR. MARSCHKE: Active and open may
21	be different.
22	MEMBER ZIEMER: I got you, yes. In

1	other words it may be open versus what, in
2	abeyance?
3	CHAIR MUNN: Well, in process.
4	MR. STIVER: In abeyance would
5	still be considered active.
6	MR. MARSCHKE: In process
7	CHAIR MUNN: In process would be
8	open.
9	MR. MARSCHKE: may also be
10	active.
11	MEMBER ZIEMER: Gotcha.
12	MR. MARSCHKE: And I don't know
13	what we determined transferred and I guess
14	CHAIR MUNN: We said transferred
15	and in abeyance and addressed would be
16	would not be considered active.
17	MR. MARSCHKE: So basically the
18	active was just the open ones and the
19	CHAIR MUNN: It was open and in
20	progress.
21	MR. MARSCHKE: in progress ones.
22	So

MR. STIVER: Steve, I've got a
quick question for you. When I click on the
little plus sign over on the right-hand column
under IG-001, all I get is a note that the
Subcommittee on Procedures Review I'm not
getting a list of the open findings.
MR. MARSCHKE: Where are you?
MR. STIVER: I was just looking at
that same document, OCAS-IG-001. Now if I
click on the little icon, the little negative
<del></del>
CHAIR MUNN: The little plus?
MR. STIVER: the little minus
sign and a little plus, I'm not getting a list
under there of the findings. Back out one
level. Right there, see, now click the little
blue icon there.
MR. KATZ: To minimize.
MR. STIVER: Yes, minimize it.
MD MADCGIRE THILL GO OFFI
MR. MARSCHKE: It'll go away.
MR. STIVER: Yes, open it up. You

MR. MARSCHKE: Did you do a sort?

Basically did you do the -- have you done the status filters -- have you done a filter?

MEMBER ZIEMER: Sort on open.

MR. MARSCHKE: If you did a filter on the open -
MR. STIVER: It's strictly pilot

MR. STIVER: It's strictly pilot error then. Okay.

MEMBER ZIEMER: There it is.

MR. STIVER: Yes, there we go. Strike that from the record, please.

(Laughter.)

CHAIR MUNN: That wasn't said. Could we then leave as an item for NIOSH to specifically review the open items that we have from this sort and identify whether these are actions that we can begin to address, or if for some reason, these, although they are shown as open, cannot be or should not be worked at this time? Just in an effort to try to identify the level of concern that we have with respect to these open items we haven't

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

addressed.

10

11

12

13

14

15

16

17

18

19

20

21

22

DR. ULSH: Okay, hold on a minute.

I have as an action item for us to review the status of the findings and make sure they're correct.

CHAIR MUNN: Yes.

DR. ULSH: Is that what you're saying?

CHAIR MUNN: Correct, and the second thing I'm asking is that you review them for their meaningful nature.

DR. ULSH: Okay.

CHAIR MUNN: That is to say should we be addressing these? Do we need to be closing these open items? Statistically it looks like we should be closing some of these open items, but statistics are only the first blush. If these are of such a nature that it would be creating a problem for extremely current work for us to begin to close them, then we need to know that. If not, then we'd like you to assess, that is I would like you

### **NEAL R. GROSS**

to assess whether we need to be paying some attention to these. Is it time to move these up on your list of priorities? MEMBER ZIEMER: So you're asking whether they have an importance level that we should do something now versus just leave it on the back burner? CHAIR MUNN: Exactly. MEMBER ZIEMER: I got you. 10 KATZ: And you want DCAS to those determinations as 11 make to what your priorities should be? 12 13 MR. HINNEFELD: Well, we'll know for instance if there's a finding against the 14 15 procedures -- or process -- you know, things 16 not being done anymore. 17 MR. KATZ: I see what you're 18 saying. 19 HINNEFELD: We'll be able to say things like that. I don't know that we 20 would suggest prioritizing beyond that very 21 much. 22

1	MR. KATZ: Right.
2	CHAIR MUNN: Yes.
3	MEMBER ZIEMER: It's sort of like,
4	well, even if you don't close this, it doesn't
5	affect anything.
6	CHAIR MUNN: Yes, and I think
7	MEMBER ZIEMER: Because we're not
8	doing that or
9	CHAIR MUNN: the Subcommittee
10	needs to know that. We need to have some feel
11	for whether these are important, and are being
12	overlooked, or whether it's
13	MEMBER ZIEMER: Well, particularly
14	if you can do that easily.
15	CHAIR MUNN: Yes.
16	MEMBER ZIEMER: Just look at it and
17	say there's no particular problem if we delay
18	any action on this item, so that we can focus
19	on things that are critical.
20	MR. HINNEFELD: It's a part of the
21	other. It's an add-on to the original task.
22	CHAIR MUNN: It is. It is.

MR. HINNEFELD: The original task was let's see if the statuses are right and by what we think -- see if we think they are current and up to date. One thing that should be clear is some in abeyances might be ready to be closed, if we issue the revised document. So that's one thing.

And then -- but then following onto that, of the ones that statuses are open, are there any in there that we feel are unimportant or not relevant anymore and that we would suggest maybe these aren't worth the effort to resolve.

DR. ULSH: Okay. I gotcha.

CHAIR MUNN: As I understand, for example, IG-001 was a very, very early one, even though we are looking at Rev 2 in these findings.

MR. MARSCHKE: This was like the second review by SC&A of IG-01. We reviewed Rev 1. I believe it was Rev 1. And we had a bunch of findings on that, and you can see

### NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

that those have all been taken care of, at least they're no longer open, and then we went through and did a second review of Rev 2 of IG-01 because I guess it's a very important procedure.

CHAIR MUNN: It is.

MR. MARSCHKE: And we really

MR. MARSCHKE: And we really haven't talked about -- all these findings being shown as open means we really haven't even talked about that second review from SC&A yet.

CHAIR MUNN: And if we have not, the question for NIOSH is are you now ready to talk about those? Is it something that we need to --

MS. THOMAS: This is Elyse. If I can jump in here.

CHAIR MUNN: Please do.

MS. THOMAS: That is one that I did look at, as I mentioned. I did start this work. I am just not ready to report everything.

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

But if you look at all the NIOSH responses for the Rev 2 review, Rev 3 has been issued. So I would suggest that, you know, the step here now is for SC&A to look at Rev 3 to see if those items have been addressed in Rev 3 as NIOSH is saying they are. CHAIR MUNN: Probably. THOMAS: Do you see what I'm saying? Yes, if these -- if CHAIR MUNN: these are all essentially items that were a result of -- that were pushing Rev 3, and Rev 3 has incorporated them, then we need to know that. MR. KATZ: That's fine. So that's just an example --CHAIR MUNN: Yes. MS. THOMAS: Yes. MR. KATZ: -- of the updating that we are looking for because we can't really task SC&A until we know what's on base. Exactly. CHAIR MUNN:

# NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

10

11

12

13

14

15

16

17

18

19

20

21

1	MS. THOMAS: Right, exactly.
2	MR. KATZ: So, right.
3	MS. THOMAS: So that's that's
4	just one that I'm familiar with because I did
5	look at that one.
6	CHAIR MUNN: Good.
7	MR. MARSCHKE: I believe Kathy
8	Behling I think did the review of IG-01 and
9	maybe, Hans, maybe you did it as well, maybe
10	you were involved with it as well.
11	But I mean if you want to take an
12	action if you want us if the
13	Subcommittee wants SC&A to take an action item
14	and look at Rev 3 of IG-1 and see whether
15	how much it addresses these
16	MR. KATZ: Remaining open items.
17	MR. MARSCHKE: the remaining
18	open items before the next meeting, we can
19	actually do that.
20	MR. KATZ: That's fine. Might as
21	well. Might as well pick it up since it's
22	been raised.
	1

DR. MAURO: Ted, this is John.

MR. KATZ: Yes.

DR. MAURO: This cascade effect which I think is good, what's happening here, should this be something that would be automatic? That is, given that we have an active review, for example Rev 0, when we -- and if we are watching the store and Rev 1 comes out, should we automatically go into -- and do it, or should we await direction from the Subcommittee?

CHAIR MUNN: Well, I think direction is in order, personally.

DR. MAURO: Okay, so we don't take any action on Rev 2, 3 -- this will be like a general, you know, fundamental protocol, that though there may be a new revision of a particular procedure that has been issued in the interim, that may very well have addressed many of the issues, we don't look at it or take action on it until we are authorized to do so by the Subcommittee?

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

CHAIR MUNN: I believe that's been the general process in the past. DR. MAURO: Okay. That's good, but then we MR. KATZ: need -- so we need notice when there's a new rev of something. MR. STIVER: Well, yes, I could see that happening where a new rev comes out just right after a meeting and --10 MR. KATZ: Well just so the matter sit there forever before 11 doesn't even realize it, but --12 13 DR. ULSH: I think the way that that would work would be -- like for instance, 14 15 okay, SC&A has some findings on a particular 16 document. We do a revision in response. So if we go in to respond in the 17 18 Board Review System, we should let you know, 19 hey, we've added some responses. We should this 20 probably add to the Procedures Subcommittee --21 MR. KATZ: Right, it should be on 22

the agenda for the next meeting. Right. That would be great.

MR. MARSCHKE: Yes, because I don't think we've always been following that. Because I remember on OTIB-52, Rev 1 of OTIB-52 came out, and I don't think -- and SC&A reviewed that to see how it would -- and it's on the agenda for later this afternoon.

But I don't think -- I think we just took that on our own initiative to see how it addressed the findings that were with Rev 0. So -- but this is, you know, more formal, a little bit more formal if we go through the Subcommittee.

CHAIR MUNN: Well, I thought we had discussed 52 though, at the time that the new rev was coming out. I thought we had it here on our agenda at one point. Perhaps I was wrong.

MR. MARSCHKE: Could be, I don't -CHAIR MUNN: I don't know.

MR. MARSCHKE: I don't know.

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	DR. ULSH: Well, it just seems to
2	me that any time, at least on our side, that
3	we put a response in the Board Review System
4	we should shoot you notice that we
5	MR. KATZ: Put it on the agenda and
6	then we don't have to wait until a
7	Subcommittee meeting to task you but
8	MR. MARSCHKE: Okay.
9	MR. KATZ: It's going to be on the
10	agenda and you would be prepared to address
11	it.
12	MR. MARSCHKE: Right, yes.
13	MR. STIVER: As long as Wanda is
14	notified and then we can
15	(Simultaneous speaking.)
16	MR. MARSCHKE: Going forward that's
17	the way we can
18	CHAIR MUNN: That'll be fine.
19	MEMBER ZIEMER: One other question
20	on this summary findings table, where there
21	are items indicated as being active I'm
22	looking for example at the one called

processing claims for construction workers and there are 10 active items, but there's no list under it. Does that mean none of them are in the category that we call open?

In other words, the only ones showing up in the grey bars are the open items.

CHAIR MUNN: Yes.

MEMBER ZIEMER: So if there's active items but there's no list underneath, I'm assuming that means the active items are in categories other than open.

CHAIR MUNN: They should be in progress, then, if that's the case.

MEMBER ZIEMER: Maybe Elyse, when she reviews this -- do you understand what I'm saying, Elyse?

MR. MARSCHKE: I understand what you're saying. I don't -- I, again, we've had problems with the active finding columns and I don't know how this is -- if you go down construction worker, OTIB-52, you go down

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	here, basically there should not be any you
2	are correct, there aren't any open ones
3	MEMBER ZIEMER: Well, we've sorted
4	for opens and none are listed
5	MR. MARSCHKE: So why does this one
6	even show up on the sort?
7	CHAIR MUNN: Well it should be that
8	they are in progress then.
9	MR. MARSCHKE: But we sorted we
10	filtered on open so why is this why is this
11	document even showing up on the table?
12	MEMBER ZIEMER: why are some of
13	these showing up without open items?
14	CHAIR MUNN: Well, because it has a
15	heading for total active findings, and
16	MEMBER ZIEMER: But we sorted for
17	opens
18	CHAIR MUNN: We sorted for opens
19	and open gave us the total findings and the
20	total active findings.
21	MS. THOMAS: This is Elyse, and I
22	think some of them may be that there was no

initial NIOSH response. There's not a lot of those, but there are a few where, like for example, in a document that may have had, you know, five or six findings, we provided responses for — or NIOSH provided responses for maybe four of those, and there's maybe one or two that, you know, we still haven't provided a response for.

So it may not -- it may be open but there's not a response, or maybe it was never given the status of opened to begin with.

MEMBER ZIEMER: Well yes, but see, that's what's a little puzzling, if it's not given the status of open, why does it show up on the sort, because if you're sorting against that category --

CHAIR MUNN: Well, open should be an automatic category. If we haven't addressed it, it's open.

MS. THOMAS: Yes, it's -- I was just thinking maybe it's because there's a finding but no response and so there's no

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	status of
2	MEMBER ZIEMER: Well, it's almost -
3	-
4	MR. MARSCHKE: There's been
5	responses on on 52, the one that Paul
6	pulled up, there's been a number of responses
7	back and forth between NIOSH and SC&A. This
8	has been going on since quite a while.
9	MEMBER ZIEMER: There were 16
10	original findings, and there are 10 active,
11	but none show up as being open. That's what's
12	a little puzzling.
13	MR. STIVER: If you look on in
14	progress though, it's giving you the right
15	information, 13 and 14 show up there.
16	MEMBER ZIEMER: Where is that?
17	MR. STIVER: If you filter on in
18	progress.
19	MEMBER ZIEMER: I see, okay. Okay,
20	so it does mean that they are not open in the
21	usual sense, but they are active.
22	DR. ULSH: Okay, if I can maybe

perhaps look at the forest through the trees here. It seems like a priority item for us is to again check this column of total active findings and see --

MEMBER ZIEMER: Maybe it's sorting active versus open.

DR. ULSH: Yes, there's something going on there still. We thought we had it fixed, but we apparently don't have it fixed. So that will be a priority item.

The second priority item is to look at all of the findings that are still out there and make sure the statuses are up to date, current, accurate. And I think once we do that, maybe it will at least cut down on the number of problems that we are trying to deal with here.

MR. MARSCHKE: The other thing I can like, say, on this sort, on open items is it's showing DCAS-TIB-10 as having -- everything is open, all the nine issues as being open.

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	I think when it was OCAS-TIB-10, I
2	think we have, we have addressed a number of
3	those. So you have when Elyse goes through
4	this, she might want to look, I think a lot of
5	those open ones that are associated with DCAS-
6	TIB-10 will go away, if you look at what was
7	done on OCAS-TIB-10.
8	DR. ULSH: Okay, that goes back to
9	the problem that we were having with the
10	DCAS/OCAS
11	MEMBER ZIEMER: Yes. Yes.
12	MS. THOMAS: Yes, and I think that
13	isn't that an item a little bit later on in
14	the agenda?
15	CHAIR MUNN: Yes, we do have 10.
16	MS. THOMAS: Yes, because I do
17	that is another one that I looked at
18	carefully, and I have, you know, suggestions
19	as to which one should be closed, in abeyance,
20	or in progress or whatever.
21	I sent those to Brant in an email
22	so we can talk about that when it comes on

further on in the agenda. CHAIR MUNN: Yes, it's in our carryover items. All right. Are we all on the same page with respect to what our action items are for next time? Good. Anything else, Steve? (No response.) CHAIR MUNN: Anyone else have anything they want to say about the database, 10 where we are, other than applause and gold ribbons? 11 (Laughter.) 12 CHAIR MUNN: Then let's move on to 13 item of business, which is the 14 our next 15 OTIB-70, status of the database entry review 16 for accuracy. Mutty was going to take a look at 17 that. NIOSH has a report. 18 19 DR. ULSH: Mutty, you still there? MR. SHARFI: 20 Yes. KATZ: You're hard to hear, 21 MR. 22 Mutty.

MR. SHARFI: Can you hear me now? MR. KATZ: Oh, yes. Perfect. CHAIR MUNN: Yes, good. So I don't know if you DR. ULSH: heard, Mutty, we are on the OTIB-70 agenda item. MR. SHARFI: And the question for me is? CHAIR MUNN: Our notes from our 10 last meeting said that you were going to review the status of the entry for accuracy, 11 to see if OTIB-70 was being reported properly. 12 13 Do we have what we need in our official database? 14 15 MR. SHARFI: The only thing that I 16 have to verify was on the revision, there was a question about whether or not the 10 to the 17 18 minus 6 resuspension was more of a guidance 19 document in the revision, and I did verify that was true. 20 The revision has been approved, so 21 that is now out there. 22

1	MR. MARSCHKE: So there's a revised
2	OTIB-70, recently revised OTIB-70 out there?
3	MR. SHARFI: Yes.
4	MR. MARSCHKE: That addresses some
5	of these
6	MR. SHARFI: Should address all of
7	them.
8	MR. MARSCHKE: Should address all
9	of these so this should be the same thing
10	as we did for IG-1? We should basically take
11	a look at the revised OTIB-70 and see whether
12	we concur that it does address all the in
13	abeyance findings?
14	MR. SHARFI: Yes.
15	CHAIR MUNN: Yes. It appears so.
16	It looks like the action is now SC&A's. Good.
17	That was quick and easy. At least we don't
18	have to spend 15 minutes on that.
19	The status of the PERs. We have
20	three of them: 008 transcript notations. The
21	last time Ted had said he was going to send
22	those over to Science Issues and it hadn't
	i

happened.

10

11

12

13

14

15

16

17

18

19

20

21

22

MR. KATZ: No, I copied you sending those to Dr. Richardson.

CHAIR MUNN: That is done. And a written notation due to LANL Working Group. I started to do that last week and discovered that one of the wonderful things our database does for us now, is it gives us all the links when we pull up -- we have the PDF file issued so we now can do that, but it also gives us the links that we need for -- these things have been transferred to another procedure.

So my -- what I was going to do, then, which was only forward the two outstanding items. By the way, the Work Group Chair already knows this and the Work Group has assumed this responsibility. This is just a formality of my getting this in writing so that we have it for the record.

I had a little trouble getting the PDF file that I wanted to the links up there. But that's happening. It just has not

### **NEAL R. GROSS**

happened yet.

10

11

12

13

14

15

16

17

18

19

20

21

22

The other item is PER-20 and NIOSH was going to check to see whether any claimants were being affected by those two items that we had on that -- on the Blockson PER.

MR. HINNEFELD: Well, I'm only preliminarily done with that, and maybe, SC&A may -- I'll tell you what I get in and maybe SC&A may have some comments on whether this is sufficient.

The findings here related to the choice of class and solubility as the solubility of uranium at Blockson. DCAS's position is that the process that was used at Blockson would generate Class M uranium and there wasn't a heavy -- a high roasting, a high temperature roasting that would maybe make it Class S.

CHAIR MUNN: There wasn't. There wasn't.

MR. HINNEFELD: And so that's the

# **NEAL R. GROSS**

nature of the finding. The findings are that if you use Type S, then these doses, you know, the PER calls everything Class M so there would be some doses would be higher if you used Class S. And that's a true statement.

And so I said, you know, it's not clear to me that anybody would even be affected if you used S or M because by and large that is a respiratory tract, lung and respiratory tract target organ. It wouldn't be an issue there.

So what I did was I took the list of all the Blockson claims that had a dose reconstruction with a PoC of less than 50 percent and looked for claims that would have had either lung, ET 1 or 2, or LNPH, or LNEP, probably, but I don't think any of them did

In other words, had internal target organ that were Class Y -- Class S, Class S now, would cause a higher dose. There are about 12. Eleven of those are SEC cancer cases and they all have sufficient -- they all

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

have a year of employment.

There's one claim that has -- that is a Hodgkin's disease, which is a non-SEC case, Hodgkin's disease in the supraclavicular lymph node, so the target organ is LNE.

So that's the one. There is one that might be affected and that's as far as I've gotten. I haven't determined whether it would actually determine, you know, change it or not.

MR. STIVER: Whether it would be a change or not, yes.

MR. HINNEFELD: Yes. So we haven't gone that far yet.

MR. STIVER: Okay.

MR. HINNEFELD: And we have verified that the 11 that should be SECs were actually before the SEC -- because these were dose reconstructions that were done before the Class was added. So we won't necessarily now. We'd have to send those to Labor to see if they actually made it.

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

So that's where we are now. Our position is still that it was Type M, that it was Class M uranium and I have tried to find - - what I've been studiously doing here is doing this and looking at transcripts from Blockson Work Group. The last discussion I saw that talked about anything other than radon was on October 15th of 2008.

At that time Bob Anigstein expressed reservation about whether Class M was really the right way to go or whether there should be some consideration of Class S.

That's the last thing I saw. Jim

Neton said at that meeting, "Well, we've

established long ago that this is a Site

Profile issue, and this was all SEC

discussion," and so on. I couldn't find that

it actually went farther than that.

MR. STIVER: If there was any resolution to that.

MR. HINNEFELD: Yes. That I can't find out. Our opinion still is that it was

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

Class M uranium that came out of Blockson. CHAIR MUNN: That was certainly the opinion of the Blockson Chair. I can tell you. HINNEFELD: That's where we MR. are. MR. STIVER: So the next step is to reevaluate --MR. HINNEFELD: There's -- yes, I 10 mean, we can -- the two ways to go here are to drag back out the evidence for Class M versus 11 Class S in a future meeting and try to work 12 13 through that. Or the possible shortcut is to take 14 this one case and say, okay, if it were 15 16 reworked with Class S material, would See, the person had, oh, somewhat 17 change? less than three years of employment. 18 It might 19 not change. 20 So I mean we can -- we'll do that, but that's, that's a possible shortcut, 21 which case we would say none of the claimants 22

would be affected.

CHAIR MUNN: It would be my suggestion that we do exactly that, unless there's strong opposition to that position.

DR. MAURO: This is John. To add a little bit to that, the reason we could take this quick approach, I mean, rather than have to resolve the fundamental issues, is: I think the Blockson situation was unique to Blockson. It wasn't that the issue of M versus S that we had before us was one that had far-reaching implications. I think that it probably was something that we expressed concern over that was specially unique to Blockson and what they were doing there.

And so all I am really saying is that by dealing with it in a more practical way, the way Stu just described, you know, is a quick way to expedite the process without, you know, needing to go to the Board arena.

MR. STIVER: John, this is John Stiver. I wasn't around for the Blockson

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

discussions. This is kind of a pre-employment period for me.

What was the issue, without having to drag all this out again, if you could just

DR. MAURO: Yes, bottom line you've got the phosphogypsum material coming up from Florida, being processed for uranium using a relatively unique methodology --

kind of give the 30-second sound bite?

CHAIR MUNN: All wet-process.

MR. STIVER: Oh, okay. All right.

CHAIR MUNN: All wet-process.

DR. MAURO: And it generated what we were calling yellowcake but it was a unique form of yellowcake, and our position was well, is it going to be Type M or Type S?

And typically NIOSH would assume the worst, but in this particular case I believe you adopted -- Jim felt strongly that no, this stuff is Type M, all right, I'm familiar with it, this is a special problem and it's Type M.

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

And that's where we left it, and we still had this concern that maybe, you know, it's -- if a person has respiratory cancer you should assume it's S, because that would of course give you a -- and we left it there.

But the material itself, when we studied it, it became apparent that it wasn't your classic U308. It had its own unique characteristics because of the way in which it was produced.

MR. STIVER: Okay, that satisfies me. That makes sense from a chemical standpoint.

MR. HINNEFELD: One additional thing to keep in mind is, you know, those of us who have been in health physics probably will remember the last classification of solubilities, which was days, weeks and years, D, W and Y, where W was the intermediate.

The Type M now, which now stands for middle, actually shows a much longer retention in the lung than the old Class --

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	actually pretty close. The retention is
2	actually pretty close to the old Class Y.
3	So you know, from our standpoint,
4	you know, when you think about this, you don't
5	want to translate W to M necessarily, because
6	they don't it's not really the same model.
7	MR. STIVER: It's not a one to one
8	correlation.
9	MR. HINNEFELD: The model stretches
L O	it out, and the retention is longer for M than
11	the old model, the W.
L 2	So in our view, M covers this
L3	material. There was some drying done. It
L 4	wasn't like it was never heated. It was
15	filtered and then dried, but that's the extent
L 6	
L 7	(Simultaneous speaking.)
L 8	MR. STIVER: But it wasn't hardened.
L 9	MR. HINNEFELD: That's the extent
20	of the heating that was applied.
21	CHAIR MUNN: No, it was not
22	hardened. The drying wasn't in the process.

1	MR. STIVER: Well, I'm satisfied
2	with that explanation, so I think we can leave
3	it
4	MR. HINNEFELD: You know, if we do
5	the lung and using Class Y would change it,
6	then we are back in here talking. But if it
7	doesn't change it, then we're done.
8	MR. STIVER: Yes, that sounds like
9	the best approach, do the shortcut.
10	CHAIR MUNN: All right. Very good.
11	MR. KATZ: So, we'll check on this
12	at the next meeting.
13	CHAIR MUNN: Yes, we will.
14	MR. HINNEFELD: I'll send I'll
15	try and send
16	MR. KATZ: I'll send an email
17	before.
18	MR. HINNEFELD: I'll try to send
19	the report before.
20	MR. MARSCHKE: These issues are in
21	the BRS and so if you really just want to put
22	your response in the BRS, then

MR. HINNEFELD: And then send an email that says -MR. MARSCHKE: And send an email. The next item that I CHAIR MUNN: inserted here didn't have to do with PERs. Ιt was OTIB-54 that had it brought to my attention, we had an action on it and I'm not sure exactly what action we had on OTIB-54. Can you help me out, Ted? 10 MR. KATZ: No, all I can say is I don't know whether there's something ready to 11 be discussed, but it's still in progress. 12 13 DR. ULSH: Is this the one I sent an email on? 14 15 KATZ: I think you did. MR. 16 think you said you're not ready. DR. ULSH: Right. The status on 17 this one is we owe a revision of OTIB-54 to 18 19 address some of the comments. I think the comments are largely in abeyance and we are 20 see whether the revision just waiting to 21

22

addresses those.

1	But we have not yet completed that
2	revision. It is ongoing. We have made a lot
3	of progress. But it's not finished.
4	MR. HINNEFELD: It's not finished
5	yet.
6	MR. KATZ: So, I just I keep
7	these on the agenda until they're
8	CHAIR MUNN: Yes, that's wise.
9	MR. KATZ: until they're cleared,
10	that's all.
11	DR. ULSH: I don't want to
12	interrupt, but Wanda, before you move on to
13	the next
14	CHAIR MUNN: Yes, please.
15	DR. ULSH: Okay. While we were
16	talking I emailed Tom James with the problem
17	about total active findings definition. He
18	reported back that it is now fixed.
19	Steve did a quick spot check and it
20	looks like it
21	MR. MARSCHKE: Basically OTIB-54 up
22	there, the third one down, the one with the

1	finger on it, before it had 26 total and 26
2	active, and now basically with the fix it's
3	got 26 total and 9 active.
4	So, and then if you click on it,
5	and go to the detail, you can see I don't
6	know if you want to count the ones that are
7	active, but there are a few in progress ones.
8	I think John, you had counted up
9	nine
10	MR. STIVER: Yes.
11	MR. MARSCHKE: before so that
12	seems to be so that portion of the database
13	seems to be working.
14	DR. ULSH: Well, that was a quick
15	fix, according to this one spot check.
16	MR. STIVER: Based on a sample size
17	of one.
18	(Laughter.)
19	CHAIR MUNN: It's better than the
20	sample size we had.
21	MR. STIVER: That's true.
22	MR. MARSCHKE: So what you're
	NEAL R. GROSS

1	saying is basically all these nine that are in
2	progress, you expect to have a resolution to
3	in the next revision, or
4	DR. ULSH: I expect to have a
5	response.
6	MR. MARSCHKE: Response.
7	CHAIR MUNN: Do you think the
8	revision will be done by the time we meet two
9	months from now?
L O	DR. ULSH: I don't know. It's
11	quite a complicated revision.
12	CHAIR MUNN: Okay.
L3	DR. ULSH: There are a lot of
L 4	CHAIR MUNN: Okay, we'll just ask
15	for a status on our revision next time.
L 6	DR. ULSH: a lot of reactor
L 7	modeling type
L 8	CHAIR MUNN: Okay.
L 9	MR. STIVER: This is the mixed
20	fission products issue. It's going to be a big
21	one.
22	CHAIR MUNN: Yes. It is

complicated. All right. That's a good thing. We are a little ahead of schedule. MR. KATZ: So I'll check before we put out the agenda, the Federal Register notice for the next, as to whether you think it will be on the agenda. CHAIR MUNN: Yes. That'll be good. We'll have it on the agenda and your response will determine what we have on the agenda. 10 Thank you both. 11 ahead and start the Let's go carry-over items and see if we can get one or 12 13 two out of the way on TIB-10, updated database 14 status. 15 had a note to question Brant 16 whether the updates were made, specifically on Finding 8, something about correction factor 17 18 on MCNP. 19 MR. MARSCHKE: I think this might have been what we talked about, what I started 20 talking about a little bit earlier on the OCAS 21

versus DCAS problem, and when you get into --

I mean, right now, the document that is in the database is DCAS-TIB-10. I believe we did our review on OCAS-TIB-10, which I think DCAS is a little bit more generic than OCAS but -- and I also believe that we had resolved, or at least I know we discussed, so there wouldn't be any open any longer, many of the OCAS-TIB-10 findings.

SC&A did not explicitly review DCAS-TIB-10. We --

CHAIR MUNN: DCAS-TIB-10 is the glove box workers.

MR. MARSCHKE: Right. Well, OCAS-TIB-10 was also glove box workers. You know, this -- what I believe these are, these findings that are in here for DCAS-TIB-10 are the OCAS-TIB-10 findings, but the statuses from the OCAS-TIB-10 findings, I don't think the statuses are correct for the -- as I recall.

CHAIR MUNN: When I search for OCAS-TIB-10, what I get is DCAS-TIB-10.

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	DR. ULSH: That's all I'm getting.
2	MR. MARSCHKE: That's right, that
3	OCAS-TIB-10 is not in the database. I mean,
4	and it would be a duplicate, I mean, because
5	DCAS-TIB-10 basically was a replacement, as I
6	understand it, of OCAS-TIB-10.
7	MR. HINNEFELD: It was the earlier
8	rev. it would be Rev 2 or Rev 1.
9	MR. STIVER: So we have reviewed
10	Rev 0, essentially.
11	DR. ULSH: All right this is one
12	where this document, DCAS-TIB-10 I asked
12	where this document, DCAS-TIB-10 I asked Elyse to go through and check the status of
13	Elyse to go through and check the status of these findings. It's one that we had to
13 14	Elyse to go through and check the status of these findings. It's one that we had to actually go back and load the findings in
13 14 15	Elyse to go through and check the status of these findings. It's one that we had to actually go back and load the findings in
13 14 15 16	Elyse to go through and check the status of these findings. It's one that we had to actually go back and load the findings in manually into the Board Review System.
13 14 15 16	Elyse to go through and check the status of these findings. It's one that we had to actually go back and load the findings in manually into the Board Review System.  Elyse, do you want to walk through
13 14 15 16 17	Elyse to go through and check the status of these findings. It's one that we had to actually go back and load the findings in manually into the Board Review System.  Elyse, do you want to walk through it or do you want me to?
13 14 15 16 17 18	Elyse to go through and check the status of these findings. It's one that we had to actually go back and load the findings in manually into the Board Review System.  Elyse, do you want to walk through it or do you want me to?  CHAIR MUNN: Go ahead, because we

DR. ULSH: I prefer you. MS. THOMAS: Okay. CHAIR MUNN: Just walk through them one at a time, Elyse, so we know where we are, if you would. MS. THOMAS: Okay. So yes. I'll just call it TIB-10. I did check all the findings with the old Access database so the findings are the same. So --10 CHAIR MUNN: We can stop worrying about that. 11 THOMAS: I quess what 12 MS. 13 reviewed was OCAS-TIB-10. Anyway, TIB-10 Finding 1, I think this status should be 14 15 closed. Let's see. It's -- the Subcommittee 16 discussed this at their meeting on three --March 22nd of 2011, and so in the transcript 17 for that meeting, on page 77, they I think 18 19 decided to close it. So I think this one 20 should be closed, and if you'd like you can open that transcript and check that page. 21 22 MR. MARSCHKE: What was the date of

the transcript, Elyse? MS. THOMAS: It was March 22nd of 2011, and that's page 77. Thank you. MR. MARSCHKE: CHAIR MUNN: And this is finding number one, right? MS. THOMAS: Yes. CHAIR MUNN: That says internal review objective 1, rating 3, the TIB lacks 10 transparency. The radioactive source is not identified, neither is its exact dimensions 11 nor location given, nor is the thickness of 12 13 the walls presented. The TIB lacks transparency. Oh, it repeats itself. 14 15 MS. THOMAS: Yes, everything here 16 says changed to in abeyance. But, like I said, in the transcript --17 18 MR. MARSCHKE: Excuse me. Anything 19 from 2011 would not be in the BRS, I don't 20 believe. looking at the Access, Ι am printout of the Access database that I printed 21 22 out quite some time ago. It has -- it's

1	showing it being in abeyance as well but that
2	was as of August 21st, 2008.
3	CHAIR MUNN: And the current
4	database shows it open so at the very least,
5	you need to change status from open to in
6	abeyance.
7	MS. THOMAS: To in abeyance, at the
8	very least, yes.
9	MR. MARSCHKE: Well, if we, you
10	know what was the let me see. Let me pull
11	up
12	MS. THOMAS: The transcript? Yes
13	it was for the meeting on March 22nd, 2011.
14	DR. ULSH: Hold on, Elyse we are
15	getting the transcript.
16	(Simultaneous speaking.)
17	MR. HINNEFELD: Go to our web page,
18	which is www.cdc.gov/niosh/ocas. Go to the
19	Advisory Board box.
20	MR. MARSCHKE: I know how to get it
21	from here.
22	MS. THOMAS: March 2011.

1	MR. MARSCHKE: Twenty-second, right
2	here. And here's the transcript.
3	MS. THOMAS: Okay, and then page
4	77.
5	MR. MARSCHKE: Okay. 91 is new.
6	It was in abeyance. We recommend that it be
7	closed. Wanda Munn, Chair Munn
8	MR. STIVER: We were recommending
9	that it be closed. I just asked Bob to call
10	in. So he should be getting online.
11	DR. ANIGSTEIN: Yes, I'm here.
12	MR. STIVER: Okay.
13	CHAIR MUNN: "They did provide the
14	information" source, spectrum and
15	dimension.
16	MR. STIVER: In Appendix B.
17	CHAIR MUNN: Yes. So that should
18	be closed. NIOSH just needed an opportunity
19	to look at what it was seeing.
20	MR. MARSCHKE: I don't see I see
21	where Bob recommended it being closed. I
22	don't see where Wanda or the Subcommittee
	1

**NEAL R. GROSS** 

1	actually said this is closed.
2	MR. STIVER: We're not seeing any
3	concurrence here.
4	MEMBER ZIEMER: Go back a little
5	bit.
6	MR. MARSCHKE: Basically, "We
7	recommend that it can be closed. Finding 1 is
8	in abeyance. We recommend that it be closed."
9	And Wanda says, "All right. Again" I
10	don't know if that's concurrence when she
11	says, "All right."
12	CHAIR MUNN: No, it's not, because
13	later Bob says, "The finding is that they did
14	not specify, it had not changed. It was not
15	addressed. Rev. 3 did not address this
16	finding. We were asked to see that it did,
17	and in fact, it did not."
18	MEMBER ZIEMER: As long as your
19	confirmation is that it is appropriately
20	CHAIR MUNN: So I said, "All right.
21	Well, we will stand by our statement that not
22	only item 8, which we have addressed at

1	length, but, also, the other items that are
2	involved in this response will be reviewed by
3	NIOSH and we will see those back here next
4	time, right?"
5	MR. STIVER: I think that's in
6	relation to Finding 9.
7	MR. HINNEFELD: I think that's
8	nine, because one and nine are kind of
9	similar.
10	MEMBER ZIEMER: Item 9, is that
11	MR. STIVER: Look at Finding 20
12	on page 78, starting at Dr. Anigstein.
13	MEMBER ZIEMER: "We are
14	recommending it should be closed?"
15	"Yes."
16	"Okay. I think that should be part
17	of the record."
18	That's John Mauro.
19	MR. MARSCHKE: "The Subcommittee
20	wants to close it at this time, it sounds
21	like, no, you would rather wait and hear back
22	from NIOSH "

1	"Not on 1."
2	"Not on 1."
3	"Not on 1."
4	CHAIR MUNN: Well, this is clear as
5	mud.
6	MR. MARSCHKE: It is pretty clear.
7	MEMBER ZIEMER: I think we were
8	saying 1 was closed and 9 is not.
9	MR. STIVER: There's still some
10	issues on 9, but 1 was closed.
11	MR. KATZ: Right.
12	MS. THOMAS: Yes, you'll see when
13	we get to 9, NIOSH did provide more
14	information. So I interpreted that to mean
15	for Finding 1 as well.
16	MR. MARSCHKE: So, basically we
17	should go in and edit the status of Finding 1
18	and change the status to closed, as per the
19	March 22nd meeting Subcommittee meeting
20	minutes transcript.
21	CHAIR MUNN: Correct. Well, you
22	see, Stu said, "John, my recollection of the

situation is that it was that passage was supposed to come --" is that passage we are talking about 1 here again? No, 9.

MR. STIVER: Yes, they are kind of going back and forth on 9 and 1 here.

CHAIR MUNN: Back and forth between 1 and 9. "That passage that was supposed to come out in Rev 3. It is a recommendation to remove something. Apparently it just got moved to an appendix. So, we will have to check on that."

And Bob said, "I held Rev 2 and Rev 3 side by side and there was absolutely no difference except for changing a figure, number and reformatting a table and adding the appendices. The main body of it was word for word."

"I expected it to come out, and I don't think you will see my signature on there."

"We will close No. 1 and everything else that is on this current report we are

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	looking at will be reviewed by NIOSH, and we
2	will have your report next time."
3	But we didn't get it next time.
4	Right?
5	MR. STIVER: Yes, so 9 is still in
6	question.
7	DR. ULSH: Bob, do you want to get
8	out of order
9	MS. THOMAS: Well, do you want to
10	go on to 2, or do you want to go on to 9?
11	MR. STIVER: Just jump to 9, since
12	it's related?
13	MS. THOMAS: Okay.
14	CHAIR MUNN: Are the others still -
15	_
16	MR. MARSCHKE: Well, wait a minute,
17	I mean, why don't we just go through them in
18	order?
19	CHAIR MUNN: Yes, let's do.
20	MS. THOMAS: Okay.
21	CHAIR MUNN: Let's make sure that we
22	are getting them, since we have we

originally had 2 in abeyance and that's not what we have now, right? MR. MARSCHKE: Based upon -- again, based upon the old Access database, as of 2008, it was in abeyance. DR. ULSH: Okay. Elyse, do you want to talk about Finding 2 now? MS. THOMAS: Finding 2, Yes. again, I am suggesting, should probably still 10 be in abeyance. However there is a new NIOSH response in the Board Review System, and it's 11 dated 11/1/2011. 12 13 So that response must have been distributed by an attachment to an email. 14 In other words, it wasn't able to be entered in 15 16 the Board Review System when it was originally written. 17 But the date on the document is 18 19 11/1/2011. And so I kept that original 20 response date when I put it into the Board Review System, if that makes sense. 21 22 in other words, it is a new

response in the Board Review System but I guess it was originally distributed back in 2011.

That's for Finding 2.

MR. KATZ: Right, so can we pull that up?

MR. MARSCHKE: It's right here.

MR. STIVER: It's just out of order.

MR. MARSCHKE: It's just out of order.

DR. ULSH: Okay, I know who wrote this. That would be me. That's what I thought. I just wanted to read it first before I -- basically, to look at the big story on this document, it's the glove box TIB and SC&A questioned some of the MCNP runs that we added to address their concerns, and after going round and round about this, I just decided that the appendices, the additional MCNP runs, did not really -- they weren't necessary for the TIB. We just added them to

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

respond to SC&A's comments.

They didn't serve that purpose. They wound up raising more issues than they solved. So we issued Rev 4 where we took that material out and you see that here in the response. So that's kind of what's going on.

MR. MARSCHKE: As I recall, when Bob looked at this, he looked at the MCNP -- he looked at the attachment. Bob, correct me if I'm wrong. I don't want to -- but he looked at the attachment and you're right, he basically said there wasn't enough information in the attachment for us to duplicate the MCNP run, so that's why we said it wasn't -- we didn't, we weren't --

DR. ULSH: Right, I think the original issue here was that SC&A questioned our use of the Attila software, and so we did some MCNP runs to try to show that it was okay to use that and it did not satisfy SC&A's concerns. It just wound up raising a whole lot more issues.

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	MR. MARSCHKE: At one point we were
2	basically asking for the MCNP runs themselves,
3	and I think the way you tried to address that
4	was to put them in the attachments, and then
5	when we looked at the attachment, they weren't
6	you know, again, like I said, there wasn't
7	enough information
8	DR. ULSH: Well, I remember we
9	provided the runs to Bob and
10	CHAIR MUNN: Well, there's another
11	finding. Finding 8 has something to do with
12	the version that was
13	MR. STIVER: I think Bob can weigh
14	in on this.
15	DR. ANIGSTEIN: Yes, the issue was
16	I mean, first of all it was just a
17	technical issue that the that we did not
18	actually have the format of the attachment
19	was such that it was not usable in MCNP, so we
20	asked for that. That's a purely technical
21	issue.

The real issue was that -- and I'm  $\,$ 

going from memory now -- if I remember correctly, the source now was changed. In the Attila code they had used a point source. And here they used a flat disc of plutonium and what happened was the way the MCNP run, the MCNP geometry was formulated, you were looking at this flat disc of very dense metal edge-on.

So there was a huge amount of self-absorption and therefore you actually got low doses immediately in the -- if you draw a plane that is, a horizontal plane that intersects with this, you actually got relatively low doses because the radiation couldn't get out.

CHAIR MUNN: Now, wait just a minute, Bob. I think you are talking about what I believe is Finding 8. We're on Finding 2.

DR. ANIGSTEIN: Oh I see. Okay. Well, we were talking about the MCNP run. That was the only place where MCNP runs were - okay, I'm sorry if I'm talking out of turn.

# **NEAL R. GROSS**

9

10

11

12

13

14

15

16

17

18

19

20

21

1	CHAIR MUNN: That's all right.
2	DR. ANIGSTEIN: Taking this out of
3	turn.
4	CHAIR MUNN: We're going to have to
5	talk about that while we're talking about
6	TIB-10. But the number 2 finding is just that
7	the four lower torso organs were not
8	specified.
9	DR. ANIGSTEIN: I have that in
10	front of me. And yes, that is correct. I
11	went ahead because you were talking about
12	MCNP, otherwise MCNP doesn't
13	CHAIR MUNN: Right.
14	DR. ANIGSTEIN: Why was I'm
15	sorry, but why was MCNP mentioned in this
16	context then?
17	CHAIR MUNN: I don't know.
18	DR. ANIGSTEIN: Okay.
19	CHAIR MUNN: I think it was because
20	this all has to do with TIB-10 and it's hard
21	sometimes to just sort out one of the
22	DR. ANIGSTEIN: Okay. I'm sorry

then. I just --

CHAIR MUNN: No, that's okay.

MS. THOMAS: This is Elyse again. If I can interject something. As I was studying this, I -- it appeared that there's a -- that SC&A provided a response that was dated on March 21st, 2011 that doesn't appear in the Board Review System.

So again, that would help kind of 
- if that response were entered into the Board
Review System, it might help this sequence -you know, reading this sequence and the
history --

DR. ANIGSTEIN: Okay. I have this
-- I see this here on my system, on my
computer. Steve, wasn't that passed on?

MR. MARSCHKE: It was passed on. It wasn't entered into the Board Review System. I have that up on the screen right now, and basically Finding 2, lower torso organs not specified, and basically it says, "On September 7th, 2007 --"

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	MS. THOMAS: Yes. Yes, that
2	response needs to get entered. And I think
3	that will help the flow of the history.
4	MR. MARSCHKE: I can take that as
5	an action item to enter these
6	MS. THOMAS: Yes, and one other
7	item
8	CHAIR MUNN: That's Finding 8
9	again.
10	MR. MARSCHKE: No, that's Finding
11	2.
12	DR. ULSH: Finding 2.
13	MR. MARSCHKE: Finding 2, right
14	there.
15	CHAIR MUNN: Finding 2. Oh, I'm
16	sorry. I was reading the one underneath it.
17	MR. MARSCHKE: The date on the
18	response is March 21st, 2001. The meeting
19	MS. THOMAS: That's 2011.
20	MR. MARSCHKE: 2011, I'm sorry, I'm
21	a decade behind the times. So it was the
22	DR. ANIGSTEIN: I also I have a

1	revised version I don't know whether it
2	would help on 7/14/2011. I don't know
3	whether that was just something local here, or
4	whether that was submitted.
5	MR. MARSCHKE: Email it to me, Bob,
6	and I will enter whichever is I will enter
7	that probably into the BRS and then it will be
8	up and then it will be in the BRS system.
9	DR. ULSH: Okay, so that will help
10	with, like Elyse said, that will help with the
11	flow of reading the history of this. But I
12	think the latest item is: we have entered a
13	response to this dated 11/1/2011, and I think
14	going forward, the action will be for SC&A to
15	review our response.
16	MR. KATZ: Or the Subcommittee
17	right now to review
18	CHAIR MUNN: The Subcommittee have
19	to review it, because the recommendation is to
20	close it.
21	MR. KATZ: Right.
22	CHAIR MUNN: and it's very clear
	NEAL R. GROSS

that we, both the agency and the contractor, have looked at the specific finding, which is what's in lower torso, what do you mean by lower torso, and it's been very clearly stated here what's meant by lower torso, by both parties. We should be able to close this.

MR. MARSCHKE: I guess that the thing is: we have to go -- we should probably go back, by rights we should go back to the -- and pull up Rev 4.

MS. THOMAS: Right, there's been a whole new rev since these reviews and responses were written.

DR. ULSH: And to make it easy, I can give you the short story on Rev 4. The only difference between Rev 4 and Rev 3, because I did it, was to pull out the MCNP material from the appendices, delete that, modify the parts of the text that referred to it. Those are the major changes. There's nothing else, really.

CHAIR MUNN: So essentially that's

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

2	MEMBER ZIEMER: So we can close it
3	based on this.
4	MR. MARSCHKE: Well, what were we
5	waiting for, then? Why, I mean, we were
6	waiting before to close it. We had it in
7	abeyance and we were waiting for some reason.
8	It was in abeyance before, so we had agreed
9	and Rev 3 "Rev 3 presents no additional
10	explanation of which organs are in the lower
11	torso, requires the use of the dose conversion
12	factor presented in this bulletin."
13	So I guess the question is: does
14	Rev 4 provide the additional explanation of
15	which organs are in the lower torso
16	DR. ULSH: If you pull up the BRS
17	and look at our response
18	MR. HINNEFELD: Our response from
19	November of '11 says why we have specified it
20	as far, to the extent that we can, and that
21	Rev 3 specified it to the extent that we can.
22	DR. ANIGSTEIN: Excuse me. This is

**NEAL R. GROSS** 

Finding 8.

1	Bob Anigstein. I just went on the web, and
2	the latest one is Rev 3 that's posted.
3	DR. ULSH: All right. We'll take
4	as an action item to post Rev 4.
5	MR. STIVER: Okay, so we're going
6	to keep this one in abeyance until
7	MR. HINNEFELD: I think you can
8	still close it, because Rev 3 and Rev 4 say
9	the same thing with respect to this issue.
10	Do you believe our explanation
11	that's in the BRS that says we have specified
12	it as clearly as we can, and we don't specify
13	it completely because we may not think of all
14	the organs and all the cancers that may occur
15	in that region? We have defined the region by
16	the organs that we have listed and anything
17	else that occurs in that region. I don't know
18	what else we can do.
19	MR. STIVER: Seems reasonable just
20	to
21	MEMBER ZIEMER: You guys are
22	comfortable with that, right?

4	MR. SILVER: I'M COMIOTIADIE WITH
2	it.
3	MEMBER ZIEMER: I don't see why we
4	shouldn't close it here.
5	CHAIR MUNN: Certainly item 2, yes.
6	MR. KATZ: Okay, so today's date we
7	close item 2.
8	MEMBER ZIEMER: Could I ask just a
9	quick format question? I hate to keep coming
10	back to format. These things don't seem to
11	sort automatically in the order of the
12	finding. When you get to when you get to
13	this list of findings here, it goes 1, 4, 5,
14	6, 7, 8, 9, 2.
15	CHAIR MUNN: And then 3.
16	MEMBER ZIEMER: Are these showing
17	up in the order that we are dealing with them
18	or why don't they jump into
19	CHAIR MUNN: I think this is an
20	error. I think it's a glitch.
21	MEMBER ZIEMER: It's not a big deal
22	but
ĺ	

1	CHAIR MUNN: No.
2	MEMBER ZIEMER: one might
3	otherwise say well, 2 must have been closed
4	because it's not there, and then you find it
5	at the end of the list for some reason.
6	MR. HINNEFELD: I've got to believe
7	there is a typing anomaly that made that sort
8	out. So that would be something
9	MEMBER ZIEMER: Something sorted
10	before the number looks somewhat different
11	than
12	DR. ULSH: Okay
13	MEMBER ZIEMER: It's not obvious.
14	DR. ULSH: Finding 2 on DCAS-TIB-10
15	shows up out of order. That's the issue.
16	CHAIR MUNN: Correct. It's 2 and 3
17	are both out of order.
18	MEMBER ZIEMER: Well, 2 and 3 show
19	up at the end of the list, so it goes 1, 4, 5
20	and 2, 3 end up at the bottom of the list. So
21	it looks a little strange, I just
22	MR. HINNEFELD: Well, it's easy to
	NEAL R. GROSS

1	look past something when it's
2	CHAIR MUNN: Yes.
3	MEMBER ZIEMER: Because you say,
4	well, it must have been closed, it's not
5	MR. KATZ: The response date is
6	11/1/11.
7	MR. MARSCHKE: It's 11/1?
8	MR. KATZ: 11/1.
9	MR. MARSCHKE: November? Or 11
10	slash
11	MR. KATZ: Yes, that would be
12	November.
13	MR. MARSCHKE: 11/01/2011.
14	MEMBER ZIEMER: But as they are in
15	here now, they all have the same response
16	dates on them, so that couldn't have been part
17	of the problem.
18	MR. KATZ: Oh, no, no, I was
19	helping Steve.
20	MEMBER ZIEMER: Oh, I know. I
21	thought at first it could have been what dates
22	are in here, but those are the same thing.

MS. THOMAS: And this is Elyse again. I'm sorry, Dr. Ziemer, if you -- I didn't mean to interrupt you.

MEMBER ZIEMER: No, that's fine.

MS. THOMAS: Okay. I have one other little housekeeping thing that I think probably just for -- if Steve is making some changes.

There was a comment in Finding 1 that I think belongs in Finding 2 because it makes more sense in that thread, and I just wonder if it was maybe entered correctly but if you want to just maybe make a note, Steve, to look at that, and maybe if you think it belongs in Finding 2, I guess you could change it. But the finding says something, what changes are going to be made to TIB-10 as a result of this issue.

MR. MARSCHKE: Well, just a minute, Elyse. Let me close out Finding 2, if Wanda and Paul and Mike agree, I'd just add this little note here and change the status to

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	closed based upon the explanation provided by
2	NIOSH on the
3	MEMBER ZIEMER: Just put a past
4	tense to closed.
5	CHAIR MUNN: Is that okay with you,
6	Mike?
7	MEMBER GIBSON: It is.
8	MR. MARSCHKE: Closed based upon
9	the explanation provided by NIOSH on November
10	1st, 2011, and if everybody agrees then we
11	will close this item.
12	MEMBER ZIEMER: And agreed to by
13	SC&A, or does that need to be in there?
14	MR. STIVER: Just probably put some
15	comment about that
16	MR. HINNEFELD: You can say that,
17	you can say that. You don't have to.
18	MR. KATZ: You don't need SC&A's
19	approval.
20	MEMBER ZIEMER: No, well, for the
21	record, but I guess I
22	

1	at some future date.
2	MEMBER ZIEMER: Okay, forget it.
3	(Laughter.)
4	MR. MARSCHKE: We need plausible
5	deniability here, you know?
6	CHAIR MUNN: Did I hear you, Mike?
7	MR. HINNEFELD: Yes, he said okay.
8	MR. MARSCHKE: So, issue 2 is
9	closed. Issues 1 and 2 are closed.
10	CHAIR MUNN: Okay.
11	MR. MARSCHKE: Now, Elyse, you said
12	go back to issue or Finding 1?
13	MS. THOMAS: Yes, like I said, it's
14	just it's kind of a minor, kind of
15	housekeeping type of issue, and I'm wondering
16	whether I should just email it to you, because
17	especially if the item is closed.
18	MR. KATZ: That sounds fine.
19	DR. ULSH: Yes, don't email it
20	to Steve.
21	MS. THOMAS: Okay. Ready to go to
22	Finding 3? Again, this is one that I think

1	should be closed because if you look at the
2	history of the Subcommittee comment for
3	10/14/2008 states it should be closed. It's
4	also closed in the previous Access database.
5	MR. MARSCHKE: I agree with Elyse,
6	and this is showing up on the I'm showing
7	the Subcommittee or the people in the room
8	here what it says in the Access database on
9	item 3, issue 3, and it's showing it as
10	closed, and as Elyse says, October 14th, 2008,
11	was the date that the Subcommittee closed it.
12	So item I've got to find it, since
13	they're out of order.
14	MR. STIVER: It's at the bottom of
15	the page.
16	CHAIR MUNN: Right, it's all the
17	way down at the bottom.
18	MR. MARSCHKE: Can somebody give me
19	the that was October
20	MS. THOMAS: October 14th of 2008.
21	MEMBER ZIEMER: 2008.
22	MR. MARSCHKE: Okay, so change the
	NEAL D. CDOCC

1	status to closed based upon the discussions
2	discussions held on October 14th, 2008. Or
3	basically, the status was closed
4	MS. THOMAS: Yes.
5	MR. MARSCHKE: Shouldn't it be
6	changed to, basically, the status was closed
7	on October 14th, 2008. How's that?
8	MR. KATZ: Good.
9	MR. MARSCHKE: Okay.
10	DR. ULSH: Ready for issue 4?
11	MR. MARSCHKE: Four is also closed.
12	MS. THOMAS: Yes, four is the same,
13	exactly the same situation as far as I can
14	tell.
15	MR. MARSCHKE: Does the
16	Subcommittee concur?
17	CHAIR MUNN: Yes.
18	MEMBER ZIEMER: Which one is that?
19	CHAIR MUNN: Four. Analysis is
20	needlessly complex, was the finding.
21	MR. MARSCHKE: Fourteen?
22	DR. ULSH: October 14, 2008.
	NEAL R. GROSS

1	Elyse, number 5?
2	MS. THOMAS: On number 5
3	CHAIR MUNN: I am going to make a
4	suggestion here before we go on. I hate to
5	break in the middle of our work on 10 here,
6	but the truth is we are past due for a comfort
7	break and we are going to have, I suspect, a
8	discussion on eight, when we get there.
9	And so let me suggest that we take
10	a break right now in the midst of TIB-10 and
11	be back in 15 minutes. Let's come back at 11
12	o'clock and let's give ourselves a break.
13	MS. THOMAS: Okay.
14	MR. KATZ: Okay, so I'm just
15	putting the phone on mute.
16	CHAIR MUNN: Thanks, we'll take up
17	with item 5 when we return.
18	(Whereupon, the above-entitled
19	matter went off the record at 10:47 a.m. and
20	resumed at 11:01 a.m.)
21	MR. KATZ: We're back. It's 11
22	o'clock.

1	MEMBER ZIEMER: Mute your phones.
2	MR. KATZ: And we're working on
3	OTIB-24.
4	MR. HINNEFELD: DCAS-TIB-10.
5	MR. KATZ: DCAS, I'm sorry, TIB-
6	10. What was I DCAS-TIB-10.
7	CHAIR MUNN: We're starting with
8	item 5.
9	MS. THOMAS: Okay, for Finding 5,
10	if you look down the string of comments and
11	responses, 10/14/2008, it was determined to be
12	in progress, so I think that's the correct
13	status for now. It was in progress in the
14	previous Access database also.
15	CHAIR MUNN: So that's a change for
16	us.
17	MR. MARSCHKE: What was the date,
18	Elyse?
19	MS. THOMAS: 10/14/2008.
20	MR. MARSCHKE: Oh, again the 10/14
21	date.
22	MS. THOMAS: Yes.
	NEAL R. GROSS

1	MR. KATZ: So and what is when
2	it's in progress, what progress is being made?
3	What are we waiting on?
4	MS. THOMAS: This one has to do
5	with the angular dependence and so I don't
6	know, there was I'm not sure that that
7	issue has been resolved, and I think angular
8	dependence got bumped to another group and
9	whatever, so it may be waiting on that.
10	MR. STIVER: Yes, I think on
11	October 10th there's a hint here, the factors
12	that affect conversion of particle flux to the
13	dose rate must be accounted for by dosimeter
14	calibration. Discussion of dosimeter
15	calibration to be site-specific and cannot be
16	resolved in discussion of the glove box TIB.
17	MEMBER ZIEMER: Well, they also
18	referred to TIB-13 where it will be handled
19	apparently.
20	MR. MARSCHKE: NIOSH will respond
21	to that finding in discussion of TIB-13 where
22	the issue was raised, rather than here, the

1	factors that affect conversion of particle
2	flux to dose rate must be accounted for by
3	dosimeter calibration.
4	MR. KATZ: So, can we check. If
5	this is under TIB-13, it seems like then we
6	can close it here and
7	MR. MARSCHKE: Change it to
8	addressed in TIB-13 or close it or
9	MR. KATZ: Close it here, with a
10	notation that this is whatever, this is
11	being addressed under TIB-13.
12	CHAIR MUNN: Is anyone familiar
12	CHAIR MUNN: Is anyone familiar enough with TIB-13 to know that that is in
	_
13	enough with TIB-13 to know that that is in
13 14	enough with TIB-13 to know that that is in fact what we are doing?
13 14 15	enough with TIB-13 to know that that is in fact what we are doing?  MR. KATZ: Pull it up.
13 14 15 16	enough with TIB-13 to know that that is in fact what we are doing?  MR. KATZ: Pull it up.  CHAIR MUNN: I guess we'll have to
13 14 15 16	enough with TIB-13 to know that that is in fact what we are doing?  MR. KATZ: Pull it up.  CHAIR MUNN: I guess we'll have to look and see.
13 14 15 16 17	enough with TIB-13 to know that that is in fact what we are doing?  MR. KATZ: Pull it up.  CHAIR MUNN: I guess we'll have to look and see.  DR. ULSH: Is it DCAS-TIB-13 or
13 14 15 16 17 18	enough with TIB-13 to know that that is in fact what we are doing?  MR. KATZ: Pull it up.  CHAIR MUNN: I guess we'll have to look and see.  DR. ULSH: Is it DCAS-TIB-13 or ORAU-TIB-13?

1	MR. MARSCHKE: DCAS-TIB-13.
2	MR. HINNEFELD: It's either OCAS or
3	DCAS, I think, because it's
4	MR. MARSCHKE: No findings in the -
5	_
6	DR. ULSH: Okay. This goes back to
7	the problem with the DCAS/OCAS TIBs, the
8	findings.
9	MR. MARSCHKE: OCAS, there is no
10	OCAS, so there is no OCAS-TIB-13 that I can
11	see.
12	MR. STIVER: DCAS-TIB-13 Rev 1 is
13	the latest.
14	MS. THOMAS: If you put in just
15	TIB-0013, it comes up.
16	MR. MARSCHKE: I get DCAS-TIB-13,
17	OCAS-TIB-2. I get ORAU-OTIB-13. I don't get
18	OCAS-TIB-13. Maybe it's just a
19	MR. STIVER: I got OCAS-TIB-13.
20	DR. ULSH: Wait. There's a DCAS-
21	TIB-13 and then there's an OTIB-13, which is
22	an ORAU document, so I think

1	MEMBER ZIEMER: Well, the DCAS one
2	has to do with geometric
3	(Simultaneous speaking.)
4	MR. MARSCHKE: OCAS-TIB-13, wait a
5	minute, I got it. I got it. It's not 0013.
6	It's 013.
7	CHAIR MUNN: Let's make sure we
8	have that right now.
9	MR. MARSCHKE: Now what are we
10	looking for? We are looking for angular
11	dependence.
12	DR. ULSH: I think that's in
13	general what the issue was.
	general what the issue was.  MR. MARSCHKE: Writing style.
13	
13	MR. MARSCHKE: Writing style.  That's not it. Well, the only one that is
13 14 15	MR. MARSCHKE: Writing style.  That's not it. Well, the only one that is
13 14 15 16	MR. MARSCHKE: Writing style.  That's not it. Well, the only one that is still in progress is Finding 4.
13 14 15 16	MR. MARSCHKE: Writing style.  That's not it. Well, the only one that is still in progress is Finding 4.  DR. ANIGSTEIN: This is Bob
13 14 15 16 17	MR. MARSCHKE: Writing style.  That's not it. Well, the only one that is still in progress is Finding 4.  DR. ANIGSTEIN: This is Bob Anigstein, if I could break in and comment.
13 14 15 16 17 18	MR. MARSCHKE: Writing style.  That's not it. Well, the only one that is still in progress is Finding 4.  DR. ANIGSTEIN: This is Bob Anigstein, if I could break in and comment.  CHAIR MUNN: Speak up, Bob.

looked at it but then when we got to TIB-
13, not OTIB-13 at the time, it was TIB-13,
which is related, it was originally for
Mallinckrodt workers and then it got expanded
to other sites, and then we found very similar
issues as in TIB-10 and then in addition, we
brought in the angular dependence, which made
the correction factor, the recommendation for
a correction factor, even larger.
And so it would really apply here
too. Procedurally, if I recall correctly,
rather than addressing the same item twice,
the Subcommittee decided we'll handle it as
part of TIB-13.
CHAIR MUNN: Okay, so you are
talking about the Mallinckrodt workers.
DR. ANIGSTEIN: We are talking
about TIB-13.
CHAIR MUNN: Right, which is
Mallinckrodt.
DR. ANIGSTEIN: Which has been

expanded beyond Mallinckrodt.

1	MR. KATZ: So it's now the DCAS
2	if you go back to the DCAS, isn't the DCAS
3	just an expansion of the Mallinckrodt
4	procedure?
5	MR. STIVER: Yes, if you look at
6	the revision description under DCAS
7	MR. MARSCHKE: I don't think the
8	DCAS
9	MR. STIVER: DCAS-TIB-13 has the
10	changes that Bob was describing.
11	MR. MARSCHKE: It's not filled out.
12	MR. STIVER: But there's no
13	findings associated with it, not in the
14	system.
15	MR. MARSCHKE: It's not populated.
16	The findings have not been populated into
17	DCAS.
18	
	MR. KATZ: Okay, but this is the
19	MR. KATZ: Okay, but this is the document Bob's referring to, it's the expanded
19 20	
	document Bob's referring to, it's the expanded

1	have been already addressed. You don't have
2	this laid out yet, but it may have been
3	addressed in this document.
4	CHAIR MUNN: So, we're going to
5	need DCAS-TIB-013, right?
6	MEMBER ZIEMER: I think it's 0013.
7	CHAIR MUNN: Is it, 00?
8	MR. HINNEFELD: Well, it depends on
9	where you look at it.
10	MEMBER ZIEMER: In the database
11	it's 0013, right?
12	CHAIR MUNN: Okay.
13	MR. HINNEFELD: But the findings
14	are available as 00.
15	MEMBER ZIEMER: Oh, I see.
16	MR. MARSCHKE: Well, the database
17	has no findings associated with DCAS-TIB-13.
18	MR. KATZ: We understand, right, so
19	that's the issue, is the findings are under
20	the old version of the document. There's a
21	new version of the document and we need to
22	sort out, it sounds like, whether these
	1

findings have been addressed. CHAIR MUNN: And do we need to populate --DR. ULSH: Yes. CHAIR MUNN: 0013. DR. ULSH: Yes. CHAIR MUNN: Okay. Is that a NIOSH action? DR. ULSH: Yes. 10 CHAIR MUNN: So we are going to populate the database and we are 11 going to verify that angular dependence is addressed 12 13 properly. MR. KATZ: We're going to see what 14 15 the status is of these findings. 16 DR. ULSH: Right, we're going to --I have as a NIOSH action item to populate 17 with findings on 18 DCAS-TIB-13 the 19 document. I think what we've said here under 20 the finding on DCAS-TIB-10 is that this issue of angular dependence has been addressed in 21 22 DCAS-TIB-13. Is that what saying, we are

1	Elyse?
2	MR. HINNEFELD: No, it says it will
3	be.
4	CHAIR MUNN: Will be. But we don't
5	know what's in DCAS-13.
6	MS. THOMAS: Yes, I think the
7	safest thing to do right now today for Finding
8	5 on TIB-10 is just to put it in progress,
9	instead of open.
10	CHAIR MUNN: Agreed.
11	MR. KATZ: I would just close it,
12	because close it, we are moving it to TIB-13,
13	and why do we want to track two? We have
14	enough craziness without having to double
15	track things. We are moving it to TIB-13
16	MR. STIVER: As long as we don't
17	lose it in the interim.
18	MR. MARSCHKE: Yes, if you close it
19	now before you open it, do you want to close
20	it now before you open another one?
21	DR. ULSH: Let me make sure that
22	that particular issue was captured in the
	NEAL R. GROSS

1	findings for DCAS-TIB-13.
2	MR. KATZ: And you may find them
3	under the findings for the TIB-0013, the
4	precursor, is where they may be.
5	MR. MARSCHKE: So, basically 5 is
6	changed to in progress.
7	MR. KATZ: So you're going to put a
8	note under there that it's being moved to
9	DCAS-TIB-13.
10	DR. ANIGSTEIN: Likewise, get a
11	strenuous workout that I'll have to talk
12	about.
13	CHAIR MUNN: Yes. Okay. Are we
14	okay with it?
15	MR. KATZ: Yes.
16	CHAIR MUNN: Very good. Ready for
17	item 6.
18	MS. THOMAS: Okay. I think Finding
19	6 has been that same is not the same exact
20	same issue but it's the exact same thing, that
21	it should be in progress, and if you look down
22	at the end of the string, there's an entry

1	there for 10/14/2008 that says it should be in
2	progress. It also refers back to TIB-13.
3	CHAIR MUNN: So, we're still in
4	progress here.
5	MR. MARSCHKE: Okay, so we want to
6	change this to in progress with the same note
7	that we made on
8	MR. KATZ: Right, move the finding
9	to 13.
LO	DR. ULSH: Wait, you're looking at
11	6. This is 5.
L 2	MR. MARSCHKE: I thought we just
L 3	did 5.
L 4	DR. ULSH: Oh, you're right.
L 5	CHAIR MUNN: Five and six.
L 6	MR. MARSCHKE: Issue TIB
L 7	basically I've got that on July 14th, 2011, we
L 8	have issue TIB-13-06 is closed, since it is
L 9	the same issue as TIB-13-04. Resolution of
20	TIB-13-04 will also resolve TIB-13-06, so 6 is
21	already closed in the database.
22	CHAIR MUNN: Rather than in

1	progress. Okay.
2	DR. ULSH: And four is closed. So
3	
4	MS. THOMAS: And 10, TIB-10-06 is
5	closed?
6	MR. MARSCHKE: 10-06 is closed. Oh,
7	no, I'm looking at 13. Oh, my spread is
8	screwed up here. I might have screwed up.
9	(Simultaneous speaking.)
10	MR. MARSCHKE: No, I did that right.
11	CHAIR MUNN: No, you're still on
12	13.
13	MR. MARSCHKE: I'm still on 13,
14	yes, I know, I just want to make sure I didn't
15	change the
16	MR. STIVER: Inadvertently make any
17	changes.
18	MR. MARSCHKE: I mean, it changed
19	to 13, when I was trying to make a change to
20	10. DCAS-TIB-10. Is that the one we're
21	doing?
22	CHAIR MUNN: Yes. Glove box

1	workers. Got it.
2	MEMBER ZIEMER: When we transfer
3	it, do we always close it, or do we put it in
4	abeyance? Do we always close it?
5	CHAIR MUNN: We just call it
6	transferred.
7	MEMBER ZIEMER: Oh, is that a
8	category?
9	CHAIR MUNN: Yes, it is a category.
10	DR. ULSH: That's when we transfer
11	it to a different Work Group.
12	CHAIR MUNN: And transferred is
13	considered
14	MEMBER ZIEMER: Isn't that what we
15	are doing
16	MR. STIVER: Wasn't that
17	transferred within the document though, if
18	there's a
19	MR. HINNEFELD: That's addressed in
20	
21	CHAIR MUNN: That's addressed in
22	MR. HINNEFELD: Addressed in the
	NEAL D. ODOGG

1	findings.
2	(Simultaneous speaking.)
3	MR. STIVER: That's right.
4	CHAIR MUNN: moved it to some
5	other Work Group to deal with.
6	DR. ULSH: Procedure on Procedures.
7	CHAIR MUNN: Yes. Let's not
8	suggest that. A little macabre humor here
9	MR. MARSCHKE: Six, basically. Now
10	what did we decide on six?
11	MR. KATZ: Six is the same as five.
12	MEMBER ZIEMER: Is five transferred
13	then?
14	MR. KATZ: It's not transferred.
15	It's just being dealt with.
16	CHAIR MUNN: It's in abeyance.
17	MR. MARSCHKE: Right now it's in
18	progress.
19	MR. KATZ: It's in progress and as
20	soon as it's the finding is put into 13, it
21	will be closed here.
22	MEMBER ZIEMER: Closed or
	1

1	transferred?
2	MR. KATZ: Closed.
3	CHAIR MUNN: It is in progress.
4	MR. KATZ: Right now, but it's
5	CHAIR MUNN: Because it's going to
6	be taken care of.
7	MEMBER ZIEMER: No, but when it's
8	transferred, does it show up here as closed or
9	transferred?
10	MR. MARSCHKE: That depends on how
11	the Subcommittee wants it
12	CHAIR MUNN: When it's transferred
13	it shows up as it shows up as transferred.
14	MR. KATZ: We're not transferring
15	here. We're closing here. We're not
16	transferring.
17	MEMBER ZIEMER: That's why I'm
18	asking the question.
19	CHAIR MUNN: For our purposes, when
20	we are looking at the database, anything that
21	has been closed, transferred and in abeyance
22	is closed for us. There's nothing we can do

1	about it. Something is going on somewhere
2	else.
3	MEMBER ZIEMER: So it's going to
4	show up as closed?
5	CHAIR MUNN: Yes. It won't be in
6	our list of closed files. It will be shown in
7	those three categories. But when we are
8	working with our agenda and what we are
9	looking at, those are three things that we
10	don't look at, simply because they are in the
11	hands of someone else.
12	MEMBER ZIEMER: Well, I was just
13	asking, in this case, how is it going to show
14	up here, as closed
15	CHAIR MUNN: It will show up in
16	progress.
17	MR. STIVER: Once it's closed it
18	will be transferred though
19	MEMBER ZIEMER: Once it's
20	transferred where will
21	(Simultaneous speaking.)
22	CHAIR MUNN: Stop. Stop. It's

the reason it's in progress is because NIOSH actively is working it, and then --MEMBER ZIEMER: I understand that, but --CHAIR MUNN: Yes, and --MEMBER ZIEMER: But even if they're working it under the other one, how does it -going to show it's up here once transferred in as closed. 10 CHAIR MUNN: Yes. Once the --MEMBER ZIEMER: I want to make sure 11 Ted is saying the right thing. 12 13 you're saying is --CHAIR MUNN: Once 13 is answered, 14 15 But 13 is not in the database yet. yes. 16 MEMBER ZIEMER: I understand that. CHAIR MUNN: Okay, ready for seven. 17 18 MS. THOMAS: Okay. On Finding 7, 19 again I think the status should be closed. you look down at the end of the string it says 20 that for the entry on 10/14/2008, and it was 21 closed in the previous Access database, so --22

1	CHAIR MUNN: So it was carried over
2	as open in error. Closed.
3	MEMBER ZIEMER: As per
4	CHAIR MUNN: October 14 October
5	one-four.
6	MEMBER ZIEMER: As per the October
7	
8	DR. ULSH: The third word is a
9	spelling error too.
10	CHAIR MUNN: October 14, 2008.
11	MEMBER ZIEMER: The status has
12	changed to closed as per October 16th, 2008.
13	MR. MARSCHKE: Fourteenth.
14	CHAIR MUNN: Fourteen, at least
15	mine says 14.
16	MEMBER ZIEMER: It's got both dates
17	here, see that? Well, it's interesting, it's
18	got both 14
19	MR. MARSCHKE: It didn't happen
20	until
21	(Simultaneous speaking.)
22	MEMBER ZIEMER: Oh, that's a
	NEAL R. GROSS

different thing, yes, October 14. MR. MARSCHKE: Seven is closed. MR. KATZ: Okay, so that brings us to eight. Okay, so Finding 8, MS. THOMAS: NIOSH provided a response for November in November of 2011, and this response is now entered in the Board Review System with that date, so it's newly entered, it's not a new 10 response. The status in the previous Access 11 database was in progress. This is one that 12 MR. MARSCHKE: also Bob discussed in his March 2011 -- he 13 gave a very long discussion on it, and it is -14 15 just scrolling down to the end, and 16 basically SC&A recommends the status of Finding 8 be made in progress. 17 So I need -- again, I already have 18 an action item to go back and to enter Bob's 19 March -- well, or his revised version of the 20 March 2011 write-up and enter that into the 21 database. 22

1	So I think that and I assume,
2	Elyse, when you say that NIOSH, the finding
3	here that is newly entered, is this in
4	response to Bob's
5	MS. THOMAS: Yes. Yes it is. So
6	you probably need to enter Bob's response and
7	review the NIOSH response.
8	MR. MARSCHKE: And review the NIOSH
9	response and see whether or not we can so
10	Bob, this is an action item for you, really.
11	DR. ANIGSTEIN: To do what?
12	MR. MARSCHKE: I will give you,
13	when I get back, or you can go onto the Board
14	review database, but I can give you or when
15	I get back, I'll give you a printout of the
16	NIOSH's response to your March response.
17	MR. KATZ: Well, wait, I mean, can
18	these
19	DR. ANIGSTEIN: But that's what he
20	transmitted I have a version that was
21	transmitted July 14th.
22	MR. MARSCHKE: Okay, the July

1	the one I'm looking at is March, but the July
2	one, then.
3	MR. KATZ: Before we just bat it
4	back can the Subcommittee take it up? I mean,
5	Brant, you responded to it.
6	DR. ULSH: I don't think it's going
7	to be one where SC&A and us are easily in
8	agreement.
9	MR. KATZ: But do you want to
10	discuss it before we just bat it back to SC&A?
11	MR. MARSCHKE: Well, we can Bob,
12	I don't know that Bob can even look at it.
13	Let's see.
14	CHAIR MUNN: This was what Bob was
15	talking about earlier when he was talking
16	about the difference between the Attila and
17	MCNP positions and results.
18	MR. KATZ: Right, and Brant has
19	responded to Bob's comments.
20	DR. ANIGSTEIN: If I can comment on
21	that, the issue we raised the issue about
22	Attila, but at this point the issue is not a
1	

technical one between the two codes. It's an issue -- the issue is the NIOSH model in the MCNP is radically different than the model they used in Attila, not the model of the code, but the model of the glove box and the geometry. DR. ULSH: Yes, you're correct, Bob, however you'll see in our response that we have revised the TIB to delete all that So we are kind of back to MCNP stuff out. square one --DR. ANIGSTEIN: But the result -but the issue is not the MCNP runs and whether you are to include them. We are still -- I mean we are talking about the results. the only thing that's of significance. DR. ULSH: Okay. DR. ANIGSTEIN: And we disagree with the results. really DR. ULSH: I know. suggest that you take a look at our response

in here.

10

11

12

13

14

15

16

17

18

19

20

21

1	DR. ANIGSTEIN: Okay, will do.
2	DR. ULSH: And then if you don't
3	like it, you can come back to the committee
4	with a response to that.
5	DR. ANIGSTEIN: Very good.
6	DR. ULSH: This is not something we
7	are going to be able to iron out today.
8	DR. ANIGSTEIN: Okay. But this is
9	something, Steve, you will send me.
10	MR. MARSCHKE: Yes.
11	DR. ANIGSTEIN: Very good.
12	CHAIR MUNN: All right.
13	MEMBER ZIEMER: Just a question.
14	So there is an earlier SC&A response that is
15	not in here. Is that what you're saying?
16	MR. MARSCHKE: There is yes.
17	There is a version
18	DR. ULSH: It's March 2011.
19	MR. MARSCHKE: It was in March or
20	July of 2011. I have the March version and we
21	will look and Bob says he revised this
22	slightly.

1	MEMBER ZIEMER: Okay, I see.
2	There's a whole well, let's see.
3	MR. STIVER: It never made it into
4	the
5	MR. MARSCHKE: The database wasn't
6	working at that point in time.
7	MEMBER ZIEMER: And it looks like
8	there's another placeholder that has your name
9	on it, Brant, for March 16th. Is that the one
10	that should have been a placeholder for
11	there. Right? See that?
12	March wait a minute. Yes, see
13	the March see the March 16th thing?
14	DR. ULSH: Yes, where it says,
15	"Files provided to SC&A" on 3/11/2011?
16	MEMBER ZIEMER: Oh, okay, that's
17	your response.
18	DR. ULSH: That's me saying
19	MEMBER ZIEMER: And then there's
20	yes, got you.
21	MR. MARSCHKE: And there should be
22	below that there should be

MEMBER ZIEMER: Below that is where the --MR. MARSCHKE: -- where Bob's should be brought in. MEMBER ZIEMER: Got it. MR. MARSCHKE: So, at the minimum, we should change the status from -- right now the status is open. We should change the status to in progress at a minimum. 10 CHAIR MUNN: Yes, right. 11 MR. At the next meeting, KATZ: this will be on the agenda for the 12 13 meeting. CHAIR MUNN: Question. Are any of 14 15 those responses -- it appeared that the --16 Bob's most recent response, if that's what we were seeing on the screen earlier, was fairly 17 lengthy. Do we need any links to any of that 18 19 or is this all --MR. MARSCHKE: Well right now we 20 should be able to basically -- if we do need a 21 22 link to it, we should be able to do a link to

1	it.
2	CHAIR MUNN: Yes, that's why I
3	asked.
4	MR. MARSCHKE: So we can either
5	we can either bring it in as a you know, we
6	can either paste it into the spot provided, if
7	it works that way, or we can link it to either
8	a PDF file or a Word file whichever one we
9	pick.
10	CHAIR MUNN: It depends entirely on
11	the length of that response. It appeared to
12	me that it was two pages long. And if it's
13	two pages long then clearly we need to link it
14	rather than copy it into the database.
15	Is it in a document we can link
16	easily?
17	MR. MARSCHKE: The only problem
18	with linking it, Wanda, is, basically right
19	now the document is, is
20	CHAIR MUNN: Internal
21	correspondence.
22	MR. MARSCHKE: Well, internal

correspondence, but it's -- it also has discussion of four findings as opposed to just the one finding, so I wouldn't -- if we're going to link it, what I would like to do is I would like to pull out the one finding, the information on the one finding and then include that.

CHAIR MUNN: Well, my only question is, without reading it, it's difficult for me to identify whether the verbiage there is really and truly pertinent to what we are trying to do, or if it needs to be summarized. And that's something we would have to read I suppose to see if it is.

My instinct is that perhaps it could be summarized, but if that's not going to be feasible, now there's a diagram too. Perhaps this is one that you should pull out and make that response a standalone. We could do that okay?

MR. MARSCHKE: We can do that.

CHAIR MUNN: All right.

## **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	MEMBER ZIEMER: There is an 08
2	portion of the total report of the you can
3	just pull that out.
4	CHAIR MUNN: That's what he's
5	looking at right here.
6	MR. MARSCHKE: We'll pull out the
7	08 portion and link it in, either as a Word
8	file or as a PDF file.
9	MR. KATZ: Sounds good. Is that the
LO	end of the line for this?
11	DR. ULSH: No.
12	MR. KATZ: No? Okay.
L 3	DR. ULSH: Finding 9.
L 4	MS. THOMAS: Okay, are you ready
L 5	for nine?
L 6	MR. KATZ: Yes. Thanks, Elyse.
L 7	MS. THOMAS: Okay. This was
18	originally closed so if you look at the old
L 9	Access database, Finding 9 was closed. But it
20	was reopened at the Subcommittee meeting on
21	March 22nd of 2011.
22	That's what we were looking at

before. So that was pages 80 and 82 of that
transcript. However there is a new NIOSH
response dated 11 November 2011 and then a
new version, Rev 4.
So this one was originally closed.
It was reopened. So I'm not sure what the
status should be today.
MR. KATZ: So we can take up the
DCAS response then, from November '11?
CHAIR MUNN: It appears that the
action at this point should be SC&A's to
respond to the
MEMBER ZIEMER: This may be similar
to the earlier one. It may be a lengthy
MR. STIVER: It's similar to
Finding 8.
MEMBER ZIEMER: We may need to
analyze that and
CHAIR MUNN: It appears to be in
progress.
DR. ULSH: Well, to make a fairly
lengthy response short, SC&A questioned the

use of Rocky Flats data and in Rev 4, we deleted it. So I don't know. If you want to take time to look at it you can, but --

MR. HINNEFELD: Yes, the history that the original document behind this was pulled out some risks and whole body measurements from Rocky Flats glove workers as sort of a check on what Attila came And SC&A felt like that was up with. really a relevant check. I forget the whole nature of --

MEMBER ZIEMER: It was sort of a validation effort?

MR. HINNEFELD: Yes, sort of a validation thing, and so since it really critical to the argument that was being the document, thought, well, made in we there's no need to put that in there, because I think there are -- there were clearly some weaknesses in using it, as SC&A pointed out. that we objected. We kind of It's not understood their objection to its use.

## **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	And so based on that, we said,
2	well, not that we write a lot of these
3	documents but we have developed a technique
4	and say this is the technique without trying
5	to throw in a validation approach also.
6	So why don't we just take the
7	validation approach out? So in ultimately
8	I guess, in Rev 4, we say it has been taken
9	out, whereas in Rev 3 it wasn't. It was just
10	moved. So
11	CHAIR MUNN: Since Bob is reviewing
12	it
13	MR. HINNEFELD: someone would
14	have to look at the Rev 4.
15	CHAIR MUNN: Yes, it's my
16	understanding that we tasked Bob to look at
17	Rev 4 in any case, and since he's going to be
18	looking at Rev 4, then it appears logical that
19	we can close out eight and nine simultaneously
20	when that review has been complete.
21	MR. KATZ: Is that clear to you,
22	Bob?

WASHINGTON, D.C. 20005-3701

1	DR. ANIGSTEIN: No.
2	CHAIR MUNN: No?
3	DR. ANIGSTEIN: It appears that you
4	want to review I'm not sure what we are
5	supposed to do about nine. I mean, nine is
6	particular because nine was closed back in
7	way back early and then we were told to look
8	at it, even though it was closed.
9	MR. MARSCHKE: Well, what you don't
10	know, Bob, is that on November 1st of 2011,
11	NIOSH provided a response and they also
12	revised DCAS-TIB-10 that was right before
13	DR. ANIGSTEIN: I thought they just
14	I thought, from what I heard was that the
15	revision only consisted of taking out the
16	appendix.
17	MR. MARSCHKE: Well, they also took
18	out the Rocky Flats data.
19	DR. ANIGSTEIN: I see, okay. Well
20	I haven't you know, I was, I was not
21	apprised of that and I have not seen either
22	the version Rev 4, nor the November

1	response. So
2	MR. MARSCHKE: That is what you are
3	being tasked to do right now.
4	DR. ANIGSTEIN: Excuse me?
5	MR. MARSCHKE: You are being at
6	this meeting you are
7	DR. ANIGSTEIN: Okay, right, okay,
8	so you'll
9	MR. MARSCHKE: You are receiving a
10	task to do that.
11	DR. ANIGSTEIN: You know, I
12	obviously am not clear what to do, but I
13	haven't seen it. But once I see it, I'll
14	figure it out or I will consult.
15	MR. MARSCHKE: Right, so you'll
16	review it between now and the next
17	Subcommittee meeting.
18	DR. ANIGSTEIN: Which is?
19	CHAIR MUNN: We haven't set it yet.
20	MR. MARSCHKE: Probably three or
21	four months down the road.
22	DR. ANIGSTEIN: Okay.

1	DR. ULSH: So, status as of today
2	is in progress.
3	MR. KATZ: In progress.
4	CHAIR MUNN: Yes.
5	MR. KATZ: So, are we on is
6	there a finding ten?
7	DR. ULSH: That's the end of the
8	findings for this packet.
9	MR. KATZ: Okay.
10	CHAIR MUNN: Very good, that should
11	clear us up with 10. Right, Elyse?
12	MS. THOMAS: Yes, that's it.
13	That's all the findings there.
14	CHAIR MUNN: Good. All right.
15	Then let's move on to our next thorn in the
16	side, TIB-13.
17	Our agenda says we were to re-
18	review Finding 4 and determine whether this is
19	an overarching issue or whether it's site-
20	applicable. And NIOSH was going to look at
21	that, right?
22	DR. ULSH: Yes, I mean that's what

1	it says here, it's a DCAS action item. I
2	don't think that we have done that yet.
3	CHAIR MUNN: Haven't done that?
4	MS. THOMAS: That one's also tied
5	up in the previous issue we were discussing
6	about OCAS-TIB-13 versus DCAS-TIB-13.
7	CHAIR MUNN: And this is 013 TIB.
8	MEMBER ZIEMER: Is this the
9	original Mallinckrodt one?
10	CHAIR MUNN: Yes, it's the
11	Mallinckrodt one, yes.
12	MR. MARSCHKE: I screwed up earlier
13	on this one and I changed the status of
14	TIB-13-5 when I was supposed to change the
15	status of TIB-10-5.
16	And so what was the status of TIB-
17	13-5 going into today?
18	MS. THOMAS: I think it was closed
19	because the only one that was not closed, was
20	04.
21	MR. MARSCHKE: That's what I show.
22	I show that on July 14th, we
	NEVI D CDOCC

1	MEMBER ZIEMER: We closed it.
2	MR. MARSCHKE: we closed it.
3	MEMBER ZIEMER: Right.
4	MS. THOMAS: Yes.
5	MR. MARSCHKE: And so
6	MEMBER ZIEMER: Right, so we need
7	to remove that last wait a minute.
8	MR. MARSCHKE: I don't know how we
9	remove, but I do know I can just basically go
10	in and re-change it.
11	MEMBER ZIEMER: Try editing, maybe
12	the editing will allow you to delete it.
13	MR. KATZ: I think this could I
14	think you'll be able to go in and change the -
15	_
16	MR. MARSCHKE: See, the editing
17	allows me to edit the response. It doesn't
18	allow me to change the status.
19	MR. KATZ: You just have to change
20	it and re-delete the
21	
	MR. MARSCHKE: I'm just going to

1	that the above entry was made in error.
2	(Simultaneous speaking.)
3	CHAIR MUNN: If you're allowed to
4	edit it.
5	MR. MARSCHKE: Every time you make
6	a mistake it's going to be
7	MEMBER ZIEMER: Recorded for
8	posterity.
9	CHAIR MUNN: If you're allowed to
10	edit it, can you make that statement inside
11	the same
12	MR. MARSCHKE: I can't make it
13	inside the same I can edit the same one and
14	basically say that
15	CHAIR MUNN: That's right. The
16	previous sentences were entered in error.
17	MEMBER ZIEMER: Well, you don't
18	even have to mention that. You can just say
19	that we confirmed that it's closed or
20	something.
21	DR. ULSH: We didn't make a
22	mistake, we just
	1

1	MEMBER ZIEMER: You are doing a new
2	finding then, or I mean, a new entry. Are you
3	editing the
4	MR. MARSCHKE: No, I'm making a new
5	entry because I can't edit the status. I can
6	edit the words that explain the status. I go
7	back and take but I can't edit the status
8	itself.
9	MEMBER ZIEMER: The top line there,
10	change "the".
11	MR. STIVER: Also, "remains."
12	MR. MARSCHKE: What other one?
13	MEMBER ZIEMER: Remains, the second
14	to last word.
15	MR. MARSCHKE: Now I can go back
16	and enter I can go back and change the I
17	can go back and change this one.
18	MEMBER ZIEMER: The paragraph
19	marked between them sort of stands out.
20	There.
21	CHAIR MUNN: Good. Now we can go
22	to our agenda item, which is the previous

finding, number 4. So we are looking at TIB-
13, finding 4. We have a final statement that
we had from that entry was from last
September, where we said NIOSH was going to
reexamine the SC&A comments and report back to
the Subcommittee with respect to whether this
was going to be considered an overarching
issue or a site-applicable issue.
MR. MARSCHKE: Right, and we didn't
get that done.
CHAIR MUNN: That is not done
It's going to be another carryover, which is
fine, because we have to populate that anyway
right?
MR. MARSCHKE: Right.
CHAIR MUNN: The next item is OTIB-
52 Rev 1, reduced dose. That's an SC&2
action.
MR. MARSCHKE: Yesterday I updated
the BRS on OTIB-52. So basically there was 13
and 14 needed to be we had them in
progress, and the entry that I made :

reviewed the NIOSH response for 13. This is 13 which is on the screen right now, and I reviewed the response for 13 and I concur with it and I recommend -- this is the whether or they calculate the ratio not, when construction worker to other workers, whether they use other workers as defined as nonconstruction trade workers or is it defined as all monitored workers, which includes construction trade workers.

And I agree with NIOSH that it really, really doesn't make much difference, just a few percentage points difference, which is less than the 20 percent -- what they're using as a cutoff error, cutoff margin.

So -- and I used SRS data. Actually I used SRA data, probably it should be SRS data, to come to that conclusion. So I agree with the NIOSH response on this one, and SC&A agrees with the NIOSH response on this one, and so we'd recommend that this -- at this time that this finding be closed.

## **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

CHAIR MUNN: Any objection to that on the Subcommittee?

MEMBER ZIEMER: No objection.

CHAIR MUNN: Hearing no objection, Finding 13 on OTIB-52 will be closed.

MR. MARSCHKE: Finding 14. This -Finding 14 has to do with -- when you
calculate the ratio of construction trade
worker dose to other worker dose, whether or
not you include the missing dose component.

And you can see in the December 16th, 2011, a reply from Matt Smith that they added a paragraph to 52 kind of explaining why they did it that way.

Some sites, the all-monitored group includes construction trade workers, others it dose not. Some sites the comparisons are made using -- they have been corrected for external missed dose while others made without that correction, analysis made was appropriate -- was adopted to the differences in data but in all cases, the comparisons are consistent for

## NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

each site.

10

11

12

13

14

15

16

17

18

19

20

21

22

I don't think that really addresses the concern. The -- and I would like to see some kind of an analysis where the -- compares the dose -- the ratio of the construction trade worker to all-monitored dose worker dose, including the missed dose component versus when you take out the missed dose component.

What concerns me is, when you add a constant to both the numerator and denominator of a fraction, you are going to drive that fraction towards one, since you're doing this across DOE sites, the fact that it's -- you do it constant or you do it consistently within a site, is good, but it's not sufficient.

I mean, you have to do -- it should be done consistently across the sites because you are trying to come up with one fraction, this factor of 1.4, which is then going to be applied across sites.

So I would like to see a little

1	more about analysis as to what the differences
2	are when you take out the missed dose
3	component.
4	MR. HINNEFELD: I think we just
5	should take this latest entry and write
6	MEMBER ZIEMER: Yes, this we
7	just got this, right?
8	MR. MARSCHKE: Yes, I just yes,
9	I just put this up yesterday.
10	MR. HINNEFELD: Rather than trying
11	to respond on the fly.
12	MR. STIVER: Yes, take some time
13	with it.
14	MR. MARSCHKE: The one you yes,
15	again, I do mention in here, you know, Rocky
16	Flats in particular was one of the files that
17	I looked at where they include them, the
18	missed dose component, and they specifically
19	include the missed dose component.
20	They have it you know, they
21	specifically add it in. And you can see the
22	Excel file I've documented it there that

I used.

10

11

12

13

14

15

16

17

18

19

20

21

22

And so my recommendation at this point is to maintain the status as in progress and to ask for a little bit of additional --

MEMBER ZIEMER: Just help me get a feel for it. Obviously if you had a constant numerator and denominator, it does drive it towards one. But how big is what you're adding, because compared to what's already there?

I mean, what you say is conceptually true, but is it true as a practical point, if you are adding small increments to --

MR. STIVER: It should depend on the increments.

MEMBER ZIEMER: Yes, I just -- let me kind of get a feel for -- is it likely to change the ratio to like, 1.39 or is it going to drive it down to 1.1 or 1.2? That's a kind of a feel for --

MR. MARSCHKE: Well, that's one of

1	the things that we are asking to find out for
2	sure.
3	MEMBER ZIEMER: Oh, you're asking
4	sort of the same
5	MR. MARSCHKE: But I think you can
6	get a what I'm calling up here now, Paul,
7	is the Rocky Flats file and I take it it's a
8	big file so it will take some time to pull it
9	up. But
10	MEMBER ZIEMER: Maybe the answer to
11	that is something that NIOSH wouldn't even
12	look at. I mean, I think the point is
13	theoretically correct. Whether it's of any
14	practical value, I think, depends on what
15	those starting numbers are and what you are
16	adding to it.
17	MR. MARSCHKE: Some of the missing
18	dose components are rather large in the early
19	years.
20	MEMBER ZIEMER: Ah, compared to
21	what the ratio
22	MR. MARSCHKE: That's what I'm
	NEAL R. GROSS

trying to --

10

11

12

13

14

15

16

17

18

19

20

21

22

MEMBER ZIEMER: Well, we don't really know --

MR. MARSCHKE: I'm not sure --

MEMBER ZIEMER: Okay.

MR. MARSCHKE: I think that if you can look at this, let's see.

MEMBER ZIEMER: Well, I don't know that we necessarily solve this right now. I thought maybe you had a feel for something that was telling you that that ratio is changing significantly.

MR. MARSCHKE: This is the file that they used -- that was used to calculate - - to generate this figure here. This is one, a figure 5.5 in the OTIB, and this shows -- the blue line shows the all-monitored worker. This is for Rocky Flats and it shows the monitored worker doses versus the construction worker doses, and again, if you put your thing here, you can see the data comes from the comparison worksheet.

So if we go all the way here to the
comparison worksheet, you can see and also
if you go back here, you can see that the
for example, the construction workers are from
column M of the comparison worksheet.
So if we go back and we look at
column M, we can see that column M is the sum
of G, which is the missed dose component, and
I. See what we've got up here, we've got G
and I.
So G is the missed dose component,
and we are talking about 1,000 millirems. I
is the measured component, and we are talking
about 200 millirems. So the combined factor
here is you know so, more than, what is
that
MR. STIVER: That's almost a factor
of five.
MR. MARSCHKE: The majority of it
is coming from the missed dose component.
MEMBER ZIEMER: Got you, okay,
well, take a look at it then. I was going to

say as soon as I saw that, I'm not going to answer that question. (Laughter.) MEMBER ZIEMER: I mean, there is -obviously there's cases and cases, and you have to see what it -- okay. MR. HINNEFELD: Yes, it is --Thank you. MEMBER ZIEMER: HINNEFELD: -early missed MR. 10 doses can be pretty big because of frequent --MEMBER ZIEMER: 11 Yes. HINNEFELD: That's the bad MR. 12 13 There is some good news --ZIEMER: So this one is 14 MEMBER 15 going to remain in progress. 16 CHAIR MUNN: Yes, it will be progress still. 17 MR. MARSCHKE: Now, let's see. 18 For 19 Findings 1, 15 and 16, we basically had 20 transferred those to OTIB-20 and requesting that some wording change be made to OTIB-20. 21 OTIB-20 has been revised since the issuance of 22

Rev 1, the OTIB-52 and since the issuance of SC&A's critique of Rev 1. And in fact it does include the wording that we were requesting. CHAIR MUNN: I'm looking for it. MR. MARSCHKE: And I'm just going to see if I can pull that up here for you. MEMBER ZIEMER: Okay, this is an example of what I was asking about before. 10 Once it's formally transferred, does it have to be closed in the other system before it's 11 closed here? 12 13 CHAIR MUNN: Yes. See, that wasn't 14 MEMBER ZIEMER: 15 what I heard before. 16 MR. KATZ: Right, and I don't see why. 17 MEMBER ZIEMER: See, that's -- see, 18 19 this shows as transferred and I think what Ted was saying before it -- once the transfer 20 occurs, it's closed here, and I think you are 21 saying, no, it's not closed here until you 22

1	close it in the other system.
2	CHAIR MUNN: Well, that's the
3	reason we track the transfers.
4	MR. MARSCHKE: The other fact of
5	the matter is I don't think it ever there
6	was never a new issue opened under 20 that
7	would have tracked this.
8	So I don't even though we
9	transferred it to 20, we transferred it saying
10	that the action was going to occur in 20, but
11	I don't think we ever opened an issue
12	specifically to under 20 to track this
13	particular problem.
14	MEMBER ZIEMER: So it sort of isn't
15	transferred
16	MR. KATZ: Right, it never was
17	transferred actually. It was just that it was
18	going to get resolved by a change in 20.
19	MEMBER ZIEMER: So this is really
20	intent to transfer.
21	MR. STIVER: We need a new category
22	here.

MEMBER ZIEMER: Okay. I just wanted to make sure we are being consistent. I agree with how you want to do it. CHAIR MUNN: Well, mechanically it should have been in progress. MEMBER ZIEMER: It hasn't really been transferred yet, but --MR. MARSCHKE: Basically this is the sentence right here. Basically it also 10 notes that in certain construction trade, pipe 11 fitters may have received higher exposure than the construction trade in general, therefore 12 13 they might fall into a category expected to have been monitored. 14 15 mean that was really the I sentence that we were looking for. We wanted 16 the dose reconstructors to be aware that there 17 are certain categories of construction workers 18 19 that may require special attention. The 1.4 multiplier from OTIB-52 may 20 particular construction 21 not cover some workers, not just pipe fitters. So -- and now 22

1	this has been showing up in OTIB-20. What we
2	are recommending back in for example 15,
3	52-15, basically we said you can see here
4	we had it transferred to OTIB-20 and we are
5	saying that on November 14th, OTIB-20 Revision
6	3 was issued with the requested change to
7	address the OTIB-52 findings. Thus SC&A
8	recommended that these three findings be
9	changed to closed.
10	So that same wording has been
11	I've added that same wording to basically each
12	of these three 52 findings, 52-15, 52-16 and
13	52-1.
14	CHAIR MUNN: All three of them now
15	have the same statement in it?
16	MR. MARSCHKE: They have the exact
17	same statement.
18	CHAIR MUNN: Any objection from the
19	Subcommittee?
20	MEMBER ZIEMER: So that means they
21	are transferred?
22	CHAIR MUNN: No.

1	MR. KATZ: They're closed.
2	CHAIR MUNN: They're closed now.
3	MEMBER ZIEMER: They're closed?
4	MR. MARSCHKE: Well, they will be
5	closed if the Subcommittee agrees to close
6	them.
7	CHAIR MUNN: They were transferred
8	and to
9	MEMBER ZIEMER: And have been
10	addressed.
11	CHAIR MUNN: And have been
12	addressed, yes.
13	MR. MARSCHKE: And they have been
14	addressed. And the action was taken by
15	whoever was responsible for OTIB-20, the
16	action was taken by that person and so now we
17	can close these here.
18	CHAIR MUNN: Any objection from the
19	Subcommittee?
20	MEMBER ZIEMER: Sounds good.
21	CHAIR MUNN: If not, OTIB-52,
22	Findings 1, 15 and 16 are closed. How very
	NEAL D. ODOGG

1	nice. And this means what finding did I
2	have where I made a note to myself that NIOSH
3	was going to respond to SC&A's request for
4	more analysis. What finding was that?
5	DR. ULSH: Finding 14.
6	CHAIR MUNN: That was 14?
7	MR. KATZ: Yes, it's in progress.
8	MEMBER ZIEMER: It's in progress.
9	CHAIR MUNN: All right.
10	MR. MARSCHKE: Wait a minute, I'm
11	just let me catch up, Wanda, because I want
12	to talk about one more thing while we're on
13	here.
14	CHAIR MUNN: On 52?
15	MR. MARSCHKE: Yes. Kind of on 52.
16	It's another one of these transferred things.
17	CHAIR MUNN: Thank you very much.
18	MR. MARSCHKE: OTIB-14, finding
19	number one, if we can go to that for a second.
20	MEMBER ZIEMER: What's the title of
21	it?
22	MR. MARSCHKE: It's assignment of
	NEAL R. GROSS

environmental internal doses to employees not

-- wait a minute.

MEMBER ZIEMER: Yes, not exposed to
airborne?

MR. MARSCHKE: Airborne
radionuclides in the -- something.

MEMBER ZIEMER: Yes, got you.

MR. MARSCHKE: Basically there was only one finding in it and that one finding was transferred to OTIB-52, but obviously, again nothing had ever -- nothing was ever opened in OTIB-52 to receive it, so it's a similar type of thing as with OTIB-52 and OTIB-20.

Now that we have this -- the wording in OTIB-52 and OTIB-20, I believe that the concern here was -- this was just a very generic concern saying that particular care must be taken when assigning a construction worker to a given category of exposure due to the highly diverse nature of exposures that some construction workers experience.

## **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

ı	
	So really the question is: what
	does the Subcommittee want to do with this? I
	mean, I would recommend, I guess, at this
	point that this probably should be closed,
	because pretty much for all intents and
	purposes, OTIB-20 or OTIB-52 has all been
	taken care of
	CHAIR MUNN: Well, back in December
	didn't we close it? We recommended that it be
	closed. NIOSH did.
	MR. MARSCHKE: NIOSH recommended
	that it be closed.
	CHAIR MUNN: And we didn't close
	it? Why not?
	MR. MARSCHKE: Because OTIB-14 is
	not applicable to construction trade workers.
	Finding well, I'm not sure that that's
	true. That's not really a true statement, I
	don't believe.
	Last time I looked at OTIB-52
	OTIB-14 I should say OTIB-14, I mean if you
	go down and say they have this this is

another reason for closing it, but I mean they say OTIB-14 specifically says, addresses, right here, it says construction workers and it has you know, pipe fitters, plumbers, and so on and so forth, so they do talk about OTIB-14 does apply -- to me it does apply to construction workers.

MR. HINNEFELD: Can you just scroll up most of the three categories of workers that are on this page? So there's potential for workplace exposure -- hang on -specific, some potential for workplace exposures, and then have little or no potential for workplace exposures.

So let's go to the top of the document, because if this is assigning environmental dose, that should only be done for people who have little or no potential for it.

MR. MARSCHKE: That's what this is.

This is basically -- these people up here
have no potential. These people get the

## **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	environmental dose.
2	MR. HINNEFELD: Right.
3	MR. MARSCHKE: The people in the
4	middle here get the, you know, basically would
5	receive the 50 percentile dose and the people
6	<del></del>
7	MR. HINNEFELD: What's the title of
8	the document?
9	MR. MARSCHKE: The title of the
10	document is environmental. Assignment of
11	environmental internal doses to employees
12	not exposed to airborne radionuclides.
13	MR. HINNEFELD: Okay, so the fact
14	that construction shows up in those bottom two
15	categories means that you wouldn't do this for
16	them, because this is a document that you
17	would this tells you to assign
18	environmental to people who are not exposed
19	MR. MARSCHKE: That's right.
20	Basically, yes. The fact that the fact
21	that the construction workers show up here in
22	categories 2 and 3, you would not assign I

1	agree with you on that.
2	MR. HINNEFELD: So my thinking, the
3	statement in a the statement here from
4	December is correct, that 14, you know the
5	assignment of environmental dose, which is
6	what 14 speaks of, doesn't apply to
7	construction workers. In fact, it
8	specifically excludes construction workers
9	from the assignment of environmental dose.
10	And so we think I would support
11	closing the finding based on that.
12	DR. MAURO: I agree with Stu. It's
12	DR. MAURO: I agree with Stu. It's
13	John.
13 14	John.  MR. HINNEFELD: Thank you.
13 14 15	John.  MR. HINNEFELD: Thank you.  CHAIR MUNN: Any opposition?
13 14 15 16	John.  MR. HINNEFELD: Thank you.  CHAIR MUNN: Any opposition?  (No response.)
13 14 15 16	John.  MR. HINNEFELD: Thank you.  CHAIR MUNN: Any opposition?  (No response.)  CHAIR MUNN: Please close this.
13 14 15 16 17	John.  MR. HINNEFELD: Thank you.  CHAIR MUNN: Any opposition?  (No response.)  CHAIR MUNN: Please close this.  DR. ULSH: That wasn't even on the
13 14 15 16 17 18	John.  MR. HINNEFELD: Thank you.  CHAIR MUNN: Any opposition?  (No response.)  CHAIR MUNN: Please close this.  DR. ULSH: That wasn't even on the agenda, was it?

1	brownie points for all the things that need
2	done but we didn't do.
3	CHAIR MUNN: We can give you a big
4	hurrah.
5	MR. STIVER: And some compensation
6	
7	CHAIR MUNN: Now, while Steve is
8	working away at our last entry that we just
9	discussed, it's time for us, I think, to break
10	for lunch.
11	MR. KATZ: Before we do can I just
12	a clarification for me if only for me. So,
13	if Finding 14 is in progress, is everything
14	else closed in 52?
15	DR. ULSH: Finding 14.
16	MR. KATZ: Fourteen, yes, that's
17	what I said.
18	DR. ULSH: I thought you said four.
19	MR. KATZ: It is in progress.
20	Finding 14 is in progress, but is everything
21	else associated with 52 closed, so we
22	MR. MARSCHKE: Oh, wait a minute.

1	Hans, are you on the phone?
2	CHAIR MUNN: No, we have Finding 14
3	is outstanding.
4	MR. KATZ: That's what I said. I
5	said 14 is in progress, but is everything else
6	other than Finding 14
7	MR. MARSCHKE: Well, of the 16
8	findings, I believe what you said is true.
9	MR. KATZ: Okay. That's what I
10	thought. I understand.
11	MR. MARSCHKE: Now on 52 I'd like to
12	bring up one more thing, and when Hans was
13	preparing PER for this, I think it was PER-14.
14	MR. STIVER: PER-14, yes.
15	MR. MARSCHKE: He had some concerns
16	about the way the database of doses was being
17	utilized. Specifically, let me try to
18	paraphrase what Hans's concern was, and John
19	Mauro or John Stiver, you can correct me if
20	I'm wrong.
21	DR. MAURO: Yes, I'm listening.
22	DR. H. BEHLING: I'm here too.

**NEAL R. GROSS** 

WASHINGTON, D.C. 20005-3701

MR. MARSCHKE: Oh good, Hans.

DR. MAURO: Okay, we're all here.

MR. MARSCHKE: Good. The concern was that construction workers do not spend -- may not spend the entire year at the site, so their annual exposure may represent not really an annual dose, but maybe a dose over a couple of months, a month, six months, some shorter time period.

So if you include that shorter time period exposure, or that exposure is included in the database, and then it gets factored into the, kind of the roll-up, the 90th percentile, it may underestimate a true annual 90th percentile, because the 90th -- the doses are being made up of -- the annual doses are not being made up not of annual exposures, but of exposures that occurred over a somewhat shorter period of time.

So the concern is that the, you know, the coworker dose model, which is coming up, and coming up with the 90th percentile or

## **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

the 50th percentile based upon these roll-ups, is not claimant-favorable.

DR. H. BEHLING: And let me just make a comment here. This is Hans. I made an assumption that goes back to my experience within the utilities, with the utilities, which may not be specifically applicable here.

But in the utilities, you'll hire transient workers during outages which are very, very brief, and in some cases you hire people from the union hall on an as-needed basis.

And so when I look at the data that reconstruct these values, I was used to assumed that they used annual doses for people who considered construction trade were workers, versus all others, which in some cases also includes construction workers, and the assumption that on construction trade workers may have very brief periods of exposure, their annual doses are not exactly based on 50 weeks of work,

## **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

therefore when you look at those comparisons, you may be short-changing the true values that should have been used, and I will also assume that if you have now a construction worker and you go back to his employment history, if he, for instance, is shown to have an employment for one year for, let's say, a two-month period, I would assume that he will be prorated for that dose for two months as opposed to for the whole year, which means that in the end, you are mixing apples with oranges, and that was my concern.

MR. HINNEFELD: Well, sitting here today, I don't know how they did that. I understand the point.

MEMBER ZIEMER: Well, I think you can also -- this is, partially you can have a little bit of philosophical debate on this, is that the -- you have the workers that are, as Hans described, which have a shorter time span, but they are part of the distribution that represents the real distribution of the

## **NEAL R. GROSS**

real workers. It actually spreads it maybe toward the low end a little bit. Whether it affects the upper tail would remain to be seen because you do have a distribution. That's number one.

Number two, you can probably argue that even regular workers have the same sort of thing in that they are not always in the exposure mode all the time they are working. They have other things that they are doing. Maybe they are doing paperwork. I mean, as an HP, I was not exposed 24/7 as it were. I was in the office recording surveys and so on part of the time. My exposure would not have been every workday either.

So I am not necessarily saying that you shouldn't make it -- you know, normalize it to a year, but I think you have to think carefully about whether using the true distribution, which is what you have, versus -- because then, why wouldn't you do that with other workers, saying well, they are actually

## NEAL R. GROSS

1	out in the radiological area only 50 percent
2	of the time, so we are going to normalize
3	their numbers upwards, and I think you have to
4	have that discussion. I think Hans's point is
5	one that is worth thinking about, and maybe
6	NIOSH needs to think about that too, but I
7	think you have to be careful in how you
8	interpret that.
9	DR. ULSH: Also, I suspect that
10	even non-construction workers, if we didn't
11	prorate the construction workers, we didn't
12	prorate anyone else either. I do agree
13	DR. H. BEHLING: If I could make a
14	comment
15	(Simultaneous speaking.)
16	MR. KATZ: One at a time.
17	DR. ULSH: Let me finish. I do
18	agree with Hans that it would be a bigger
19	issue for journeyman-type construction
20	workers.
21	MEMBER ZIEMER: Yes.
22	DR. H. BEHLING: But let me just
	NEAL R. GROSS

make a comment here. For instance, when I was in the utilities, we had obviously rad techs who spent every day in the field too, and they would do obviously job coverage on RWPs and so forth.

But then comes an outage, and you have people who are now representing rent-a-techs who are there for the duration, and oftentimes just for a few weeks or a few months, a couple of months.

And you would now have, obviously, technicians, rad technicians who are in the field, who are in-house, versus the rent-atech who may be there obviously for a very brief period of time or at least only a fraction of the year.

And then both parties would be exposed, obviously, throughout the time period they were employed. One, the in-house tech would be by and large exposed for the 12 months duration of a year, and the rent-a-tech would be there for perhaps two or three

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

months.

10

11

12

13

14

15

16

17

18

19

20

21

22

And so those are the comparisons that I was looking to draw attention to.

I believe that there MR. MARSCHKE: discussion at some point about necessarily construction workers, but the -all site workers, about what to do with the first year and last year of their dose because, just exactly because records, this, there may not be a complete year annual record, and I just can't put my finger on where that discussion was held and in what context that discussion was held, but I think that this has been brought up, not necessarily for the context of construction workers, which probably is more of a concern for them, but I do think that partial year exposure has been discussed as to you know, workers' beginning dates and workers' ending dates. So --

CHAIR MUNN: Yes, for some reason that I can't put my finger on, I'm thinking Rocky Flats. We had some kind of discussion

many, many years ago about that. But Hans and John, aren't your concerns captured in Finding 1 of your evaluation -- review of the PER?

DR. H. BEHLING: Let me see here.

CHAIR MUNN: Your Finding 1 says,
"In the event of annual doses for a CTWs and,
to a lesser extent, for AMWs, we are not
adjusting to account for exposure on
employment periods of less than a full year,
the recommended deep dose adjustment factor of
1.4 may not be claimant-favorable."

Although you only mentioned the deep dose adjustment, doesn't that capture the basic concern?

DR. H. BEHLING: Yes, that's pretty much the sum of my concern, is that in your actually have write-up you the actual I don't know if anything like comparison. that was normalized. In other words, if the employment period between construction non-construction workers adjusted were reflect any changes or differences in terms of

## **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

exposure period or employment period.

CHAIR MUNN: I guess my only question is, our discussing this now, at this particular moment, I don't see that this particular PER has been populated yet on our database.

It's showing in the database but not yet populated, as I see it, and if that's the case, then we have not had an opportunity to address your review here in this forum.

Perhaps the discussion, although pertinent, is a little early for us to be addressing it. Am I misreading what the information is here that I have?

DR. H. BEHLING: No, I think in fact I wasn't really prepared to even discuss it because I didn't really see it on the agenda for today.

DR. MAURO: Wanda, this is John. I think the dilemma we have here is in the process of working through a PER which referenced OTIB-52, Hans said, jeez, I'm

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

noticing something. There might be an issue on 52, even though it wasn't brought up, found as an issue. When we review OTIB-52, it may very well be an important issue to OTIB-52, so we are in this sort of uncomfortable position. We already sort of signed off, said everything's fine. But then Hans said, wait a minute, what about this? You know, when you OTIB-52, did take reviewed you into consideration this time period issue? example, if you've got а guy who construction worker and you're going to the OTIB-52 approach as a coworker model, and if that OTIB-52 approach, you know, didn't into consideration that construction take workers very well may not have been monitored for a full year, you have a dose for 1969 or whatever, but he really was only exposed for three months in 1969, so that coworker model -- you see the nuance here.

So unfortunately, what I think we are saying here is that I think we have a new

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

issue for OTIB-52, or we might, that we really never explored, and we may not have it right, but the concept, as articulated by Hans, I think is worthy of some consideration by NIOSH.

I think everyone understands the issue and I do believe that it goes to OTIB-52, and of course it also goes to the PER, which relies on OTIB-52.

MR. KATZ: Right, and John, there's nothing unfortunate about this. It's good. It's an issue that we need to resolve, and I agree that it should be added and we'll --

CHAIR MUNN: This is an interesting process question, because, to the best of my knowledge, we have not had an additional finding brought up after we have essentially closed out the original findings, and the question in my mind is how best to do that so that it establishes a precedent if we have this occasion.

DR. ULSH: But it's already

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

captured under the PER-14, so it could be addressed there rather than under --

MR. STIVER: Yes. Instead of putting it back under 52, we could address it under PER-14 --

MR. HINNEFELD: We've actually had

MR. STIVER: -- with appropriate linkages.

MR. HINNEFELD: We actually did have an analogous finding, in the lymphoma PER when there was discussion -- it ended up not really being resolved or resolvable on the NIOSH side, but the discussion was about historically, how do we know that lymphomas really correctly characterized were as Hodgkins or non-Hodgkins, and that came up in the PER, and so we said, well, that was not something we could deal with because it's I mean, Hodgkins is one -- and the law, since it distinguished between the two, it assumes the distinction.

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	MR. KATZ: So that's fine. So if it
2	stays under the PER and the resolution is that
3	there's some change needed to OTIB-52, then
4	OTIB-52 will get changed.
5	MR. HINNEFELD: Yes.
6	MR. STIVER: It's just another way
7	of giving back to the
8	CHAIR MUNN: So it appears that our
9	primary necessity right now is to get the PER-
10	14 database, I mean 13
11	DR. ULSH: Fourteen.
12	CHAIR MUNN: It is 14 database
13	populated the way we already have TIB-13 that
14	needs to be populated. Is there any problem
15	with seeing to it that these two findings for
16	PER
17	DR. ULSH: I've taken it down as an
18	action item for us.
	assisis is as as .
19	CHAIR MUNN: Good.
19 20	
	CHAIR MUNN: Good.

DR. ULSH: I'll put it down as an action item for Steve. (Laughter.) MR. HINNEFELD: If you guys have got your, you know, your finding summaries written, Steve, the database does that. It'll allow -- it should allow you to assign it to this Subcommittee and move it over. MR. MARSCHKE: Yes, I agree. 10 MR. HINNEFELD: PER-14 looks to be 11 unassigned. If you go to the front page of 12 our --13 CHAIR MUNN: Is it not a summary? MR. HINNEFELD: Yes, it's in the 14 15 unassigned queue. If you go up --16 CHAIR MUNN: Oh, okay. HINNEFELD: Go to the Board 17 MR. review unassigned queue, 18 and then it will 19 build it and then if you want, you can -- you can just look at PER, which you are not going 20 to type --21 22 MR. KATZ: So then this will be --

1	this could be an agenda item for the next
2	CHAIR MUNN: Yes.
3	MR. STIVER: It should be for the
4	next meeting.
5	MR. KATZ: PER-14.
6	CHAIR MUNN: Yes, it would be.
7	DR. ULSH: To talk about SC&A's
8	findings.
9	MR. HINNEFELD: Yes, in fact, now
10	are there other PERs that I've lost track.
11	I mean, if you guys have done reviews of
12	MR. STIVER: This was really the
12	MR. STIVER: This was really the only one that is new since the last meeting.
	only one that is new since the last meeting.
13	only one that is new since the last meeting.
13 14	only one that is new since the last meeting.  We still have two others in the queue that we need to begin, 17 and 29.
13 14 15	only one that is new since the last meeting.  We still have two others in the queue that we
13 14 15 16	only one that is new since the last meeting.  We still have two others in the queue that we need to begin, 17 and 29.  MR. HINNEFELD: Okay, so, but when
13 14 15 16	only one that is new since the last meeting.  We still have two others in the queue that we need to begin, 17 and 29.  MR. HINNEFELD: Okay, so, but when I mean, I think going forward, when you finish your review, it could just be the
13 14 15 16 17	only one that is new since the last meeting.  We still have two others in the queue that we need to begin, 17 and 29.  MR. HINNEFELD: Okay, so, but when I mean, I think going forward, when you
13 14 15 16 17 18	only one that is new since the last meeting.  We still have two others in the queue that we need to begin, 17 and 29.  MR. HINNEFELD: Okay, so, but when  I mean, I think going forward, when you finish your review, it could just be the automatic step to take it from an assigned

1	that step yet.
2	MR. HINNEFELD: All right. Okay.
3	MR. KATZ: I agree.
4	MR. MARSCHKE: So all we've got to
5	do here is assign it and we can do it right
6	now.
7	MR. HINNEFELD: Yes, you can assign
8	it and then I don't know when it comes up.
9	MR. MARSCHKE: Only choice we have.
10	MR. KATZ: Right.
11	MR. MARSCHKE: Assigned to Work
12	Group.
13	CHAIR MUNN: All right. Then we'll
14	have an opportunity to address those two
15	findings at our next meeting. So we'll have
16	the database. Thank you, John and Hans. We
17	appreciate it.
18	Anything else? If not, then let's
19	break for lunch, and let's take an hour and
20	be back at 1:30.
21	MR. KATZ: Okay. Thanks, everyone
22	on the line. I'm cutting the line. See you

at 1:30, or hear you.

(Whereupon, the above-entitled matter went off the record at 12:28 p.m. and resumed at 1:30 p.m.)

17

18

19

10

## **NEAL R. GROSS**

# A-F-T-E-R-N-O-O-N S-E-S-S-I-O-N (1:30 p.m.)MR. KATZ: Good afternoon. We are back, dose reconstruction -- no. We are not. Procedures Review Subcommittee, Advisory Board on Radiation and Worker Health. Let me check on the line and see if we have our Board Member Mike Gibson. MEMBER GIBSON: Yes, I'm here Ted. 10 MR. KATZ: Oh, that's great. 11 you. Wanda? CHAIR MUNN: I'm ready. Let's take 12 13 up our agenda where we left it, with our introduction of the new overarching 14 issues database list. 15 16 NIOSH made any progress on putting together that list? 17 18 DR. ULSH: Not yet. 19 CHAIR MUNN: Okay. We have no The status of the 20 actions to carry over. two-pagers has not improved so far as I know 21

very much from the last time. It was intended

that we would try to put together a -- that three of us would be working on this in the interim. have done one additional myself but have not shared it with anyone, and that's not very helpful. Paul, do you have anything to add? MEMBER ZIEMER: Well, let me just confirm that we are talking about the 15 two-10 pagers that were distributed in March of 2011. 11 MR. KATZ: Yes. CHAIR MUNN: Yes. 12 13 MEMBER ZIEMER: About a year ago. CHAIR MUNN: Those 15 for starters. 14 15 And the other full list actually. 16 MEMBER ZIEMER: I have gone through all these and I have done markups but I had a 17 sense of deja vu going through these that I 18 19 might have done markups on these before on a tracking thing but I couldn't find it on my 20 computer here or at home so maybe I never did 21

WASHINGTON, D.C. 20005-3701

that.

CHAIR MUNN: Why don't I make an effort to --MEMBER ZIEMER: See if I sent them to you but in any event I have got handwritten markups on all of them. I think there's only two that I thought were sort of clean and --MR. KATZ: Ready to post. MEMBER ZIEMER: -- unadulterated, sort of ready to post, but I think we need to 10 have everybody look at them, not just me and 11 so --Well, we had agreed CHAIR MUNN: 12 13 last time that if you and I and Dick had agreed that they were in pretty good shape, 14 15 that we would just go ahead and accept them, 16 provide them and accept them. MEMBER ZIEMER: I can go ahead and 17 convert these to track changes format 18 19 distribute them. Well, if you have a 20 CHAIR MUNN: couple of minutes after we adjourn here, 21 22 perhaps you and I should take a look at some

1	of them and we'll go from there and commit to
2	doing a better job of bringing something for
3	the rest of the group to look at on at our
4	next meeting.
5	MR. KATZ: I think in reality, I
6	mean, what we talked about, the rest of the
7	group is not going to look at anybody who
8	wanted to provide discussions will have
9	CHAIR MUNN: Yes.
10	MR. KATZ: So it's not that, we'll
11	just post them once you and Paul
12	CHAIR MUNN: We'll just post them.
13	MR. KATZ: So if you and Paul want
14	to get together and
15	CHAIR MUNN: We'll do that and
16	we'll
17	MR. KATZ: Just send me clean
18	versions and we will get them posted.
19	CHAIR MUNN: We'll start our web
20	page here. Okay?
21	MR. KATZ: Okay.
22	CHAIR MUNN: Good. Status of new
	MEAL D. CDOSS

available for review list for SC&A. NIOSH, has that been put together? MR. HINNEFELD: Well, we've got it. It may not be entirely up to date, but it's the unassigned queue in the application. MR. STIVER: Yes, we talked about that in the hallway after lunch. CHAIR MUNN: Did you get a chance to look at that? MR. HINNEFELD: I mean we can go 10 11 through their -- we can do that now. CHAIR MUNN: It's nice to have them 12 13 in that concise list. MR. HINNEFELD: There may be a few 14 15 more that can be added because this -- it 16 doesn't get updated automatically. And when a new document comes out then -- that's 17 We can go through the list of all the 18 19 documents. We divided them between the ones that had comments and the ones that -- there 20 may actually be a couple in here that were 21

reviewed and had no comments. That's the only

thing we could do, we couldn't identify those easily and they might still be here. But for the most part these then have not been --

CHAIR MUNN: Ι quess the real question from the Subcommittee's point of view needs to be what SC&A views as of specific or particular interest to them, if at because the matter of fact that a procedure exists does not necessarily demand that require SC&A review, and if there's outstanding interest in some of these, or concern with respect to how some of these specifics are approached, the Subcommittee would like to hear it.

MR. STIVER: As at the last meeting, we have prepared a list. This is based on the 2009 summary table that Brant had produced. This was back in the time when we didn't have access to the -- the Board Review System wasn't working correctly, and we had identified 11 potential candidates for review.

At this point though I think that

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

we would want to go back and look through -take a more careful look at the latest
additions to that, maybe put together an
updated list of things that we thought might
be good candidates and then bring that back.

CHAIR MUNN: Well, you understand,

CHAIR MUNN: Well, you understand,

I don't think the Subcommittee wants to
encourage you to -- there's no interest in
giving you things to review for review's sake.

If you have --

MR. STIVER: Absolutely, that's why we had identified some that we thought might actually benefit from a review of the --

CHAIR MUNN: It would be helpful, I think, for us to have that. Are you prepared to mention any of those to us today? Or would you prefer to defer this item?

MR. STIVER: I would prefer to have a complete listing actually. I mean we have the other ones from the previous meetings which we could run through I suppose --

CHAIR MUNN: Well --

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

STIVER: I mean it wouldn't MR. hurt to do that. CHAIR MUNN: I don't see that that would merit much -- would be very productive probably at this point. MR. STIVER: Yes, I think that it would be better for us to have a comprehensive list of everything that is available at this point that we -- after we have reviewed them 10 and have a better feel for which ones might actually benefit from a review by SC&A. 11 CHAIR MUNN: I think that would 12 13 probably be helpful, especially now that you have this excellent unassigned queue 14 from 15 which to work. And as I said, we are not 16 looking for something to assign to you. are just asking if you have concerns based on 17 -- perhaps links from one to the other. 18 19 MR. STIVER: Yes, and I think that would be a good tasking for us then to go 20 ahead and prepare a list for discussion. 21 22 All right.

CHAIR MUNN:

That's a

carryover.

MR. MARSCHKE: All these documents
that are in this unassigned queue, where can
we get copies of the documents themselves?
Are they all available on the a lot of them
are basically like looking up in all these
report documents. They are in the unassigned
queue, but they are just given the number,
like report 19, report 20, report 11 and
report 10. You know, we don't know what the
title is of it. We don't know so we can't
really, from looking at this we can't really
see whether or not we can make a
recommendation as to whether it should be
reviewed or not. We'd have to get a little
bit more information than what is available in
the

MR. KATZ: So, when they are loaded on here there is not a link to the actual document?

MR. MARSCHKE: Well, let's just try that. The last time I clicked on it, that's

### **NEAL R. GROSS**

1	how we go to the that's how you get it
2	assigned.
3	MR. HINNEFELD: I think in the
4	unassigned queue that's not working.
5	(Simultaneous speaking.)
6	MR. KATZ: So maybe the thing to do
7	is just to get them so that linked so that
8	they can click on these and actually see the
9	document?
10	MR. HINNEFELD: We could do that or
11	we could put the documents where we could see
12	them.
13	MR. STIVER: Either way it would
14	work, as long as we have access to them
15	
	without having to go up and down.
16	MR. KATZ: Whatever's easiest.
16	MR. KATZ: Whatever's easiest.  MR. HINNEFELD: They're on K:
16 17	MR. KATZ: Whatever's easiest.  MR. HINNEFELD: They're on K:
16 17 18	MR. KATZ: Whatever's easiest.  MR. HINNEFELD: They're on K:  CHAIR MUNN: It would be very
16 17 18 19	MR. KATZ: Whatever's easiest.  MR. HINNEFELD: They're on K:  CHAIR MUNN: It would be very  helpful to have a

\_\_\_

10

11

12

13

14

15

16

17

18

19

20

21

22

MR. KATZ: But on K: is fine.

MR. HINNEFELD: I mean they are O:
They are not currently on their O: We would
have to put them there. We would make a file
under ABRWH and then --

MR. STIVER: And call it unassigned.

MR. HINNEFELD: And then Procedures Subcommittee and then put it in there and just say unassigned documents or something and you could write them in there, and then they come in several categories, you know, reports, PERs, they each have their own folder on our K: drive and so we can do that.

But what we'll do is we'll check with TSD and say it would be better to do that or to build a link from this application to --

MR. KATZ: Whichever's easier. So when you come up with a new version of a document that has already been reviewed, does that also automatically end up in the --

#### **NEAL R. GROSS**

MR. HINNEFELD: No, that's part of the process we have to build. MR. KATZ: Okay. MR. HINNEFELD: Because it doesn't automatically go in here and that's why I think we are several behind on this. So you got that too Brant? DR. ULSH: Yes. I'm just going to CHAIR MUNN: 10 assume that you are going to bring us some magic way that we can go from this unassigned 11 list --12 MR. HINNEFELD: Yes, and I think we 13 should have something ready on this well 14 15 before the next meeting. It shouldn't take 16 very much time --CHAIR MUNN: Good. 17 MR. HINNEFELD: -- either to decide 18 19 what we are going to do on our side and either move them to where you can see them on your O: 20 drive or build -- have the application linked 21 22 on an open --

MR. STIVER: Okay, well we'll just stay in contact with Brant and --

MR. HINNEFELD: Yes, there's no reason to wait until the next meeting to have that in place. I think we can have that in place pretty quickly.

CHAIR MUNN: That's good. That would be helpful for everybody actually. Thank you Stu. Any other comments about this unassigned list? Then --

MR. MARSCHKE: Well, wait a minute. There is one other thing. I mean, in some cases we reviewed -- I mean if you look at the list that John was talking about, in some have reviewed a version of cases we the document, and then the document has subsequently gone and been reissued as to like this morning we talked about version 4 of OCAS or DCAS-TIB-10 or whatever it was. Now there may be other documents -- just because it's in the assigned queue, there may be documents that are in the assigned queue that have one

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

or more revisions been issued since the last time SC&A reviewed it, because looking at the -- again, looking at the list that John was talking about, that was one of the reasons -- that was one of the criteria for putting it on as a potential re-review because it has a full -- been fully revised since the last time SC&A reviewed it.

Now, again, it's up to the Board or the Subcommittee as to whether or not you would like us to take another look at some of these that we have -- I know that, like, we talked about IG-1. We have reviewed that one at least twice. There may be other ones which we would want to go back and re-review. So you know, I don't know that we would want to, you know, limit ourselves to the unassigned queue, let's put it that way.

And that's why we were -- I know that in the past NIOSH has published periodically a complete list of all their documents, where they stood, and you know,

#### **NEAL R. GROSS**

1	which ones what versions they were, and
2	kind of like for their own document control
3	purposes, and that's the that's what John
4	was talking about that we a version of that
5	document we got from, that was a 2009 version
6	of that document.
7	But I don't know if they continue
8	to do that anymore or
9	MR. HINNEFELD: Well, we can I
10	don't think we routinely generate it, but I
11	think we could generate it.
12	CHAIR MUNN: It might be very
13	helpful for all involved to know exactly what
14	
15	MR. STIVER: If you could do that,
16	that would provide us that in addition to
17	the unassigned queue would probably give us
18	what we need to put together a complete list.
19	MR. HINNEFELD: Okay.
20	DR. ULSH: Can you review what that
21	was again?
22	MR. HINNEFELD: Well, generate a
- 1	1

1	list of all the current the current
2	documents, the current revisions of, you know
3	
4	MR. KATZ: The rev status of all
5	the
6	MR. HINNEFELD: Yes, the rev status
7	of the documents. The list of the documents
8	and the revs which rev that is.
9	MR. KATZ: Yes, okay.
10	MR. MARSCHKE: I could send you a
11	version of what I am talking about, Brant.
12	MR. STIVER: Yes, send him the old
13	trial that we had from before.
14	MR. MARSCHKE: Well, I don't
15	I'll send him the file that we used to
16	generate her file if I can find it.
17	MR. STIVER: I have it on my
18	machine at SC&A if you can't find it.
19	CHAIR MUNN: All right. Anything
20	else on that topic?
21	(No response.)
22	CHAIR MUNN: Otherwise, update on

1	the PER reviews? SC&A, do you have anything
2	new to add on where you are with yours?
3	MR. STIVER: We have a PER-14 that
4	we talked about just this morning.
5	CHAIR MUNN: Yes, that's out, if
6	anyone hasn't had an opportunity to look at
7	it, it's available to you.
8	MR. STIVER: Right. Hans, are you
9	on the line?
10	MS. K. BEHLING: Hans is not on the
11	line. I can put him on, hold on one second
12	please. This is Kathy.
13	CHAIR MUNN: Hi Kathy.
14	MS. K. BEHLING: Hi Wanda, how are
15	you?
16	CHAIR MUNN: Just fine. It's good
17	to hear your voice.
18	MS. K. BEHLING: Oh, thank you.
19	DR. H. BEHLING: I'm here.
20	MR. STIVER: Hans, could you give
21	kind of an overview of PER-14 for the
22	Subcommittee, just kind of a broad brush-

1	stroke overview of the issues?
2	DR. H. BEHLING: Okay. I just put
3	it away. I thought that was going to be a
4	topic for next time.
5	CHAIR MUNN: Well, we are
6	definitely going to do that next time. Well,
7	we are certainly going to
8	DR. H. BEHLING: Those who may have
9	a copy of it, I can just briefly identify some
10	of the leading findings that I had. I think
11	we touched on
12	CHAIR MUNN: We touched on Finding
13	1, there were two findings.
14	DR. H. BEHLING: Yes, hold on for a
15	second.
16	CHAIR MUNN: The two of they're
17	it's on page 11. The two findings.
18	DR. H. BEHLING: Let me just
19	yes.
20	CHAIR MUNN: And they aren't really
21	that extensive, although judging from our
22	discussion earlier this morning, and the

bearing that they have on OTIB-52, we are a
long way from being completely done with it I
think.
DR. H. BEHLING: Yes, I think
finding number two was the question that I had
between trying to decipher what it means that
the issue for condition number two for all
sites seek internal dose to be determined
using the same method as is applied to all
other workers.
I don't know what that means.
CHAIR MUNN: Yes.
DR. H. BEHLING: There were a
number of things that were very difficult for
me to get a full grasp because I was really
not part of the discussion groups that
involved the OTIB and therefore I was somewhat
at a loss to really have a full understanding
of what may have been discussed in previous
sessions.
CHAIR MUNN: That is always
difficult

DR. H. BEHLING: I don't know if someone from NIOSH can respond to that particular finding.

CHAIR MUNN: Well, we'll have an opportunity to begin to address that at our next meeting. That will be on our list.

DR. Η. BEHLING: Yes, and there were a couple of other things that I really had a question about, what happens to people whose dose reconstructions were performed prior to the development of a coworker model, and you realize -review and mу Ι identified those various states, for the facilities that currently have a coworker model, but in many instances that was only made available in recent couple of years, and anyone whose dose reconstruction took for place before that, and who do not have any assigned coworker dose, what does that mean in terms of will they be given another chance to have their dose reconstruction done at another time frame under different circumstances?

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

That was really the key issue here. MR. HINNEFELD: Yes, this is Stu Hinnefeld. What should have happened in those the claims situations is that needed coworker treatment shouldn't have been -- the dose reconstruction shouldn't have been done until the coworker was available. reconstructions that would have been done, would have used one of the overestimating approaches that were used early on in the TIB-2 or TIB-4, you know, whichever the pertinent overestimating approach was, and then -- and there shouldn't have been any dose reconstructions done for someone who needed a coworker approach until the coworker model was available, because that's, you know, in part those overestimating approaches why were adopted, because thought we we disposition some claims in advance of doing the work necessary for the coworkers, coworker studies.

Now, so that's what should have

#### **NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

10

11

12

13

14

15

16

17

18

19

20

21

happened. Now, you know, I guess the question remains: should there be an effort, or did we go back and look even when we posted coworker — I don't know, to be honest, whether we did or not, if we looked in the posted coworker model and said okay, for the people we have done so far, are there any in there that we didn't appropriately overestimate, or something, or we didn't use an overestimating, and if we looked at it now, we said, when we get this coworker model, well, we'll use this coworker model.

So, but, what -- it should not have been done if they required a coworker treatment, they should not have been done until the coworker was done. And the reason they would require a coworker treatment is because the overestimating approach would come above 50 percent, so you can proceed with that.

So we'd say, well, this is going to be a coworker. I would think that we -- there

#### **NEAL R. GROSS**

were probably a lot of cases that had that pend designation a long time ago, I mean, we've pretty much got them all over the place now, so -- but we would pend those things, say we can't work it until we have a coworker. So that's what should have happened.

MR. KATZ: That makes sense.

DR. H. BEHLING: Stu, let me ask you, because, again, since I was really not privy to some previous discussions, when you go to page 14 of my write-up I make reference to the issue that's under the criteria, 977 cases were selected that potentially would be affected, and at this point, I don't really know to what extent the criteria that I cite on page 14 have been applied to whittle down that 977 cases to something that is probably a small fraction of those 977 cases.

And under criteria 2, that's really the key issue, it says review the external dose of the claim if no external coworker dose was assigned, and internal for Hanford,

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

there's no OTIB-52 adjustment to be made. That's really the crux of the concerns that I have for this particular PER-14. MR. HINNEFELD: Okay, I'm not smart enough to -- knowledgeable enough about the PER and OTIB-52 to really respond here today, but --CHAIR MUNN: No, we wouldn't expect 10 That will be on our agenda for next time. 11 12 MR. HINNEFELD: But I mean, we can 13 work through this as we work through this PER review, I think would be the best way to do 14 15 it. 16 CHAIR MUNN: All right. We'll indicate that we will definitely -- we'll ask 17 for some addressing of PER-14 next time. 18 19 there anything else going on with the PER reviews that we ought to be on top of? 20 MR. STIVER: I guess the only other 21 thing, then, is what we brought up earlier in 22

the day about the case reviews for PER-12, and the draft approach that Kathy Behling had put together, and which is not available really for review at this point for everybody, but Kathy could certainly -- is online and could explain the basic approach that we are planning on taking, and kind of go through some of the highlights of that.

CHAIR MUNN: And refresh my memory,

PER-12 is --

MS. K. BEHLING: Okay, PER-12 was the evaluation of a highly insoluble plutonium compound, the type Super S, and yes, if I can take a few minutes, it sounds like -- I wasn't on the line this morning, and I apologize for not getting this to you earlier, but it sounds like not everyone has a copy of what I provided to John Stiver late yesterday. Is that correct?

CHAIR MUNN: I think that's correct.

MR. KATZ: Yes.

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

MS. K. BEHLING: Okay, if I can just take a few minutes, maybe I can walk you through what I have done, and because I know there is always a good deal of discussion as to how SC&A should approach the audits associated with these PERs, and so I thought if we could -- if I could work through one and briefly explain what I did to you, and maybe we could determine if I am on the right track here and maybe get some feedback.

MS. LIN: Kathy, this is Jenny with HHS. Before you go on, we haven't PA-reviewed the document that you would be speaking of, so just be careful of any claimant-specific information.

MS. K. BEHLING: Okay. I'll try to remember that, and please stop me along the way if I say the wrong thing. Hopefully, I will not do that.

What I did in this report, and I did go back to the transcript to try to get an understanding of everything that we wanted to

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

put in this report, and again, this was our PER-12, review of which is the highly insoluble plutonium compound, and like I said, the Super S, and we were issued -- we were tasked to review that PER back in, I guess, October of 2009 and I started out a report by feeding some relevant background information on when we were assigned the PER and why that existence, you know, PER was in how actually became something that was because it was determined that there was the existence of this highly insoluble plutonium and therefore NIOSH issued OTIB-49.

OTIB-49 was the estimating doses for plutonium strongly retained in the lung and that's what prompted the OTIB PER. SC&A was tasked to review that and as part of our review, we have five sub-tasks, and sub-task 4 is actually conducting the audit of DRs accepted by the PER, and this is our first opportunity to do that, obviously.

So, in my report, I indicated all

#### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

this in the pertinent information. I'm sorry, did somebody -- okay. And one thing that we determined with PER-12 was there were various criteria that needed to be looked at under the OTIB-49.

First of all, there were four different target organs that we needed to look at, and also you needed to assess how the individual was monitored.

And so based on that, SC&A had recommended that there be a selection of 10 different categories, or 10 different cases in each of the various categories or permutations that were part of PER-12.

And back in -- it was the July 15th, 2011 DR Subcommittee meeting, NIOSH provided the Subcommittee with a list of, I think, 50 cases, and from those 50 cases, there were nine cases selected that actually represented eight of the 10 DR categories. Two of the categories were not represented because there were just not enough -- they

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

were the fecal samples associated with the GI tract and systemic organs and so there were no cases selected for those two categories.

So what I did in the very first case is we selected -- I just took the first one off the list. I went in and I gave some background information on this particular case, just as we do with our normal dose indicating reconstructions, where the individual worked, what time frames he worked there, what locations. I identified both internal and external monitoring that provided for the individual, when they were diagnosed with their cancer, and Ι was actually going to go through all of that in this case but I am a little bit reluctant to do that now, based on the earlier comment.

CHAIR MUNN: Yes, there's no reason to do that now, Kathy.

MS. K. BEHLING: Okay.

MR. STIVER: Kathy, this is John.

Can I step in for just a second? I wanted to

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

let the Subcommittee know that I had just sent this document to all of your CDC accounts.

So it is available. Sorry to interrupt, Kathy. I just wanted to --

MS. K. BEHLING: Oh, that's okay.

And again, I'll keep this more brief than I was intending to. So, but once we get into the actual case review, my first section is a background information, as I just indicated, as we generally do with our dose reconstructions. And then under section 2, I did a comparison of NIOSH's original dose reconstruction, and then the rework of the dose reconstruction.

Here's where I -- I decided to go in and talk about both the internal and external, even though in this particular PER we are only focused on the internal doses associated with plutonium, just because I thought it would be nice to know if this was the total dose, this was the PoC assigned for the initial dose reconstruction, and then this

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

is how the dose ultimately changed and what the revised PoC was.

Then I went into -- the final section is just specific issues related to the PER-12 for this particular case, and I walked through what was done in the original dose reconstruction in this particular case. individual -- in both cases, the original and this rework, the dose reconstruction was done as an overestimate. The original was really a maximizing case where the internal was done with the OTIB-2 methodology, which is not even being used at this point. An OTIB-2 methodology was that when they took -- there were 28 radionuclides that were assumed on the -- that were in -- yes, 28 radionuclides on the very first day of employment were assumed, and so it was a very -- it was a hypothetical internal dose, with a very maximizing approach.

With the rework, they actually went into the monitoring data, looked at -- because

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

individuals did have bioassay samples. the They did a fitted internal dose for the period where there were bioassay samples, and then for the remainder of the individual's employment, they looked at coworker data, and I reviewed all of that data, I made sure they made comparisons of the solubility classes, Type M and Type S, they assigned the highest dose and then they applied the appropriate adjustment factors for the -- both fitted and the coworker proportion of the employment, and I was able to verify that that was all done correctly. I looked at all of the IMBA runs, looked at all the guidance in the appropriate TBDs in the OTIB-49, and for and particular case I had no findings.

And so that's how I went about going -- actually doing this pre-work and I guess we have decided that we are going to make this one report so that all nine of the cases that have been selected will be part of this one report.

10

11

12

13

14

15

16

17

18

19

20

21

But I just wanted to have the opportunity of walking you through the approach that was taken and just get some feedback as to whether that's appropriate, and if I interpreted your direction correctly.

I realize that you haven't had a chance really to look at this, but I didn't know if I had put in enough detail, too much detail or -- if you have any thoughts at this point.

DR. MAURO: You know, this is John, Kathy. I read your report this morning, and I found it very interesting with regard to one respect, and I think it might be of interest also to the Subcommittee.

I noticed that when this was reworked, it was reworked for a number of reasons. It looked like one of the main reasons was there was a second cancer, the colon cancer, I guess, came up, which then drove the need to redo this case anyway.

And when the case was redone, in

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

the process of doing that, there were a number of changes made, as is typical for a PER, one of which of course was the issue regarding high-fired plutonium, and I noticed that -- now, the question I have is, if there was no other reason to redo this one other than high-fired plutonium, would this -- because the dose went down, the internal dose to the prostate went down, I believe.

Stay with me a little bit. sort of a brain-teaser. Would there have been a need to redo this case? In other words, in a funny way, what we found ourselves doing is the reviewing under high-fired а case plutonium PER, but the reality is that the real reason this case needed to be redone wasn't because of that, it was because this other cancer showed up, which drove the need to redo this case?

So -- unless I misunderstood. I just read it pretty quickly this morning.

MS. K. BEHLING: Okay. No, you are

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

correct, John. However, this case was done for two reasons -- for the high-fired plutonium issue and for the additional cancer, and I realize the additional cancer is what you might think drove this, but there was documentation in the file that indicated that this case should be reviewed under PER-12 and that a rework was to be done because you could not make a determination until there was a rework.

So whether there would have been a second cancer or not, this case would have been looked at again.

DR. MAURO: Oh, okay.

DR. H. BEHLING: John, this is Hans. The real driver here was that the need to look at it was driven by a PoC that is —that has to be greater than 16.97 percent. So even though this was originally a maximized dose reconstruction using OTIB-2, I think it would — this was snagged on the basis of that PoC criteria.

10

11

12

13

14

15

16

17

18

19

20

21

DR. MAURO: Interesting, and as a result, by going to the more realistic model, the internal dose, to the prostate in this case of course, went down. I would suspect if it was a lung dose, it may very well have gone up, that's -- it's sort of an unexpected outcome. It's just interesting that it turned out --DR. H. BEHLING: Yes, but they did follow the guidance --DR. MAURO: Oh, yes. DR. H. BEHLING: -- that are defined in PER-12 and that is driven by signs that this guy might have been exposed to Super S, and his original PoC exceeded the threshold for snagging him. DR. MAURO: Oh, no, I did read it and I followed it exactly and I just found it interesting that -- typically you expect a redo to result -- especially in the case of high-fired plutonium -- that the internal dose

would go up. But not in this case, for the

10

11

12

13

14

15

16

17

18

19

20

21

reasons you very well explained. DR. H. BEHLING: Well, they might have, and in fact in the future maybe they may want to look at those cases if there is a that highly-maximized PoC goes above threshold of the PoC that will pull it out, they may want to look at it and sort of say, look, is this reasonable, although I think what they did is probably the correct thing. 10 DR. MAURO: Yes, yes. To realize you 11 DR. Η. BEHLING: don't want to make an assumption before you 12 13 add to one of the numbers. DR. MAURO: Got it. Good, thank 14 15 you. 16 CHAIR MUNN: Thank you, gentlemen, for the discussion, and thank you, Kathy, for 17 bringing us up to date. I think that we 18 19 probably can't do anything with this until NIOSH has had an opportunity to look at it and 20 respond. 21 22

### **NEAL R. GROSS**

MR. HINNEFELD: We agree.

1	MR. KATZ: No, no. There's nothing
2	to respond to at this point. They are just
3	asking the Subcommittee are they on the right
4	trail
5	CHAIR MUNN: Are they on the right
6	track.
7	MR. KATZ: before they deliver
8	their actual full report on all the cases,
9	because this is just the first that they have
10	gone through.
11	CHAIR MUNN: This is I recognize
12	this is not a complete report, but I guess
13	what I should be asking instead is if you have
14	a feel for when the completed PER review will
15	be available? Will there be anything for us
16	to discuss on this next time?
17	MR. STIVER: I would say that we
18	should be able to have it ready by the next
19	meeting. Kathy, is there
20	MS. K. BEHLING: Yes, that
21	shouldn't be a problem. As Ted just
22	indicated, what I am hoping to do is to get

some feedback just to say should I continue on this path, have I given you enough information with this first test case, and I can complete the other eight cases associated with PER-8 in this fashion, or would you like me to make changes? Do you want more data, less data, do you want me to go into detail in the rework? That was my -- that was what I was trying to get an answer to.

CHAIR MUNN: Paul, do you have

CHAIR MUNN: Paul, do you have anything to add?

MEMBER ZIEMER: Well, of course we just saw it for the first time. I mean, my impression is that it's fine.

CHAIR MUNN: It seems thorough to me.

MEMBER ZIEMER: But I guess ultimately I would like to reserve judgment a little bit on that, but my feeling is she should proceed. I think she's on the right track here, and I'm not sure -- I mean, what else would you add at this point? It's not

### NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

clear to me that there's any big pieces missing.

MR. KATZ: So, let me give you some food for thought from just -- I haven't read it, Kathy. I just listened to you, that's all. But just my sort of thought in listening to you is, I mean, your final product is going to be a report on the review as a whole and of course you'll call out any instances or concerns that there may be with respect to implementation. I mean, that's sort of the purpose of this, to see was implementation done correctly.

MEMBER ZIEMER: Right, but it's not so much that it's the final numbers --

MR. KATZ: The individual cases are not important at all --

MEMBER ZIEMER: -- whether they go up or down because you know, with high-fired plutonium, you've got a longer residence time in the lung, and in a sense it's not surprising that it's the other organs that go

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

down then because the material is not available for them to accumulate. MR. STIVER: Okay. This was kind of a unique case in that you did have the two drivers and one -- so you are trying to combine those in this particular thing, where really -- for the purposes of PER-12, you know, where really only the --MR. KATZ: And I think you may find 10 that you have quite a few instances of that because there are -- I think there will often 11 be more than one driver of a redo. 12 13 MR. STIVER: So in those cases, then, we should just strictly stick to the 14 15 PER-12 aspect of it. 16 MR. KATZ: The PER-12 issues are the ones that we are trying to examine, you 17 know, their ultimate PoC and all that really 18 19 doesn't matter. I mean, it --Right, and the --20 MEMBER ZIEMER: I'm not sure if the second cancer sort of 21 matters in this case even --22

MR. KATZ: Right.

MEMBER ZIEMER: -- so much.

CHAIR MUNN: Well, but with nine individual cases, by the time all nine of them have been covered, you are going to have such a variety of types and PoCs that certainly as far as the process itself is concerned, it looks thorough to me.

DR. MAURO: Yes, Kathy, when I looked at it, you focused right in on the prostate and how the dose changes because of these changes, and of course you did not address the colon, which would not have been within the scope of this PER review process.

MR. STIVER: There was a mention of it but, you know, there wasn't any --

DR. MAURO: Oh, no, it's mentioned, but I mean to -- so I think what my reaction, I guess, is when I read it, it did follow our instructions from what I understood at the time to be what we are supposed to do for a PER, and you know, so I guess I -- my sense

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

is, I think, you know, the SC&A people have only recently looked at it is that, this is, this is, you know -- you are on the right path. That's my suggestion, yes.

MS. K. BEHLING: And I guess what I was thinking about is: and I realize I believe that the -- our direction was supposed to be focused on the PER issue. But I know that there was a lot of discussion and dialogue back and forth, should we be making the comparison, should we be looking at PoC from the first -- from the original and compare it to the rework.

And so I tried to blend both of those, you know, there were two different schools of thought, I think, when I read back through the transcript, and I tried -- I decided I was going to try and blend both so that we'd have everything here, so that we could look at the big picture.

MR. KATZ: So, Kathy?

MS. K. BEHLING: Yes.

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

MR. KATZ: Kathy, so again, sense for that, as far as how that dialogue went, was that it was really not, I mean, the conclusion of that dialogue was we are not interested in -- I mean, it really is about focusing in on the correct implementation of the PER and not other matters, you know, with respect to comparing the original dose reconstruction to the redo. It really is focused on the PER-12 question: is it implemented correctly? And everything else is really not germane to the process, and it's just going to slow you down in completing your evaluation.

MEMBER ZIEMER: Well, unless it's easy to do, I think knowing how it impacts is informative in a sense, that it gives you a feeling for the impact that you are having with the change, you know what I'm saying?

The numbers are informative simply to give you a feel for the importance of the change. I mean, if you were finding that with

### NEAL R. GROSS

10

11

12

13

14

15

16

17

18

19

20

21

or without this PER, it had very little effect on anything, then you'd be wondering about in the future --MR. KATZ: Well, the PERs are done because they do have an impact, and that is sort of a foregone conclusion --MEMBER ZIEMER: You're saying it's a priori -(Simultaneous speaking.) MR. KATZ: -- if they don't get done 10 in the first place. I mean, the point of this 11 is to make sure, again, and then there's an 12 13 evaluation of the methodology to make sure that's straight and Hans has done, I think, 14 15 many of those. 16 But then this process here and the tail end of it is simply to ascertain: was it 17 18 actually implemented on cases correctly? 19 MEMBER ZIEMER: So that's really all we 20 MR. KATZ: are trying to get at. 21 MEMBER ZIEMER: Whether or not it 22

kicked them over the line or not --

CHAIR MUNN: That's moot.

MR. KATZ: Is really not the issue.

MR. STIVER: I guess it is. But -this is Stiver again -- but if you were able
to get some of that after-diagnostic
information, like Kathy has done, without an
inordinate amount of extra effort, wouldn't
that be something useful to the program that
we might want to --

Well, I mean I guess you say inordinate effort. But I don't see why we would just have any extra effort. Why not just do the task it done and get as efficiently as possible? Why spend time and matter that gets addressed money on elsewhere? Because we do case reviews for dose reconstruction in the Dose Reconstruction Subcommittee and that's really not the function here.

DR. MAURO: Along these lines, let me jump in, this is John, a little bit. The

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

key here, I think, I'm looking right now at Table 2 in Kathy's report where she shows the difference in the internal dose between -- before and after -- the difference, I am presuming, is entirely due -- and it's the prostate -- entirely due to going from OTIB-2 to going to high-fired plutonium, which is the essence of what we were trying to do here.

But what she also did in this very same table is that context. It showed the before and after for some of the external doses also, and medical.

And what it does is, it does set context. In theory, Kathy, I guess you could have just put the internal dose and how it changed, and whether or not, you know, it was done correctly, going from OTIB-2 to the new approach to high-fired plutonium, OTIB-29, and maybe that's the question that should be before us at this time, because, I think, Kathy, you have presented your vision of what these case reviews will look like, and in this

### **NEAL R. GROSS**

particular case, this had context by showing before and after for the full range of exposures, but of course the whole analysis and discussion where you want vertical, so to speak, is on how did the internal dose change because that's where the action is.

And I guess that's a fair question maybe the Subcommittee doesn't want to address right now, but do they want to see context the way you have laid it out?

I for one did like seeing it, because I understood the -- where this particular -- where the PER aspect, OTIB-49 had play within the overall context of the case, so it helped me be oriented.

But Ted, what you had just mentioned is a little bit more, I would say, narrow interpretation and I think that's the reason why, Kathy, you sent this out, to make sure that you are maybe not doing more than needed, or maybe we are not doing enough.

MR. KATZ: That's exactly right.

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

MEMBER ZIEMER: Well, in order to accomplish the task of determining that the information for IMBA was correctly entered, you don't actually have to do the final step and run it and calculate the dose, do you?

MS. K. BEHLING: No, you don't.

MEMBER ZIEMER: But do you have to do everything up to that point? In other words, is the dose step simply a matter of pushing the button and letting something calculate, or is it -- I mean, some of these things don't change anyway, medical x-ray or so on, but -- ambient -- but you are going through and looking at the entry of all the other data, right, up to that point? You are verifying -- in fact, let me look at your words here -- you are verifying that the assumptions were appropriate and the data were entered into IMBA correctly.

MS. K. BEHLING: That's correct.

MEMBER ZIEMER: Now, doing that last step, are you just looking at the input

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

that they have used, just saying, yes, here's the number and they put it in correctly? that what's happening here? MS. K. BEHLING: Yes, and I did go -- that's where I went into detail, in this section 2.3, because those were the issues that were pertinent to the PER-12. It just felt to me when I went to write this that I couldn't help myself. felt like I needed to tell the whole story and I thought perhaps others, you know, we'll have other discussions coming out of this, although I do agree with Ted, that really, it's my section 2.3 that is the -- that's the key, that's what we're trying to do here. MEMBER ZIEMER: Well, if you are saying they entered the that numbers correctly, then they have already generated the table, the right-hand column of the table. Is that not correct? MS. K. BEHLING: Table 2? MEMBER ZIEMER: Ιf they Yes.

10

11

12

13

14

15

16

17

18

19

20

21

entered the numbers correctly, you've verified that step, then wouldn't Table 2 be the numbers that they would have generated? MS. K. BEHLING: That's correct. MEMBER ZIEMER: So you don't have to do that. MS. K. BEHLING: No, I was just trying to give the big picture. That's all I was trying to do. I had gone in and made sure 10 No, but what I'm 11 MEMBER ZIEMER: saying is if you just went to NIOSH's final 12 13 thing and said here's what they put down, you don't have to do anything. I'm trying to 14 15 figure whether out or not SC&A is 16 recalculating something that NIOSH is already calculating when they have already confirmed 17 18 that they put the right numbers into the 19 program. 20 I mean, it's sort of getting at what you said --21 22 Yes, again, my only KATZ: NEAL R. GROSS

1	issue is
2	MEMBER ZIEMER: I mean, it's nice
3	to have these numbers, but if there is any
4	extra work in doing it, it's beyond what we
5	need. That's all I'm saying.
6	CHAIR MUNN: The question, though,
7	will be asked by someone.
8	MR. STIVER: What was the net
9	effect?
LO	CHAIR MUNN: Yes, what was the net
L1	effect.
12	MEMBER ZIEMER: But I'm saying
L 3	NIOSH already has determined that, I guess,
L 4	right? Isn't this what you would generate?
15	If they say we put all the numbers, we checked
L 6	all the numbers that NIOSH put in, and they
L 7	are the right numbers, in the IMBA.
L 8	MR. MARSCHKE: Well, isn't the
L 9	ultimate check that the right numbers were
20	entered into IMBA comparing the results that
21	come out of IMBA?
22	MEMBER ZIEMER: I don't know the
1	1

WASHINGTON, D.C. 20005-3701

That's why I am asking the question. MR. MARSCHKE: That basically if the results come out the same, that means that they must have input the same -- the correct -MEMBER ZIEMER: But that's not how she's verifying. I think she's verifying by looking at the numbers. MR. HINNEFELD: Well, based on the 10 write-up, I don't know, Kathy, correct me if 11 I'm wrong, but it appears that Kathy looked at what was different between -- really what she 12 13 is writing about here is what was different in the internal dose between before and after. 14 15 Okay. She wrote down those others 16 for context because it will influence the net result of PoC. You know, when -- it will have 17 an influence on actually what the PoC was, 18 19 which she also describes, both before and the after. 20 So it provides a complete picture 21 of how that comes out. But the entire write-22

up is about the internal dosimetry. She doesn't dwell -- she doesn't even describe why the those external doses went down. It's just reported on the table they went down. There's no description of why. The description is all about what was done on internal, which was the focus of it.

You know, I don't know what's necessary and what's not. When I have just been reading through this, I can, it's kind of a pretty complete story, and it puts me in a good mood because she didn't find anything wrong with what we did.

So -- but it seems like it's kind of a -- it's a little complete story there and you've got the idea, but it really is -- what she has really spent her time on is what was the internal done later, how does it compare to earlier and did they do what they should have done when they reworked this case.

So to me, I don't -- we can, I guess you can equivocate. I don't know that

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

there's a particularly better way to tell the
story, because if she doesn't put those other
numbers up there, then there's then you
don't really have a full picture of what
happened on the PoC and why did the net change
in the PoC happen, if you're interested in it.
MEMBER ZIEMER: I think Ted is
saying: do we need that information?
MR. KATZ: Yes, my only question
was: who cares about that?
MR. HINNEFELD: About the PoC?
MR. KATZ: If it was done
correctly, we are not reviewing this case
MR. HINNEFELD: Right.
MR. KATZ: as a dose
reconstruction review. All we are trying to
answer is a simple question, which is: did we
implement PER-12 correctly?
MR. HINNEFELD: The way we said.
MR. KATZ: And that's all we are
interested in, so the other story, which is a

were intending to spend resources on, the bigger picture. But I don't have a strong -you know, if it's not taking much resources then it's not a big issue to me. I just don't want us to just be spending our time, because then you know, whatever else there is, not only consumes their time in putting the story together, but it consumes, you know, it's so easy for everyone else then to start to talk about anything that is of interest, whether it is on topic or not, and I am just trying to help the Subcommittee stay on topic. That's all.

MEMBER ZIEMER: Let me ask Kathy.

Kathy, are the numbers in Table 2, the righthand column, are those the same as the NIOSH
numbers?

MS. K. BEHLING: Yes. As a matter of fact, I pulled this table out of the rework of NIOSH --

MEMBER ZIEMER: So you didn't have to generate this --

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	MS. K. BEHLING: No.
2	MEMBER ZIEMER: Well, so she didn't
3	
4	MS. K. BEHLING: I'm simply trying
5	to tell the whole story, just to make it a
6	picture.
7	MEMBER ZIEMER: I thought they were
8	
9	MR. STIVER: It's not like we went
10	through them and recalculated all the doses.
11	MEMBER ZIEMER: So you just
12	confirmed that the right numbers in and here's
13	what NIOSH said the answer was.
14	MR. STIVER: Right.
15	MEMBER ZIEMER: So there okay.
16	MR. KATZ: So I mean, for example,
17	you talked about external dose, which isn't an
18	element of this at all.
19	MR. STIVER: But it's just in
20	there.
21	MR. KATZ: But it's in there. So
22	if it doesn't take any time, it is not a

matter to me to raise to you. MEMBER ZIEMER: There's no additional calculations --MR. STIVER: There's no additional effort expended really, other than just cutting and pasting the information. MEMBER ZIEMER: I don't know, every three seconds multiplied by --(Laughter.) 10 MR. KATZ: So, Kathy just needs a nod from the Subcommittee to go forward and 11 prosper this way or do something different. 12 13 CHAIR MUNN: Well, as I said at the outset, this seems like a very thorough 14 15 process that she is undertaking here, and it 16 seems appropriate to me. If it is the general feeling that it may be overkill, then now is 17 the time to address it. That's what we edit 18 19 for. 20 I don't see that it is, frankly. Well, I think my MEMBER ZIEMER: 21 22 view it's just there's no expert work done.

Cutting and pasting an extra column in there isn't any extra work. But I was concerned whether they were going through calculation of things and confirming all the other stuff, but it looks like they are not. MS. K. BEHLING: No, no, we are No. We're just simply going through a not. reworked case, in fact, like I said, this 10 Table 2 comes right out of that rework, and I 11 just felt it told the entire story. It's really a minimal effort 12 13 getting a complete picture of this particular 14 case. 15 CHAIR MUNN: Kathy, you are good to 16 go. MS. K. BEHLING: Okay, thank you. 17 Would you please make 18 CHAIR MUNN: 19 a special note to make sure that I know when document actually hits 20 the it would be nice for 21 because us 22 whether it is going to be there early enough

for NIOSH to respond to it in any way, or whether it's only going to be out in time for us to say it's out next time. So if you'll let me know --MS. K. BEHLING: I will certainly do that, and again, I do apologize that I didn't get this in your hands a few days ago, but I don't know when -- I don't think you discussed when the next meeting is going to be, but --CHAIR MUNN: No. MS. K. BEHLING: I will definitely have this report in everyone's hands before -well before the next meeting. CHAIR MUNN: Great. Thank you very much. We appreciate it. We'll have it on the agenda one way or the other next time. MS. K. BEHLING: Okay. Thank you. CHAIR MUNN: You bet, thank you. Now I did not have on the agenda one item which I picked up when I was reviewing our

transcript from last time to make sure that we

10

11

12

13

14

15

16

17

18

19

20

21

were all okay.

10

11

12

13

14

15

16

17

18

19

20

21

22

One of the things that we spoke of was OTIB-6, which for the most part is pretty much done, but we raised a question about how tricky it would be to nest the attached files into the directory -- into a directory or the procedures list so that we don't have to save all of the PDF files in order to transmit them.

And in my working with the current database that we have, I think I was able to do that. And I thought I was able to just transmit the whole thing, but I didn't actually follow through with my transmission. I got tangled up in some of the additional linked files that I wanted to transmit as well, and didn't complete my action.

So has anyone used that aspect of the those things so that we know that they are properly nested and everything goes? Or is this something I just need to do myself and mark off my list?

# **NEAL R. GROSS**

It looks like it's one of those things I need to do myself. MR. MARSCHKE: You're talking about generating the PDF files of the history of the Is that what you are -issues? CHAIR MUNN: Well, I think that is what we were talking about. MR. STIVER: This is John Stiver. I think I recall that. The issue was about 10 whether -- I think it was about putting in links to these files, if you transferred that 11 to somebody else, whether those links could be 12 attached, would the recipients still be able 13 to reach those files? 14 15 CHAIR MUNN: And as I said that's 16 where I got jimmied up when I was trying to transmit the files that I intended to. 17 didn't follow through. I'll just check it 18 19 myself. And if it's okay, I just won't follow through, and if it's not okay, we'll talk 20 about it next time. 21

Is there any other specific issue

that we need to address before we start looking at administrative?

MR. KATZ: Yes, we do. There's -we talked about it offline but we need to talk
about it online because we didn't get through
it all.

But at the last full Board meeting, we assigned seven procedures for two-pagers that -- where the review has been completed. But I had a list from SC&A of nine procedures that were ready for two-pagers.

The two that we did not assign at the full Board meeting, as we discussed at that meeting, were IG-001 and 003. We didn't assign them because the SC&A listing that was given to me showed no findings for either of those and it didn't -- it just didn't make sense to so I didn't understand why we would be assigning them at this point because something was wrong.

So, and today we have seen on the - in reviewing the database, that 001 in fact

### **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

has a number of revisions that were findings.
So it's not that there were zero findings.
Many findings have been resolved. They are in
progress, they are resolved, we don't know
exactly what the status of all of them are,
and there's a new rev up.
So that one clearly is one that
actually shouldn't have been assigned as a
two-pager, and wasn't, but then the other one
that was in that listing was IG-003.
MR. STIVER: Ted, I think you might
have the wrong I have 003 and 005 and not
001.
MR. KATZ: 003 and 005?
MR. STIVER: Three and five.
MR. KATZ: Okay, so I'm remembering
it wrong. But, so it's 003 and 005, so
anyway, these are the ones we don't know
it shows zero findings.
MR. STIVER: There were zero
findings, yes, it was a matter of looking into
ones that had zero outstanding findings and

1	not actually
2	MR. KATZ: These others show closed
3	findings. It's not like they don't they
4	show that they have four findings, three were
5	closed, this one shows that there were no
6	findings in the first place.
7	MR. STIVER: And you know, Steve
8	Ostrow went through and generated that list
9	and I am not sure of all of the mechanics that
10	went into that and whether there might have
11	been a breakdown in doing it
12	MR. KATZ: But whatever they the
13	question
14	MR. STIVER: But I can certainly
15	check into that.
16	MR. KATZ: the question for today
17	that is just what again, so IG-003 and 005
18	then sorry about 001 003 and 005, the
19	question is, are these ready for two-pagers.
20	That's the question.
21	MR. STIVER: I guess the question
22	was I would assume they would be if there
	NEAL D. CDOCC

1	was a need for a followup, since they didn't
2	have any findings to begin with. And that's
3	like I guess where the disconnect is here.
4	MR. KATZ: So that's what I'm
5	trying to understand. I have never seen an
6	SC&A review with no findings. These two
7	MR. STIVER: There have been a
8	couple.
9	MS. LIN: Ted, at least 005, it's
10	just the use of classified information is how
11	we would the agency's commitment to use as
12	little classified information, you know
13	MR. KATZ: Okay.
14	MS. LIN: It's more of a
15	MR. KATZ: And we actually
16	MS. LIN: It doesn't necessary
17	impact dose reconstruction processes, health,
18	or anything like that.
19	MR. KATZ: So, and SC&A reviewed it
20	nonetheless, and
21	MR. STIVER: Yes, and I think in
22	terms of putting out a short summary to
- 1	1

indicate what the procedure is all about, that's certainly something we'd want to do. Well, Ι MR. KATZ: mean, the procedure is out there, it's just a question so there's a review but the review didn't find anything -- so then it would just be sort of checking a box that the Board did review --My recollection at MR. HINNEFELD: 10 least, and my idea of what the two-pagers are 11 about, and why I was an advocate for something 12 like a two-pager, was that the procedure review was on our website, with, you know, 20 13 findings or 10 findings or whatever, and then 14 15 nothing else goes up. 16 MR. KATZ: No, I understand. HINNEFELD: And so the two-17 MR. pager then provides, just saying, okay, we 18 19 have worked through this, there have been some revisions, it's all taken care of, so 20 there is this closure rather than just --21

MR. KATZ: I understand.

1	MR. HINNEFELD: But if you've got a
2	review with no findings, it kind of obviates
3	the need
4	MR. KATZ: Not much need for
5	closure.
6	MR. HINNEFELD: for the two-pager
7	to close it out.
8	MR. KATZ: That's why I'm raising
9	it here, because it's up to the Subcommittee
10	what you want to do with these particular
11	cases.
12	MR. HINNEFELD: And it matters not
	MR. HINNEFELD: And it matters not to me, but my driver for wanting to have two-
12	
12 13	to me, but my driver for wanting to have two-
12 13 14	to me, but my driver for wanting to have two- pagers does not exist when there were no
12 13 14 15	to me, but my driver for wanting to have two- pagers does not exist when there were no findings on the original.
12 13 14 15	to me, but my driver for wanting to have two- pagers does not exist when there were no findings on the original.  CHAIR MUNN: Yes, there wouldn't be
12 13 14 15 16	to me, but my driver for wanting to have two- pagers does not exist when there were no findings on the original.  CHAIR MUNN: Yes, there wouldn't be just a heck of a lot we can say, except that -
12 13 14 15 16 17	to me, but my driver for wanting to have two- pagers does not exist when there were no findings on the original.  CHAIR MUNN: Yes, there wouldn't be just a heck of a lot we can say, except that well, the review was done and it was found
12 13 14 15 16 17 18	to me, but my driver for wanting to have two- pagers does not exist when there were no findings on the original.  CHAIR MUNN: Yes, there wouldn't be just a heck of a lot we can say, except that well, the review was done and it was found to be adequate as-is. No findings were the

1	can you have a simple statement, no findings.
2	So that statement can just go on the website,
3	you don't need to hire SC&A to tell us that
4	they didn't have any findings.
5	CHAIR MUNN: That they didn't find
6	anything.
7	MR. HINNEFELD: Because they have
8	already told us that.
9	MR. KATZ: Yes. No, but we have to
10	summarize that they told us that.
11	MR. HINNEFELD: Summarize that they
12	told us that.
13	DR. ULSH: I'd like them to repeat
14	that as often as possible.
15	MR. KATZ: I'm sure you would,
16	Brant.
17	(Laughter.)
18	MR. STIVER: You've got to enjoy it
19	when you can.
20	MR. KATZ: Okay. So if that's the
21	case, then I just wanted to because it was
22	very peculiar, I wanted to verify here

**NEAL R. GROSS** 

whatever and figure out what our path forward is, so if that's true for both 005 and 003, then we know what our path forward is. We will just have a statement on the website when we load these other ones up on the website that says no findings, no concerns. CHAIR MUNN: And it would be nice of course to get those on the website, because these -- it would be nice to get them in our database that says as much, as well, because if we go to our database and don't find --No, the database should MR. KATZ: reflect this. I mean, this is just the twopagers, right? The database should reflect the findings already. CHAIR MUNN: It should. But my question is, does it now? I do not believe that it does. MR. KATZ: I don't know. CHAIR MUNN: No. It does not. MR. MARSCHKE: I don't think IG --They don't appear on CHAIR MUNN:

# **NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

10

11

12

13

14

15

16

17

18

19

20

21

there.

10

11

12

13

14

15

16

17

18

19

20

21

22

MR. MARSCHKE: I can't find where, I mean, I looked at the three -- I've been looking in, while you guys have been talking, I have been looking at the three reports that were generated and I can't find IG-003 or IG-005. I can't find where they are even in -- when we did those reviews. So --

MR. KATZ: Okay. So it would be good to get that material --

(Simultaneous speaking.)

MR. KATZ: If DCAS doesn't have those reports, of course, I don't know. Then we need to get those in DCAS's hands.

CHAIR MUNN: It seems logical to me that somehow, they should appear somewhere in the database. If for no other reason than it's an ideal way for it to get back to the original document. It just follows, it seems to me.

MR. KATZ: Great. So SC&A will follow up on this?

# **NEAL R. GROSS**

1	MR. MARSCHKE: We'll follow up and
2	try and figure out
3	MR. KATZ: And maybe just send me
4	the final reports again for these two, the
5	SC&A reports.
6	MR. MARSCHKE: Yes, if we can find
7	them.
8	MR. KATZ: I mean, because these
9	predated me, by a long ways, so if you'll send
10	them to me I'll make sure DCAS has them and
11	they can load them up.
12	CHAIR MUNN: Good. All right.
13	Anything else that we want to make sure we
14	don't miss?
15	MR. STIVER: I have one other thing
16	I wanted to bring up regarding the PERs and
17	that is in regards to PER-17 and 29, which we
18	were authorized to review but which we had not
19	yet begun a review process.
20	And both of these are have
21	updates that the actual documents that are
22	referred to have been updated since the review

was authorized.

10

11

12

13

14

15

16

17

18

19

20

21

22

And I guess my question for the Board -- or for the Subcommittee, is whether we should hold off until the -- all PERs are updated before we were to progress on these two?

Which is kind of the problem we had with 14 in that there was a revision to TIB-52 that came out and we were -- found ourselves doing a review in relation to Rev 0 instead of Rev 1.

And so I guess the question for you all is whether you would recommend that we hold off on those until everything is updated and complete, or --

CHAIR MUNN: Thank you for bringing that issue up. It seems to me that the logical thing to do in all cases, when we have a revision, an active revision in process, that it behooves us to not reinvent the wheel by reviewing both revisions.

But that's just my knee-jerk

# **NEAL R. GROSS**

1	reaction. Anyone else's thought?
2	MEMBER ZIEMER: But you haven't
3	started the earlier version yet.
4	MR. STIVER: No, we haven't even
5	started it yet.
6	MEMBER ZIEMER: And when will the
7	new version be out?
8	MR. HINNEFELD: Which PER?
9	MR. STIVER: It's 17 and 29.
10	CHAIR MUNN: And so we are looking
11	at
12	MR. STIVER: Yes, 17 is evaluation
13	is incomplete, internal dosimetry records from
14	Idaho Argonne East and Argonne West national
15	laboratories.
16	CHAIR MUNN: That's its title.
17	What's its number?
18	MR. STIVER: This is PER-017.
19	CHAIR MUNN: 017, okay.
20	MR. STIVER: And the second is
21	OCAS-PER-029, which are Hanford TBD revisions.
22	CHAIR MUNN: Okay.

1	MR. HINNEFELD: Okay, and you've
2	found out that these were being revised by,
3	and what mechanism, did you tell them?
4	MR. STIVER: There had been, the
5	basis documents had been revised since we were
6	authorized to review
7	MR. HINNEFELD: The basis documents
8	meaning the Hanford TBD.
9	MR. STIVER: Yes, and so it's a
10	situation where we don't want to find
11	ourselves going back and reviewing a PER
12	that's outdated. If you guys are planning to
13	issue new PERs based on the changes, the
14	documents themselves, the TBDs
15	MR. MARSCHKE: Why would the PER be
16	updated? The PER is just basically shows how
17	it was how the change the previous
18	change was implemented, and whether or not the
19	previous change was implemented correctly or
20	not is really what you are doing when you
21	check the PER
22	MR. STIVER: That's true but if

there is going to be a new PER as a result of changes, additional changes since we authorized, would you want to wait until the new PERs come out --MR. MARSCHKE: I mean you are still going to have to basically look at PER-17 and see whether or not that first change implemented correctly to make -- and then go and make sure that the second change is implemented correctly. MR. STIVER: Yes, then we'd have to put you a follow-on to that, but I guess to get to the point, if it's -- there's potential lag time that you might be addressing things that are no longer relevant or have addressed in another --MR. KATZ: I understand what John is saying. DR. ULSH: I do too. My question, though, is whatever the changes were that caused the revision, it would only be a PER if

the doses went up. If the changes made the

10

11

12

13

14

15

16

17

18

19

20

21

dose go down, it so my question is, have you determined whether or not the revision would necessitate a PER, do you know that?

MR. STIVER: At this point it's

just more of a philosophical question, whether we need to wait until -- in my mind it's a moving target and there is always going to be revisions and there's always going to be refinements, and so once a PER is issued, we should probably go ahead and address those points that were tasked, and then if a new problem comes up later then we can visit that one.

MR. HINNEFELD: I think it might be a situation that has to be addressed individually, because we have some knowledge about what gave rise to this PER and what's going to be --

(Simultaneous speaking.)

MR. HINNEFELD: Specifically with the ANL internal dose records issue, this goes way back. I'm really on a memory that is

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

getting older by the day, but the issue that gave rise to this PER was a matter in which INL reported internal dosimetries in early days when we asked for an exposure, they would report no internal, essentially no internal.

But they would report that whether or not the person was monitored or not. They wouldn't give us the zero bioassay results. They didn't have an internal dose on the person so they'd report no internals, which we interpreted as meaning there is no bioassay for this person.

As a matter of fact, there was bioassay for that person. They just didn't provide it. They went through quite a lot of effort to get their records in the system where they could provide the bioassay and then we got the bioassay for people who, heretofore, had just been said no internal.

That gave rise to this, and that is a discreet piece that we had to address to see have we short-changed any of these people

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

because we thought they weren't monitored at the time.

The kind of work going on at INL -ANL =- is to take a careful look at how, on
the Site Profile, I think there are a number
of findings on the Site Profile that we are
trying to come to grips with, and there will
be some changes in the Site Profile.

This is kind of a separate issue from that earlier reporting issue. So that specific one I think there is merit in going forward with 17.

I think I know what's going on with Hanford but I don't remember exactly what gave rise to PER-29. If we get it while we do something else I'll go look at it and see if I remember it.

The revision that is going to go on at Hanford is in all likelihood going to be an extension of the SEC Class into later years than what has been handled so far. So that will then cause some changes in the Site

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

Profile because you essentially take out the
internal dose assessment, whatever it is, the
particular piece and when you said do the dose
assessment this way, you determine well it was
really not feasible to do that, you take that
part out.
And this may not be that big a
change to the Site Profile. So in that case,
probably I ought to figure out what this PER-
29 addressed and then I'll be able to speak
more well, I will feel like I know more
maybe but I may not.
MR. STIVER: Okay that's something
we need to do through emails or whatever.
MR. KATZ: Yes, we can just do
that.
MR. HINNEFELD: But I would say
that just looking at this and remembering the
17 situation I think
(Simultaneous speaking.)
MR. KATZ: It sounds like it's
likely you'll be okay with the PER-29 too.

It's just an extension of the --

MR. HINNEFELD: I suspect, I want to see what this one -- why we wrote this one, to be completely honest.

MS. K. BEHLING: Excuse me just one second, this is Kathy. I think with Hanford, those were some earlier changes that were made for Hanford on the TBD, they were just an update to the TBD, 2008, or it was that time frame I believe, for the PER-29.

But I thought that you were also in the process of changing the Hanford TBD, or it's been changed for the neutron issue, and that is a big -- that's a big issue. That's a significant change.

And that will definitely require a PER. Now I haven't seen that PER come out yet. And so I guess I was thinking along the lines that we would want to wait to see, did the PER that comes out on Hanford associate it with the neutron doses and then do all of the -- do the PER-29 along with the PER that I

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	assume is going to be coming out for Hanford
2	for neutron.
3	MR. HINNEFELD: Okay, you're right.
4	MR. KATZ: So the only question
5	really is if the neutron overlaps whatever is
6	covered in PER-29. If they don't overlap,
7	then you still can just do them independently,
8	right?
9	MR. HINNEFELD: I would think so.
10	MS. K. BEHLING: Yes, that's
11	probably true. I can go back and look at all
12	of the details that into 29 and I don't think
13	it would be an issue. I meant, sorry, neutron
14	issue.
15	MR. KATZ: So we can follow up on
16	this by email. And sort it out as to whether
17	there is an overlap or not. If there's an
18	overlap, I think what you say makes a lot of
19	sense, to amalgamate them. But otherwise, you
20	can just carry it forward with PER-29.
21	CHAIR MUNN: Okay.
22	MR. MARSCHKE: Wanda, I have an

**NEAL R. GROSS** COURT REPORTERS AND TRANSCRIBERS item I'd like to bring up.

CHAIR MUNN: Yes Steve.

MR. MARSCHKE: While we are talking about PERs and also going back to OTIB-52, Rev 1 of OTIB-52 basically limited the internal -- the applicability of the internal procedure to uranium and plutonium isotopes, as opposed to all radionuclides.

So in our review, you can see basically, what we are recommending, a PER be developed to determine whether or not OTIB-52 was used for -- to calculate internal doses to construction workers when other radionuclides besides uranium and plutonium were the radionuclides of concern.

Because basically all the OTIB-52 analysis was done only for uranium and plutonium, so I don't know whether -- again, were, you know, -- in our report here we are kind of recommending that a PER be looked at to see whether or not that is a concern.

I don't know about dose

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	reconstructions but I do that OTIB-52 was used
2	as a basis for an SEC at Savannah River
3	internal doses for tritium as opposed and
4	really there's no basis for using that for
5	OTIB-52, for tritium, internal doses, because
6	this is you know, all the analysis was
7	done, only, again, on uranium and plutonium.
8	DR. ULSH: You said tritium. Did
9	you mean thorium?
10	MR. MARSCHKE: No, tritium.
11	DR. ULSH: Okay.
12	MR. MARSCHKE: The other one, again
13	
14	CHAIR MUNN: That's surprising.
15	MR. MARSCHKE: The other one was,
16	as we mentioned this morning, right now we are
17	basically putting the caveat in there about
18	you know, being careful about applying the
19	OTIB-52 methodology to some particular classes
20	of construction workers, such as pipe fitters.
21	And so the other potential PER that
22	would be result from that would be to go

back and look and see whether or not OTIB-52 has been applied to pipe fitters, and whether or not it is still applicable to apply it to those particular individuals.

Because right now, as we saw in the modification that was made to OTIB-20, there's a caution in there about you know, blindly just applying OTIB-52 to all construction trades, or workers in all construction trades.

So again, those were two potential PERs that we identified when we did the review of Revision 1 of OTIB-52, and I don't know whether the -- I don't know how -- I don't know if there is a path forward on this, or what, if the Subcommittee wants NIOSH to take a look at it or what, but I just thought I would mention those because you know, they were in the report, and we hadn't talked about them.

CHAIR MUNN: No, we hadn't. I'm surprised about the Savannah River situation you mentioned. Difficult to see for most

# **NEAL R. GROSS**

10

11

12

13

14

15

16

17

18

19

20

21

1	construction trades why other nuclides,
2	radionuclides would be of specific concern
3	outside the transuranics.
4	MR. HINNEFELD: What report are you
5	showing us here Steve?
6	MR. MARSCHKE: This is the report
7	that we put together for our review of
8	Revision 1 of OTIB-52. It was in July of last
9	year.
10	MR. HINNEFELD: Okay.
11	CHAIR MUNN: Well
12	MEMBER ZIEMER: So that's 52-05,
13	which was closed, right?
14	MR. MARSCHKE: 52-05 was closed
15	because they put a limit in the they
16	changed what was 52-05 Paul, I
17	MEMBER ZIEMER: Let's see. Finding
18	5, determine uranium used to compare internal
19	CTW and ANW doses.
20	MR. MARSCHKE: Yes. That was
21	and the way they addressed that, the reason
22	why we closed it, was because, when they did

Revision 1, they basically put a limitation in
and said that the internal dose calculation is
only applicable for uranium and plutonium
exposures.
MEMBER ZIEMER: So it became a moot
point.
MR. MARSCHKE: So basically they
limited it. They limited the scope of OTIB-52
from being from the internal portion of
OTIB-52, from being you know, wide open,
having no limits on it, to basically limiting
it to only uranium and plutonium.
MEMBER ZIEMER: The document you
just showed us, is that the that's not the
document that's on there.
MR. MARSCHKE: That's our review.
MEMBER ZIEMER: That's the Rev 1
review.
MR. KATZ: We have about five
minutes before adjournment. Can we just have
DCAS look at this recommendation and give us
feedback at the next Subcommittee meeting,

1	Wanda? Sounds like it is a little convoluted
2	to resolve, as to whether there is a PER
3	needed for these or not.
4	CHAIR MUNN: Yes.
5	MEMBER ZIEMER: And you're just
6	saying it may be needed.
7	MR. MARSCHKE: I'm just saying, yes
8	
9	(Simultaneous speaking.)
10	MR. KATZ: I don't think we can
11	resolve it
12	MR. MARSCHKE: They went from a
13	wide scope in Rev 0 to a narrower scope in Rev
14	1 and so the question is, you know, was
15	anybody evaluated under that wider scope who
16	would be excluded now under Rev 1.
17	MEMBER ZIEMER: Gotcha.
18	CHAIR MUNN: That's worth looking
19	at. We'll ask for a look-see from NIOSH.
20	Okay. Ready for schedule?
21	MR. HINNEFELD: I just, before we
22	get to schedule, we are okay, really, right,

on proceeding with PER-17, Idaho Falls, and my response is an opinion on 21. MEMBER ZIEMER: I quess you were saying 17 is going ahead. MR. HINNEFELD: I think 17 is kind of its own little thing. I'll go back and check on 29 and provide some --(Simultaneous speaking.) MR. HINNEFELD: There's a certain, just off the top of my head, there's a certain 10 clarity in dealing with each PER on its own 11 have different 12 because you are going to 13 initiation dates, you know, for the first PER it's going to be DRs done before this date and 14 15 when the next change comes out after that 16 date, and when you kind of amalgamate and combine them, it's not going to be as easy to 17 18 say. 19 MR. STIVER: It's going to be a lot harder to deconvolute. 20 MR. HINNEFELD: 21 Yes. 22 MR. STIVER: You'll need to go back **NEAL R. GROSS** 

WASHINGTON, D.C. 20005-3701

1	later.
2	MR. HINNEFELD: When you try to
3	blend them together and just do it once, it's
4	going to be a lot harder than you think.
5	MR. KATZ: It almost sounds like
6	you should just go forward
7	(Simultaneous speaking.)
8	MR. HINNEFELD: If it's okay with
9	you guys.
10	MR. STIVER: It's fine by us. We
11	can certainly
12	(Simultaneous speaking.)
13	CHAIR MUNN: I think so. Paul, do
14	you have any problem with that?
15	MR. STIVER: All right, well we'll
16	take our marching orders then.
17	CHAIR MUNN: Just follow along with
18	it.
19	MR. KATZ: You know, the quorum
20	issue, I think, let's not do the scheduling
21	now. We don't have a lot of Subcommittee
22	Members here

1	CHAIR MUNN: Mike's gone.
2	MR. KATZ: Well, we may have Mike.
3	Mike, do we have you still?
4	MEMBER GIBSON: I'm still here.
5	MR. KATZ: We have three, but we
6	we have three out of whatever it is, five,
7	right? Four?
8	CHAIR MUNN: Well, we need to at
9	least look at a week, if nothing else. When
10	we will get
11	MR. STIVER: How far out are we
12	looking?
13	CHAIR MUNN: Yes, how far do we
14	need to go? I had thought that perhaps we
15	could do something in June, but I don't see
16	how we can with the Santa Fe meeting going up
17	in June.
18	MR. STIVER: We have the Dose
19	Reconstruction meeting. We moved that to the
20	6th, Ted, is that the
21	CHAIR MUNN: Yes, the DR is going
22	to be the 6th.

MR. KATZ: Well, it's not done yet. I haven't heard from everyone yet. CHAIR MUNN: And I don't know how much we would have done in six weeks if we It wouldn't tried to meet that same week. work. MR. STIVER: We have a lot of other things on our plate. CHAIR MUNN: So June is out of the 10 question. It puts us into July, I think, which should be far enough out for everybody, 11 and I'd be -- I think my preference would be 12 13 probably the week of the 9th. How does that look for people? Is everybody here going to 14 15 be possibly available or people on vacation? 16 What? The week of the 9th look like it's a possible? 17 MR. HINNEFELD: Looks like it works 18 19 for me. 20 No problem for me. MR. STIVER: No problem? CHAIR MUNN: 21 Mike? 22 MR. KATZ:

1	CHAIR MUNN: Mike, does the week of
2	July 9th look possible for you?
3	MEMBER GIBSON: July the 9th?
4	CHAIR MUNN: Yes. That week. Not
5	the date.
6	MR. KATZ: The week of July 9th.
7	So, say, the middle of the week, say the 11th
8	for example.
9	MEMBER GIBSON: Yes, that should be
10	fine.
11	CHAIR MUNN: Okay, I'll send out a
12	request to our Subcommittee membership all
13	of the mailing list for this Subcommittee.
14	MR. KATZ: I'll cover that but, so
15	which date are we suggesting, the 11th?
16	CHAIR MUNN: Let's suggest the
17	11th.
18	MR. KATZ: Okay.
19	CHAIR MUNN: And if not the 11th,
20	ask if people are available on one day either
21	side of that.
22	MR. KATZ: Everyone here is saying

1	the 11th is okay.
2	CHAIR MUNN: They are saying the
3	11th is okay.
4	MS. LIN: I won't be here July
5	MR. KATZ: But someone will cover.
6	Yes. Okay. July 11th, question mark. Okay,
7	I'll poll Dick.
8	CHAIR MUNN: Thank you Ted. I
9	appreciate that. And thank you Mike and
10	everyone else on the line. We certainly
11	appreciate it.
12	MEMBER GIBSON: No problem.
13	Thanks.
14	CHAIR MUNN: Thank you. And are we
15	adjourned?
16	MR. KATZ: Yes.
17	CHAIR MUNN: We are adjourned.
18	(Whereupon, at 2:59 p.m., the meeting was
19	adjourned.)
20	
21	
22	